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TERATOGENIC AGE!--TTS ANTICOI~TULSANT DRUGS 
1.1 TERATOGENIC AGENTS 
A teratogenic agent is a drug, chemical, virus, physical agent 
or a deficiency state that, by acting during the embryonic or 
fetal period, alters morphology or subsequent function in the 
post natal period ( Shepard 1979 ). Generally, a drug is 
considered a teratogenic agent if it causes, when administered 
to a pregnant patient in the critical period of organogenesis, 
congenital malformations which are specific and unexpected 
from the general rules of genetics. Such malformations would 
need to be proved to be independent of the disease of the 
mother who required the drug , and consistent in nature and 
incidence. The malformation would need to be consistent with 
the data from animal experiments demonstrating the relationship 
between the drug and the malformation ( Nakan 1980 ). 
Analysis of the above type of information has led to the 
tabulation of a number of agents said to be' known' 
teratogens in man ( Table 1. ) • 
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TABLE 1. KNOWN TERATOGENIC AGENTS I N MAN ( Shepard 1979 ). 
( causing specified % of cong~nital malformations) 




INFECTIONS ( 2-3% ) 
rubella 
cytomegalovirus 
herpes simplex ( oral and genital?) 
toxoplasmosis 
syphilis 
varicella ( 'J .) 
Venezuelan equine encephalitis 






DRUGS AND ENVIRONMENTAL CHEMICALS ( 4-6% ) 
androgenic hormones 







diphenylhydantoin and trimethadione 
coumadin derivatives 
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Other defined causes of congenital abnormalities include 
genetic transmission ( 20%) and chromosome aberrations 
( 3 - 5%); howeve~ the cause of the majority ( 65 - 70%) 
of developmental defects is yet unknown ( Wilson 1977) 
although probably produced by a combination o; several gene 
defects and environm~ntal agents. This phenomenom called 
multifactorial inheritance suggests that there is an under-
lying genetic predisposition to form congenital malformations, 
produced by the small effects of many genes interacting with 
an environmental trigge~ such as a drug. This genetic 
predisposition has two major components, a predisposition to 
react adversely to a given agent and a predisposition to one 
or more forms of maldevelopment ( Nora 1981 ). Each of these 
may have far reaching implications when one considers adequate 
screening tests and the evaluation of teratogenic agents. 
Drugs and environmental chemicals demand special attention 
since if they are found to be the causes of developmental 
defects they can be avoided during pregnancy and so reduce 
the incidence ( approximately 3% ) of congenital anomaly in 
newborns ( Shepard 1979 ). 
1.2 THE PREGNANT WOMAN AND DRUG EXPOSURE 
:Most women are exposed to environmental agents, medications, 
drugs and occupational hazards on a daily basis ( Doering and 
Stewart 1978 ). Women continue to take large quantities of 
drugs during pregnancy. A Scottish study in 1973 ( Forfar et al ) 
reported that 82% of women were prescribed drugs other than iron 
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during pregna..ncy and that these women took an, average of four 
different preparations. In the same study, self-prescribed 
medication was taken in addition by 65% of the women. In 
Sweden, Boethius ( 1978) had shown that drug consumption 
increased during pregnancy when compared witb the pre-pregnant 
or non-pregnant states. Because of the normal high incidence 
of multiple drug exposure in pregnant women, retrospective 
evaluation of a drug for teratogenic toxicity is difficult. 
In the case of epileptic patients, many are on multiple drug 
therapy and it is difficult to determine which drug or 
combination of drugs may be responsible for the defects 
obs erved ( Sullivan and McElhatton 1976 ). 
1. 3 EPILEPSY AND ANTICONVULSANT DRUGS : DIPHENYLHYDAN'rOIN 
.Anticonvulsants may be amongst the drugs administered to a 
pregnant epileptic woman. Epilepsy is one of the most 
prevalent neurological disorders. The essence of epilepsy 
is focal abnormal paroxysmal . discharge of cells of the central 
nervous system. There are clinical (behavioural) and 
electrical se izures, and recurring episodes make up the 
disorder called epilepsy. Brain damage and heredity appear 
to play aetiological r oles, however much is still unknown 
about its cause. The essential brain mechanisms, neurotrans-
mitters and related phenomena are still unknown. The 
incidence of epilepsy is approximately 0. 5~; in all populations 
surveyed ( Dreifuss 1980 ). 
Many patients with epilepsy receive diphenylhydantoin ( DPH) 
which was first introd.uced in 1938 · ( Merrit and Putnam ) .. 
- s -
Despite the introduction of some twenty other anticonvulsant 
drugs, DPH is still the preferred drug of many for the 
treatment of grand mal epilepsy ( Kutt and Penry 1974 ). 
In the brain, DPH has little effect on the e~ectrical activity 
of an epileptic focu_s, instead, it acts to contain the spread 
of propagated electrical activity by inhibiting post-tetanic 
potentiation, a method of facilitated spread of neural activity 
which occurs transiently following a sustained, high-frequency 
burst of nerve cell activity, as during an epileptic seizure 
( Conomy 1978 ). 
1.4 ANTICONVULSANTS AND A REPORTED TERATOGENIC EFFECT 
The association between epilepsy, anticonvulsant drugs and 
birth defects was first proposed by Janz a.."ld Fuchs in 196L~. 
Data from isolated reports of affected humans are now 
supported by research on both humans and animals. It was 
only recently that clinical reports have suggested that a 
specific pattern of abnormalities existsin the offspring of 
mothers receiving. hydantoin anticonvulsants during pregnancy 
( Hanson and Smith 1975 ). The link between a specific drug 
and a characteristic defect remains unsettled ( Paulson and 
Paulson 1981 ). 
The first suspicion of DPH teratogenesis was raised in 1963 
( Muller - Kuppers) and five years later Meadow ( 1968) 
noted that among mothers of cleft lip and/or cleft palate 
babies, a higher than expected number had taken anticonvulsants 
during pregnancy. In the wake of these observations, many 
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investigations were undertaken and resulted in a number of 
case series and population studies which have suggested that 
DPH may induce up to a three-fold increase in major anomalies 
in the children of ~omen who take DPH regularly during the 
first trimester ( Annegers et al 1978; Freder:ck 1973; Knight 
and Rhind 1975; Monson et al 1973 and Hanson et al 1976 ). 
1.5 ARE .AI'rTICONVULSANT DRUGS INDEED TERATOGENIC? 
Although there is considerable literature on the effect DPH 
may exert on the developing embryo and fe ·!ius, the teratogenici ty 
of anticonvulsants remains controversial ( Finnel and Chernoff 1982) 
There are several ways to interpret the increased frequency of 
congenital anomalies in the babies of treated epileptic mothers 
( Lakos and Czeizel 1977 ), and these have been summarized as 
follows . :-
Table 2. POSSIBLE CAUSES OF THE INCREASED FREQUENCY OF 
CONGENIT AL Ai°t\JOMALIES IN THE BABIES OF TREATED 
EPILEPI'IC MOTHE~S 
Conclusion 
a. due to the effect 
of the epileptic 
condition 
Details and Author(s) of Report 
The offspring of women suffering from 
a seizure disorder are at a slightly 
increased risk for congenital mal-
formations regardless of any prenatal 
exposure to anticonvulsants. There 
was no appreciable difference in the 
incidence of infants with defects 
born to treated as opposed to 
Continued/ ••• 
Table 2. Continued/ ••• 
Conclusion 
see a. 





Details and Author(s) of Report 
non-treated epileptic mothers. 
( Shapiro et al 1976; Frederick 1973; 
Meyer 1973, and Starreveld-Zimmermann 
1973 ). 
Researching the same literature as 
Shapiro et al ( . 1976 ), these authors 
searched for a particular' pattern 
of malformations 'referred to as the 
Fetal Hydantoin Syndrome , which they 
concluded as being the consequence 
of embryonic and fetal exposure to 
the hydantoins. In support of this 
conclusion, most of the known teratogens 
in man give rise to such patterns of 
multiple defect. 
( Hanson et al 1976 ). 
The malformation rate in babies born 
to epileptic mothers in a pre-
anticonvulsant therapy period ( 1929 ·· 
1945) was compared with a later era 
( 1946 - 1968) during which anti-
convulsants were available. A 
marked increase in congenital 
malformations s ince the introduction 
of anticonvulsant drug s was found. 
( Vi ~s eI\Huisjes and Elshove 1976 ). 









Details and Author(s) of Report 
In opposition to the interpretation 
noted in part a. ot~er authors have 
stated that when examining the 
frequency of congenital disorders in 
the infants born to treated and non-
treated epileptics, there is a 
significantly in~reased frequency in 
the former group. 
( Lakes and Czeizel 1977 ). 
Epilepsy may result in social and 
financial difficulties which could 
lead to a lower than average standard 
of living and detrimental effects on 
the general health of a pregnant 
woman, making infections more frequent, 
which might ultimately lead to a 
teratogenic effect. 
( Lakes and Czeizel 1977 ). 
Livingsone and colleagues ( 1979) reported that they were not 
convinced that the evidence relative to the teratogenicity of 
anticonvulsive agents was conclus ive. The data suggest that 
both epilepsy and DPH may be risk factors for ~he development 
of the congenital malformations ( Wilson 1978 ). 
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1.6 THE FETAL HYDANTOIN SYNDROME IN MAN 
There has been a great deal of variability in the effects of 
DPH on the fetus in t erms of both severity and number of defects, 
however, Figure 1. sets forth the most consistent effects, 
which constitute the predominant features of the Fetal Hydantoin 
Syndrome ( FHS ), a" broad multisystem of abnormalities" first 
described by Hanson and Smith in 1975. 
Figure 1. THE MOST COWS ISTENT FEATURES IN IND IV I DUALS i,.JITH 
THE FETAL HYDANTOIN SYNDROME ( Smith 1979) 
H Y D A N T O I N S 
l 
MILD TO MODERATE GROl..JTH ABERR.i\.TIONS 
Altered Nasal Growth 
Short nose 
•inverted nostrils 
•bowed upper lip 
Low nasal bridge 
•inner canthal folds 
Ocular hypertelorism 
General Growth Deficiency 










Low arch dermal 
patterns 
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In terms of human handicap, deficits such as mental 
retardation are often far more devastating than a structural 
malformation which could possibly be corrected surgically, 
such as cleft palate. Studies by Hanson et al ( 1976) 
have shown that there is a 10% risk of a mild to moderate 
mental retardation in the children exposed and a 30% 
incidence of one or more of the malformations described 
in Figure 1. Most organ tissues or body systems can be 
affected, hence babies exposed to DPH in utero merit a 
close overall scrutiny for defects of morphogenesis. 
DPH has also been ,stated as caus ing alterations of post·-
natal development and behaviour, acting as a' behavioural 
teratogen ' ( Barlow 1982 ) • The appearance of behavioural 
disorders may be months or even years removed from the 
precipitating event. 
Animal studies designed to determine the teratogenic potential 
of DPH have demonstrated that the type and degree of 
malformations observed are dependent on such variables as 
the time of exposure and dose ( Paulson and Paulson 1981 ). 
1. 61 EXPOSURE TIME 
Following the exposure of pregnant mice. to DPH for a short 
time during organogenesis, single malformations such as cleft 
lip, cleft palate, urogenital anomalies, ocular and neural 
defects were observed in the offspring ( Finnel and Chernoff 1982 ). 
In humans, by virtue of the nature of the malformations that 
occur, such as cleft lip and cardiac defects, it is clear that 
the hydantoins may cause serious problems in morphogenesis 
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during the first trimester of pregnancy ( Dudley 1980 ). 
During this stag.e of cell differentiation and organogenesis, 
the developing tissues are more sensitive to adverse influences 
on structural development than mature tissues and the developing 
organism is at it s greatest susceptibility. Diffe r ent organs 
commence and complete their development at different time s and 
the susceptibility to a teratoe;en applied at a specific time 
will differ from organ to organ depending on the stage of 
development concerned, resulting in selective vulnerability 
( Paulson and Paulson 1981 ). 
Whether there is a serious risk during middle or late gestation 
remains to be resolved ( Dudley 1980 ). These latter stages 
of prenatal development are the period of maturati on and growth. 
All organs have ·been formed structurally and interference with 
late development will tend to lead to deformations, growth 
retardation or functional disturbances rather than malformations. 
The biochemical, physiological and behaviour changes result in 
functional abnormalities which may not be detectable at birth 
( Goldman 1979 ). In experimental animals it has been found 
that during the latter part of the fetal period the conceptus 
becomes sensitive to transplacental carcinogens ( Shepard 1979 ). 
Where DPH is given towards the end of pregnancy, the clotting 
factors in the infant may be depressed suf'fici·ently to cause 
bleeding, leading to clotting disoders in the newborn infant 
( Dukes 1980 ) , 
The type of defect produced cannot be precisely predicted on 
the basis of the time of insult ( Shepard 1979 ). Taking 
into account the critical period for human congenital disorders 
• 
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caused by anticonvulsants, the period from the fourth to the 
tenth week of gestation may be considered dangerous ( Lakos 
and Czeizel 1977 ). 
1. 62 DOSE 
It is generally accepted that any drug given in large enough 
amounts will adversely affect fetal development. This action 
usually occurs through deleterious effects on maternal health 
and is expressed as either embryo/fetus death, or fetal growth 
and development retardation ( Shepard 1979 ). Many of the 
warnings on drug package inserts about potential teratogenicity 
are related to this phenomenom. When extrapolating the 
findings from animal experiments to humans, it is important 
to take into consideration the ratio: ( on a per kilogram basis ) 
between the teratogenic dose in the animal and the therapeutic 
dose in the human. 
It has been recommended ( Wilson 1973) that for in vivo animal 
experiments, the dosage of the test substance should be maximal 
but not interfere . with the health of the pregnant animal in.:. 
' 
order that a fetotoxic response be obtained. In most animal 
research reports, t he dosages of all medications have been ten-
fold or more than the comparable normal human dose, but 
malformations also occur at near therapeutic levels ( 20_,.µ.g/ml) 
( Paulson and Paulson 1981 ). 
It has been suggested ( Organisation Scientific Group 1967) 
that one negative control group and three dosage levels should 
be used, the highest of which should cause maternal toxicity. 
- 13 -
The lowest dosage should be well below the toxic dosage and 
should ideally cause effects similar to those caused in man 
by the therapeutic dosages of the medicine. The intermediate 
dose should ideally lie logarithmically between the highest 
and lowest dosages. _ These guidelines were accepted and 
adapted for the in vitro experiments performed in this 
inves tigation. 
1. 7 SUMMARY 
' DPH has been found to be teratogenic in mice and is believed to 
be so in humans, with multifactorial inheritance determining the 
occurrence and severity of the resultant congenit a l defects. 
Dat a suggest that it is both the epileptic condition and DPH 
which may be the risk factors for the development of the pattern 
of abnormalities known as the Fetal H;y-dantoin Syndrome, although 
it is now generally accepted that anticonvulsants can by 
themselves damage the fetus. 
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CHAPrER 2. 
DIPHENYLHYDANTOIN TERATOGENICITY AND PHARMACOKINETIC FACTORS 
TERATOLOGICAL INVESTIGATION AND PARAMETERS INVOLVED 
.Analysis of the pharmacological or toxicological effect of a 
drug, such as DPH, thought to have a teratogenic action, would 
always consist of an investigation of two types of parameters 
( Neubert et al 1978 ). Pharmacokinetic factors involve 
all parameters associated with the agent being' handled' by 
the organism. This includes the rates of absorption, distribution, 
metabolic conversion and elimination. These factors are the 
only ones which can modify the degree of an effect to be evaluated. 
In addition, there are pharmacodynamic factors which will be 
considered in the following chapter but briefly, they specify 
the kind of pharmacologic a l or toxic action at t he target with 
the resulting effects typical for the agent applied, and also the 
elucidation of its mode of action ( Neubert et al 1978 ). 
2. 2 ABSORPrION AND DISTRIBUTION OF DPH 
DPH is an organic acid of low solubility which is usually given 
orally, the daily dose totalling up to 6 mg/kg. The drug is 
not rapidly ab sorbed from the gastrointestinal tract and 
ordinarily is slowly metabolized. Its mean half - life in 
plasma is twenty two hours after an oral dose . These 
characteristic s permit onc e - daily drug administrati on in many 
patients. Effective serum levels of DPH are 10 - 20 )1.Q/ ml 
( Conomy 1978 ), however blood levels are markedly lower during 
pregnancy than before pr·egnancy or after deli very. This may be 
- 15 -
due to alterations in absorption, excretion and metabolism of 
the drug, the dilution effects of increasing weight and 
extracellular fluid volume, or fetal metaboli sm of a part of 
the anticonvulsant dose ( Nakan 1980 ). 
Once absorbed, 90% of the drug is reversibly bound to plasma 
proteins and ex 2- globulins, and the DPH
 is distributed to the 
extracellular fluid of all organs, with the brain, muscle, 
adipose tissue~ liver,pituit ary and adrenal glands having high 
affinity for the drug ( Conomy 1978 ). 
DRUGS A ... ·11rn CONDITIONS WH ICH AFFECT THE PHARMACOKINETICS 
AND TOXICITY OF DPH 
In addition to DPH, a pregnant woman may be exposed to drugs 
other than DPH , or have a condition which causes an increase 
in plasma levels of DPH thus leading to prolongation of DPH 
·half-life or DPH intoxication ( Table 3. ) • Hi th regard to 
the dose - teratological effect relationship, an .increase in 
the probability of the· off spring having a birth defect could 
result. Selective and reduced drug administration and/or 
treatment of the 
1condition ( other t han epil epsy), might 
lead to DPH levels remaining a t a constant~low but therapeutically 
effective level. Conversely, drugs other t han DPH , or a 
condition ( other t han epilepsy) might lead to a shortened 
DPH half-life or to under-dosage, re sulting in the i neffect ive 
treatment of the epileptic state ( Table 3 9 . ) • Should this 
lead to an increase in epileptic seizures, t his in it self might 
have a t eratogenic effect, whilst the concentration of the 
putative t eratogenic agent ( DPH ) is r educed ( Shapiro et al '1976 ) • 
- 16 -
Table 3. DRUGS AND CONDI"rIONS WHICH AFFECT THE PHAR1'1ACOKINETICS 
AND TOXICITY OF DPH ( Conomy 1978) 
Drugs which cause increased plasma DPH levels, prolongation of 
DPH half - life or acute DPH intoxication 
Bishydroxycoumarin ( dicumarol) I Isoniazid 
Chloramphenicol (Chl oromycetin) Methylphenidate (Ritalin) 
Chlorpromazine (Thorazine ) 
Chlordiazepoxide (Librium) 
Diazepam (Valium) 




Phenylbutazone (But az olidin) 
Phenyramidol 
Prochlorperazine (Compazine) 
Propoxyphene (Darvon, SK-65) 
Sulfaphenazole (Ori sul) 
Sulthiame (Trolone) 
Valproic acid 
Conditions which cause ·increased plasma DPH levels, pro1ongation 
of DPH half - life or acute DPH intoxication 
Hepatic insufficiency - i.e., hepatitis, cirrhosis, genetic 
(hepatic) parahydroxylation defect 
Drugs which cause low plasma DPH levels, shorten DPH half' -
life or lead to underdosage 




Conditions which cause low plasma DPH levels, shorten DPH half -
life or lead to underdosage 
Chronic renal dise ase 
Newborn state 
Intestinal absorptive defects 
Intramuscular DPH administration 
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2.4 DPH METABOLITES: FORMATION AND EXCRErION 
Metabolism of DPH is primarily by liver enzyme parahydroxylation. 
In man, the metabolism of DPH is extensive, only a minor portion 
being excreted unchanged in the urine ( Butler ~957; Maynert 1960 ). 
Figure 2. PROPOSED BIOTRfu~SFORMATION OF DPH IN VIVO 
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PHENYTOIN· 3-0·METHYL CATECHOL 
Abbreviations: 
DPH = diphenylhydantoin 
DPKi\. = diphenylglycine- ol- aminodiphenyl acetic 
acid 
m-HPPH = 5-(3'-hydroxyphenyl)-5-phenylhydantoin 
p-HPYrl = 5-(3'-hydroxyphenyl)-5-phenylhydantoin 
DHD = 5-(3,4-dibydroxy-1,5-cyclobexadien-1-yl) 
-5-phenylhydantoin 
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The hydantoin ring is opened yielding DPRA. 
DPHA is deamidated to phenylglycine. 
DPH is hydroxyl ated , vi a mixed function oxidase enzymes, 
directly to p-HPPH and fu-HPPH . 
The hydroxyl at ecl metabolites are excreted primarily as 
glucuronide conjugat es and possibly sulphate conjugates. 
DPH metabolism involves bioactivation to a toxic arene 
oxide (ep ox ide) intermediate by hepatic microsomal 
cytochrome P-450 - catalysed monooxygenase enzymes. 
Sub sequent deactivation of the arene oxide probably occurs 
by a spontaneous nonen zymatic isomer ization to the 
hydroxylat ed. metabolites. Indirect evidence for an 
intermediat e arene oxide includes detection of the DHD 
metabolite in the urine of mice, rats, monkeys, humans 
( Harbison et al 1977 ), and human neonates ( Horning 
et al 1971 ) • · - · 
In general, arene oxides are the presumptive intermediates 
in the oxidation of mos t aromatic hydrocarbons, as 
reflect ed by the occurrence of the isomerizat ion step to 
phenol metabolites , the formation of glutathione (GSH) 
conjugat e s and t he formation of DHD , catechols and their 
conjugates ( Jerina and Daly 1974 ). 
This involves the formation of DHD catalysed by hepatic 
microsomal epoxide hydras e enzymes. 
Additional met abo lic pathways of mince quantitative but 
sub s tantial toxicologic i mportance are als o possible. 
The arene oxide may also exist in equilibrium with its 
oxepin tautomer, their concentrations depending on their 
rel ative stabilities ( Jerina et al 1970b ) • This may 
be true for DPH , a lthough neither species has been 
identifi ed ( Harbison 1978 ). 
Finally, if there is either an over,,vhelrning increase in 
arene oxide production (Step 5) , or a decreas e in arene 
oxide detoxification (St eps 6,7, and 8), the high l y 
re activ 2 arene oxide will be free to bind to essential 
cellular macromolecules c ausing alterations in cell 
function or cell death. 
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Table 4. A QUALITATIVE AND QUANTITATIVE SUMMARY OF· DPH 
















p - HPPH The major metabolite, appears 
in urine largely as a 
conjugate with glucuronic 
acid and normally accounts 
for 50 - 75% of the daily 
DPH dose. 
Found in urine in greater-
amounts than m - HPPH • 
m - HPPH Normally represents 
DHD 
5 - 17'fa of the total 
urinary HPPH compo sition. 
The major metabolite. 
3 - 12% of DF.d daily dose. 
Up to 20% of DPR daily dose. 
Genetic variations in the 
conjugation reaction of DHD 
and/or variations in enzyme 
activity of the DHD-Catechol 
pathway, may affect amounts. 
Detected in urineo 
The major metabolite. 
























DPHA if present in buman urine probably does not exceed 
0.2 - 0.3% DPH daily dose ( Butler et al 1976 ). A unique 
N- glucuronide metabolite of DPH has also been reported in 
man, and other minor metabolites include phenytoin-3,4-catechol 
and phenytoin-3-0-methyl catechol, but no information i _s 
available on the quantitative aspects of these urinary products 
in man ( Dudley 1980 ). 
2.5 PRODUCTION OF THE ARE~E OXIDE INTERMEDIATE AND DHD BY 
DPH METABOLISM 
The ~echanisms of the reactions leading to the formation of 
the monophenolic metabolites ( p-HPPH and m-HPPH) are of 
particular interest because these biotransformations could 
involve a highly reactive arene oxide intermediate ( Figure. 2. 
Steps 3 and 6 ) • The arene oxide is also thought to be an 
intermediate in the formation of DHD, therefore it is presumed 
that a patient produces a considerable amount of this 
' obligatory' and possibly teratogenic intermediate in the 
metabolism of DPH ( Jerina and Daly 1974 ). 
It has been postulated that free DHD is a' masked' or devious 
form of the arene oxide intermediate ( Dudley 1980 ). If 
associations could be made between unusually high free DHD levels 
and DPH toxicity, this concept could provide an adequate 
explanat ion of how a highly reactive arene oxide could be 
produced principally at one site within the body and exert its 
adverse effect at some distant site. The arene oxide is 
presumably an extremely short-lived and reactive compound 
that has eluded attempts at detection by gas chromatography -
mass spectrometry ( Horning et al 1976 ). 
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THE DISTRI BUTION OF DPH A...~ D ITS riET~BOLITES IN FETAL 
TISSUES 
Parent drug and metabolites have been identified in different 
amounts in placenta, and in various fetal tissues ( Egger 1978 ). 
The tot a l concentration of DPH and metabolites in fetal tissues 
varied from 10 - 20% of the levels of the unconjugated fraction 
in human plasma, whereas levels in the pl acenta were found to 
be slightly higher than those in maternal plasma. Metabolites 
were al s o identified in human fet a l brain, liver and muscle 
tissues. The polar metabolites of DPH were also demonstrated 
to be present in the fetal tissues examined and were thus able 
to pass the placental, as well as the fet a l blood- brain barrier. 
The arene oxides produced in maternal liver may be stable enough 
to cross the placenta into the fetus, or may tautomerize to a 
more stable oxepin . which crosses the placenta and isomerizes 
back to the re active arene oxide. Some arene oxide could also 
be produced directly by fetal tissue metab olism of DPH, although 
this route would not be likely to contribute significantly to 
overall arene oxide_ production ( Wells and Harbison 1980 ) • 
2. 7 SUT1I'TARY 
The pregnant s t ate, drug s other t han DPH, and medical conditions may 
af fect the phar macokinetics and toxicity of DPH, and these 
must be cons i Cered when deciding DP.H dosag e for t he effective 




DIPHENYL:IYDANTOIN TERATOGENICITY AND PHARrlACODYNAI'1IC FACTORS 
3 . 1 1'1ECHJ\NISI'1 OF DPH TERNrOGENICITY 
It is still not certain whether or not DPH produces its 
teratogenic effect by acting through the parent compound or a 
toxic metabolite ( as a reactive intermediate or as a final 
metabolite). There now follows a tabulated summary of the 









TERATOGENICITY OF DPH PARENT COMPOUND 
EXPERIMENTAL CONDITIONS CONCLUSION 
Phenobarbitone stimulated DPH 
metabolism, s o producing an 
increase in the quantity of 
DPH metabolites in a short 
period of time and was 
demonstrated to antagonize 
DPH-induced resorptions and 
anomalies. In contrast, 
SKF 525-A pretreatment which 
inhibits DPH metabolism, 
produced a ~reater plasma 
concentration of DPH (maternal 
and fetal ) and slo\ved maternal 
excretion of DPH to cause a 
potentiation of DPH-induced 
resorptions and anomalies. 
The results indicated 
that under conditions 
that apparently 
stimulated DPH metabolism, 
DPH- embryot oxicity was 
decreased; when 
conditions favoure d 
inhibition of the 
metabolism of DPH 
(parent compound) it 
was enhanced . 
Continued/ ••• 
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Mouse The authors investigated the 
(Harbison relative teratogenic potency 
and of the hydroxylated and 
Becker degradative metabolites of 
1974) DPH when compared with that 
CONCLUSION 
The metabolites did not 
affect fetal growth 
and were generally less 
fetocidal than DPH. 
These results suggest 








hydroxyphenyl phenyl hydaritoin, 
o<. - amino-diphen.yl acetic acid' 
diphenylhydantoic acid and DPH 
~ffects on the fetuses. 
A study was made of the 
distribution and metabolism 
of DPH (parent compound) and 
its metabolites in maternal 
and fetal tissues. 
teratogen. 
It was concluded that 
if the distribution 
pattern of DPH and its 
metabolites in cardiac 
tissues was indicative 
of the distribution 
pattern for most tissues 
(other than kidney), it 
would appear that DPH may 
be the prime candidate to 
play the role of a 
teratogen as the parent 
compound. However, 
more direct evidence 
is warranted . 
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Numerous carcinogens and mut agens have been shown to require 
metabolic activation to ultimate metabolites inorder to exert 
toxic actions ( Jerina and Daly 1974 ). It is reasonable to 
infer therefore that teratogenic effects of some chemicals 
might also result from enzymatic activation. The toxic effects 
of DPH may be due to a metabolite or intermediate in metabolism, 
rather than due to the parent compound (Blake and Martz 1980 ). 








EXPERI MENT AL COND r rIONS CONCLUS ION 
Administration of 14c - DPH to These findings support 
pregnant mice and measurement of the hypothesis that 
the non-extractable radioactivity DPH owes its terato-
presumed to be covalently bound 
to macroproteins, was determined 
in whole embryo and placenta. 
The amount of bound label 
increased when pregnant mice 
were pretreated with an 
' inhibitor of epoxide hydratase, 
the enzyme responsible for 
degr adation of the arene oxide. 
There a lso resulted an increase 
in the teratogenic activity of 
the drug. 
genie effect to the 
production of a 
reactive arene oxide 
metabolite which binds 
to macromolecules 
critica l for normal 
development. 
Confirmation of this 
postulate in humans 
could only be obt a ined 
by examining tissue 
metabolite p atterns 
which po s es ethic al 
and log i s tical problems. 
Continued/ ••• 



















EXPERIMENTAL CONDITIONS CONCLUSION 
In a study of the comparative The parent drug 
embryotoxicity of DPH and some of or a metabolite or 
its metabolites in mice, it was intermediate other 
found that when examining the than those examined 
number of anomalies aud resorptions is responsible for 
after treatment of the mother with DPH teratogenicity. 
DPH , the diphenylhydantoic acid, 
diphenylg lycine and p - HPPH 
metabolites do not account for 
DPH's teratogenicity. 
Reviewing the work by Harbison and 
Becker (1 974), the authors 
attributed the significant decre ase 
in fetal body weight and crown-
rump and transumbilical measurement 
in th~ offspring of DPII-treated 
mothers to the teratogenic action 
of the arene oxide intermediate, 
and not to the parent comp ound. 
In an examination of DPH terato-
genesis, there appeared a 
correlation between the fet otoxic 
effect and the covalent binding 
of a putative arene oxide 
metabolite in gestational tissue. 




Arene oxide is a 
teratogenic agent 
in the mouse 
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The major metabolites of human DPH metabolism, viz. p- HPPH, 
m- HPPH, and DHD also occur in other animals including the 
mouse. An important determinant of DPH levels and its rate of 
metabolism is the genetic variation in the enzyme activity 
of individuals, which may account for the variations in 
fetotoxic response . 
Evidence suggests that the arene oxide intermediate in DP:I 
metabolism is probably the toxic agent in DPH tera togenicity 
A 
and by a covalent binding to the essentia l cellular 
macromolecules , affects cellular development. DHD, rather 
than being just a detoxification product of DPH metabolism 
may be a ' masked' form of the arene oxide which travels via 
DHD to exert effects at a distant site. 
Metabolites of DPH have b een found to pass the placenta and 
-even the fetal blood brain barrier indicating that these 
barriers are not able to prevent the fetus from being exposed 
to these products . The arene oxide may cross directly or 
indirectly via an Oxepin tautomer. All fetal tissues 
are exposed e.nd t heir development may be interfered with 
leading to congenital anomalies. 
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3. 2 MECHANISMS OF TERATOG ENI CITY AT THE MOLECULAR . 
AND CELLULAR LEVELS 
A firm binding between the causing agent and the special 
cellular target molecules may directly cause embryotoxic 
effects by one or more of the following mechanisms or 
•initial events' ( Wilson 1979b) :-
1. Chromosome breaks , nondisjunction etc., 
2. Mutation ( gene ) 
3. Mitotic interference 
4. Altered nucleic acid integrity or func t ion 
5. Lack of normal precursors, substrates, etc. , 
6. Altered energy sources 
7. Changed membrane characteristics 
8. Osmolar imbalance 
9. Enzyme inhibition 
These changes in a developing system are often not readily 
apparent because they are at subcellular or mo l ecular levelso 
To become b·etter manifes t the postul ated mechani sms must lead to 
grosser 'secondary •events which are more readily demonstrable 
cellular and tissue alterations that constitute recognizable 
events of abnormal embryogenesis and are as follows (Wilson 1979b): -
1. Excessive or reduced cell death 
2. Failed cell interactions 
3. Reduced biosynthesis 
4. Impeded morphogenet i c movement 
5. Mechanical disruption of tissues 
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3. 3 MDT AT ION AS THE• INI'r I AL EVENT• 
The various ways in which nucleotide sequences in the DNA 
molecule may be changed in the production of mutations is 
illustrated in Figure 3 • , 
Figure 3 • CHEMICAL MUTAGENESIS ( Wilson 1973 ). 
C H E I1 I C A L I1 U T A G E N 
Changes in Nucleotide Sequence of DNA molecule 
Affecting one base ~ ~g triplet 
( point mutation) 
transi~ ~versions 
incorporation 
error of analogue 
base 
reading of base 
/ 
deletion insertion 
of base of base 
Affecting long segments 
of DNA 
· (bre ak and repair errors ) 
inver~~~slocations 
if in Cells 
ALL HERITABLE DEFECTS FEW NONHERITABLE DElrECTS 
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3. 31 THE RELATIONSHIP BET\,TEEN A :mJTATIONAL ( I NITIAL ) 
EVENT, A CYTOTOXIC ( SECONDARY) EV ENT AND THE 
MANIFESTATION OF CONGENI'rAL ANOMALIES 
DNA rearrangements occur in normal development which code for 
the differentiation of specific cell communication proteins. 
These proteins are r~sponsible for the proper functioning of 
growth control in a multicellular organism. DNA - damaging 
agents ( mutagens ) could possibly induce DNA repair enzymes , 
some of which may catalyse illegitimate genome rearrangements, 
thus leading to a change in cell growth, proliferation and 
differentiation, giving rise to congenital anomalies 
( Wintersberger 1982 ). 
It has been postulated ( Newlon 1975) that some CNS 
malformations are related to the human equivalent of the 
mouse T locus using the indirect evidence that the T locus 
is linked to the mouse histocompatibility locus H - 2, which 
is clearly analogous to the HLA locus in man. If some cases 
of congenital malformations were determined by gene(s ), 
within a system akin to the T locus, the abnormalities would 
be linked to the HLA locus· .. Therefore, some human congenital 
anomalies may corre spond to those co ntrolled by mutation at 
the T locus in the Tiouse. The restricted region of the complex 
T locus in the mouse appears to contain an important centre 
controlling the steps of early embryogenesis. The T locus in 
the mouse is located on chromosome 17, near the complex H - 2 
major histocompatability locus to which it may be functionally 
related, in that both may be concerned with the recognition 
of events. Mutants at; the T locus of the mous e form a series 
of recessive lethals, each of which act at a specific stage 
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of development ( Newlon 1975 ). 
The observed effects of t; alleles on embryogenesis suggest 
that the role of th ese genes is to specify cell surface 
components required for cellular inte ractions at precise 
stages. The T locus is thought to be related to gene(s) 
which code for the F·9 antigen which is present on the 
membrane of early mouse embryos, spermatozoa and whole male 
germinal cells but not on adult somatic tissue. F 9 antigen 
in human cells is found in a distribution very similar to 
that previously described in the mouse. It supports the 
existence of a human equivalent to the T locus. However, 
' the genetic control of F 9 antigen in man, especially its 
linkage relationship with the IffiA locus remains to be 
demonstrated ( Fellous 1979 ). 
Jt could therefore be considered a possibility that DPH may 
exert its teratogenic effect by causing the ' initial event ' 
of a mutation at the human equivalent of the T locus where 
possibly the F 9 antigen is genetically controlled, and_ so 
cause altered memprane constitution and affect the cellular 
interactions which are so vital for normal tissue development. 
The' secondary event ' of altered cell proliferation rates, 
reduced cell size, altered cell morphology , or effects on 
cell migration and cell differentiation may re sult. The 
possibility of a mutagenic effect from DPH c annot be ruled 
out ( Bartoshesky and Pashayan 1982 ). 
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MUTAGENICITY OF AN INTERMEDI!\.TE/.P.RODUCT OP 
DPH MBI1 ABOLISM 
Arene oxides have been shown to be mutagenic to mammalian cell 
cultures , Drosophila, bacteriophages and strains of Salmonella 
typhimurium ( Jerina and 03.ly 197 4 ) . 
The discussion will now centre on the proposal that arene 
oxides are the bioactivated agents responsible for the 
teratogenicity of DPH in causing mutagenic and carcinogenic 
effects ( Jerina and Daly 197L~ ) • However, the possibility 
that the other metabolites of DPH, or the parent compound 
are act ive in producing these effects cannot be excluded. 
The arene oxides are prime suspects for the bioactivated 
intermediates responsible for DPH teratogenicity ( 1 •.fells and 
Harbison 1980 ). In addi tion to isomerizing to pheno ls, they 
react readily with a variety of nucleophiles, including such 
cellular macromolecules as DNA, RNA and proteins which are 
critical for normal deve lopment. Reacting as such, arene 
oxides metabolically derived from drugs can be putative 
teratogenic agents and toxic effects ca.."11 be correlated with 
the extent of binding ( Jerina and Daly 1974 ). 
Either the devious form of the arene oxide intermediate, or 
a . mischievous substance that is bioactivated to a toxic 
DHD - arene agent may react with cellular constituents to 
interrupt normal cellular processes ( Dudley 1980 ). 
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Deactivation of the arene oxide appears to be the major 
factor in reducing DPH teratogenicity. The enzymes 
responsible for the formation and destruction of the arene 
oxide are likely to be under separate control and be 
differentially responsive to environmental factors, therefore 
it is possible to postulate that individual human fetuses 
would have varying sensitivity to the teratogenic action of 
DPH, depending on the genotype and maternal exposure to 
other drugs, environmental pollutants and so forth. It is 
possible that some affected babies have a combination of 
genetic _.and environmental factors which lead to enhanced 
levels of the arene oxide intermediate ( Wells and Harbison 1980) . 
3.33 MUTATION AND CARCINOGENESIS 
A variety of chemicals have been implicated as causative agents 
in carcinogenesis. Each of the chemical carcinogens that have 
been thoroughly studied have been found to bind covalently with 
DNA, RNA and protein of the target tissue ( Miller,1970 ). 
The covalent binding of these bioactivated intermediates 
( arene oxides) to intracellular macromolecules provides a 
molecular basis for carcinogenicity ( Jerina and Daly 1974 ). 
For most cancers some of the steps involved in their initiation 
must surely be mutational because the correlation between 
mutagenici ty and carcinogenicity is so strong ( Cairns '1979 ) • 
DPH has been associated with maligna.Dt lymphoma ( Hyman and 
Sommers 1966 ), and hepatic necro s is ( Dhar et al 19?4) in 
the epileptic patient. In some instances, . oncogenic and 
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teratogenic activities have been found to coexist in the same 
individual exposed to hydantoin in utero ( Cohen 1981 ). 
Adrenal carcinomas, neuroblastomas and ganglioblastomas have 
also been found to occur ( Seelers et al 1979 ). 
3. 3 4 CARCINOGENESIS AND TERATOGENICITY 
In the offspring of pregnant animals which have been exposed 
to certain carcinogenic agents, there are recognised instances 
of increased tumour incidence, the apparent result of the 
agent which passed through the placental barrier ( Dipaolo and 
Kotin 1966 ). 
The conversion of a fetal cell to a cancer cell can be thought 
of as an alteration in its state of differentiation with the 
' freeing , of a programmed stem cell from its normal restraints 
so that it can form an invasive clone~ i.e. become a cancer 
cell ( Cairns 1979 ). Arene oxides have been found to elicit 
transformation in cultured cells ( Jerina and Daly 1974 ). 
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'SECONDARY EVENTS ' RESULTING FROM EXPOSURE TO A 
TERATOGENIC AGENT 
CELL PROLIFERATION , DEATH, SIZE AND INTERACTIONS - ·- ·-------------------------
Mesenchymal proliferation · and mitosis are active in the 
fetus at the tips of the palatial shelves and DPH may 
decrease such fibroblastic proliferation, on the other 
hand, DPH has been reported to increase fibroblastic growth 
of c ells in ' culture ( Paulson and Paulson 1981 ). 
Many important aspects of brain development such as 
proliferation and cellular migration, differentiation, 
synaptogenesis and myelination occur in lat e gestation and 
po stnat ally. By manipulating the time at which drugs 
interfere with cell proliferation, it has be en possible to 
produce selective reductions in specific cel l populati ons 
. in the CNS, resulting in particular types of motor deficit 
or behavioural change , dep ending on the structures damaged. 
In some cases, behavioural effects have been shown after 
loss of as little as 5% of the total cell population in one 
area ( Barlow 1982 ). 
In relation to DPH toxicity, Livingston ( 1957) reported 
persistent ataxia in patients treated with phenytoin and 
studies h ave been made describing the loss of Purkinje cells 
in the c erebellum of epileptic patients having ataxia from 
high doses of DPH ( Hofmann 1958, and Haberland 1962 ). 
Similar histological changes were observed by Utterback (1958) 
and Kokenge et al ( 1965 ), following the administration of 
DPH to cats. 
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There has been wide support for the stimulatory effect of 
DPH on connective tissue ( Bhussry and Raos 1963, and 
Houck 1960 ). Although studies by Robinson ( 1962) have 
indicated that stimulation of epithelial elements also occurs. 
This suggests that a te~atogenic influence is being exerted 
on the lip structures as well as on primary and secondary 
palatal development ( Massey 1966 ), and cleft palate. 
Programmed cell death is as crucial as mesenchymal proliferation 
since the apposition of the epithelial membranes must be 
associated with a fusion of the mesodermal elements and loss 
of the epithelium. Therefor~ a failure of programmed cell 
death may be responsible for cleft palate resulting from 
DPH exposure ( Paulson.- and Paulson 1981 ) • 
A recent study ( Sulik et al 1980) investigated the pathogenesis 
of cleft lip and palate and limb malformations using light 
microscopy ( LM) and electron microscopy (EM). At LM 
and EM, no evidence of cell death in tissues of treated embryos 
was observed. However, scanning EM studies of the 
developing primary palate and maxillary process and medial 
and lateral nasal processes showed a marked reduction in size . 
At this stage in the control embryos, these three processes 
normally approximate each other and fuse. In the DPH -
treated embryos, cleft lip and palate almost invariably 
resulted when this approximation·is retarded by a reduction in 
process size, especially in the nasal processes. 
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Cell morphology, ce·11 differentiation and .cell migration ( Sulik 
et al · 1980) observations in addition showed a change 
in the morphology of a subepithelial mesenchymal cell population. 
A similar cell population exhibits the same alterations in limb 
buds of embryos exposed to DPH. In both instances, numerous 
long cell processes, which were found to extend from these 
cells to form a" cell process meshwork ( CPM) "in control 
embryos, were absent or much reduced in size and number in the 
treated embryos. A notable change in morphology of the CPM, 
that is, an increase in complexity with advancing development, 
has been observed in the control embryos with the processes 
getting longer and more numerous; this was preventable with 
DPH exposure. 
It was found -( Sulik et al 1980) that the critical exposure 
period for DPH teratogenicity relates to interference with a 
common developmental phenomenom ( CPM formation) and that a 
specific stage in the development of the CPM is directly 
related to a critical period of susceptibility to DPH. A 
substantial role for the CPM in some aspects of morphogenesis 
is suggested by its morphology and location and by the fact 
that a disturbance of its integrity is associated with 
malformati on. 
With reference to nerve. tissue, autopsy findings of a twenty 
three month old child exposed in utero to anticonvulsant 
therapy; results showed effects on the cerebellum, where 
malformations of the dentate nuclei, neuronal heterotopias 
and abnormalities of the Purkinje cell dendrites were found 
( Mallow et al 1980 ). These results suggest a disturbance 
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of the migration and development of cerebellar neurones. 
It should be noted that Mccredie and M:::Leod in 1974 reported 
that there was a neurotoxic action by the well known teratogen 
thalidomide on the rabbit embryonic dorsal root ganglia , 
causing the arrest of neurona l maturation as shown by 
histological examination. 
REDUCED BIOSYNTHESIS 
DNA is found in the nuclei of cells and in mitochondria and 
is synthesized durin~ the Sor synthetic phase of the cell 
cycle . In DNA synthesis, thymine ( a pyrimidine )combine s 
with deoxyribose to form thymidine, a nucleoside. Combination 
of the nucleoside with a phosphoric acid residue leads to the 
formati on of a mononucleotide. Many mononucleotides derived 
from various purine and pyrimidine bases, combine to form 
polynucleotides and eventually DNA. The genetic message is 
coded by the sequence of the purine and pyrimidine bases,in 
DNA and this message regulates the synthesis of all proteins 
formed by the cell ( Ganong 1975 ). 
The rapidly dividing embryonic cells at the stage of 
organogenesis have high rates of DNA synthesis and consequently 
protein synthesis ( Kohler et al 1972 ). Any interference 
with the base sequence at this stage by a teratogenic agent 
may cause greater damage and result in altered rates of DNA 
synthesis. Hydroxyurea and cytosine arabinoside, both known 
teratogens, have been demonstrated to decrease nucleic acid 
synthesis in rode~t embryos ( Kochhar et al 1978, and 
Krowke and Bochert 1975 ) . 
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3. 5 DPH ( P AREl\TT COMPOUND ) AND FOLATE ANTAGON ISM 
Reduced biosynthesis, demonstrated by decreased DNA synthesis . 
measurements would also be the predicted result of DPH toxicity 
when considering the theory that DPH ( parent compound ) acts 
as a folate a.tJ.tagonist in causing a teratogenic effect ( see 
Section 4.2 ). 
DPH is a folate antagonist which may produce its teratogenic 
effect by causing fol ate deficiency or rather by inhibiting 
the conversion of folate to its active derivatives. Folate, 
the metabolically active form of folinic acid, is an important 
cofactor for many metabolic processes such as nucleoprotein 
synthesis and mitosis . If folate deficiency has an aetio logical 
role in DPH teratogenicity, it may be related to the f act that 
folate is a cofactor for drug hydroxylation reactions, including 
the metabolism of anticonvulsants ( Sullivan and McElhatton 1975 ) . 
Folnte deficiency could lead to a decrease in the rate of 
metabolism of DPH and thus to higher blood concentrations of 
the parent compound and perhaps an increase in toxicity. On 
the other hand, high serum folate concentrations could 
lead to rapid inactivation of the drug and a subsequent decrease 
in f it control which might itself have a teratogenic effect 
( Sullivan and McElhatton 1975 ) . 
Animal studies have shown that both folate deficiency and DPH 
increase the rate of fetal malformat ions . In general, women 
taking anticonvulsants who have delivered malformed infants 
have been shown not to differ from women with normal infants 
in serum fol ate levels ( Annegers 1974, and Hall 1972 ) • It 
was concluded that folate deficiency alone is U.."llikely to be a 
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cause of fetal malformationso The suggestion that 
anticonvulsants produce their effe ct via folate deficiency 
and that the offspring might be protected from this by folate 
supplements is entirely unproven ( Dukes 1980 ). 
3.6 OTHER THEORIES OF DPH TERATOGENICITY 
DPH administered to mice caus ed embryonic folate antagonism 
and was found to inhibit ornithine decarboxylase ( ODC) the 
rate-limiting enzyme in putresc ine biosynthesis, so causing 
reduced level s of this precursor diamine aswell as the resultant 
polyamines, . spermidines and spermines. Because ODC is an 
enzyme of major importance in embryogenesis , any alterations in 
ODC activity may indicate abnormal development ( Paker and 
Netzloff 1982 ). Other theories on the mechanism of DPH 
teratogenicity include altered cortisone me t abolism, interference 
with oxidative metabolism , defects in collagen formation · and 
effects on growth inducers in embryonic life ( Wilson 1978, 
and Paulson 1979 ). 
3.7 SUT1T1ARY 
Al though it is still not cert a.in \.,:hether or not DPH produces 
a pos s ible teratogenic effect by actinc through the parent 
compound or toxic metabolite ( reactive intermediate or final 
metabolite), evaluation of the evidence seems to suggest 
that the arene oxide is the toxic agent , especially when 
considering the information on epoxides per se. 
- 40 -
The mechanism of DPH teratogenesis at t he molecular and 
cellular levels may be elucidated by the examination of 
the effects grouped as ' initial ' and' secondary ' events. 
The former which occurs at the molecular level may b e 
examined by a variety of methods. The one used in this 
study involved the chromosomal method of analysis 
( Conventiona l and SCE ) which has been shown to be of val ue 
{n detecting mutational insults . 
A chemical mut agen may cause mutations by affecting the 
nucleotide sequence of DNA molecule in a variety of ways . 
In the case of fetal tissues which are somatic cells , the 
mutation would lead to non heritable defects. 
The arene oxides have been shown to be mutagenic to mammalian 
cell cultures, drosophila, bacter iophages and Salmonella 
typhimurium. A mutation in fetal cells could l ead to a . . 
change in the structure (sequence) of DNA and a consequent 
alteration in protein synthesis which could affect enzyme 
activity and lead to changes in cell growth , proliferation 
and differentiation resulting in congenital defects. 
It has been suggested that s ome CNS malformations are 
related to specific gene rearrangements associated with the 
human equivalent of the mouse T locus which appears to contain 
an import [-\nt c entre controlling the steps of early embryogenesis , 
with the genes specifying cell surface components required for 
cellular interactions at precise stages of development. 
The T locus is thought to be related to the _F9 antigen present 
on the membrane o.f early mouse embryos and spermatozoa but 
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not on adult tissue~ a similar distribution to that of hl.D1l3Il·cells . 
The covalent binding of the bioactivated intennediate ( arene oxide) 
would provide a molecular basis for carcinogenicity, with a rnutarion 
involved in their initiation and cancers have been found in epileptic 
patients and their offspring. Tumour incidence has been shown to be 
increased in the offspring of animals exposed to carcingogenic agents 
and cancer cell transformation of fetal cells has been shown to be 
elicited by arene oxides in culture. 
Deactivation of the arene oxide appears to be the major factor in 
decreasing DPH teratogenicity. The acitivity of the enzymes involved 
is genetically determined and their activation and deactivation respond 
separately to environmental factors. There is varying sensitivity 
dependent on genotype, maternal exposure to other drugs and to 
environmental pollutants. 
DPH via a possible rnutagenic effect may cause the following' secondary' 
events; altered rates of cell proliferation, reduced cell size, altered 
cell morphology, effects on cell migration and effects on cell differentiation. 
These events at the cellular level can be monitored by direct morphological 
observation and DPH has been shown to cause both an increase and a decrease 
in fibroblastic proliferation in cell culture. DPH has been shown to cause 
decreased cellular proliferation in the CNS and ataxia due to loss of purkinje cells 
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'if\. the cerebellum of epileptic patients. Stimulatory effects 
' by DPH on both connective tissue and epithelial tissue 
was demonstrated and this could possibly be the basis for 
the manifestation of cleft palate in the FHS. 
Programmed cell death and mesenchymal proliferation are both 
very important in no.rmal development ( such as palatial ) .and 
DPH c an affect approximation and fusion of processes ( palatial, 
maxi llary, medial and lateral nasal) due to overall reduction 
in cell size. Changes in cell process extension of the 
11 cell process meshwork" of mouse limb buds was t he result 
of exposure to DPH and prevented the increase complexity 
associated with normal development, resulting in malformations. 
Examination of nervous tissue at autopsy after anticonvulsant 
exposure in utero has revealed ma lformation in the dentate 
nuclei of the cerebellum, neurona l heterotopias , and 
·disturbed migration and development of c erebellar neurons. 
Hist ological examination has revealed neurotoxic action by 
thalidomide, which is a . definite human teratogen causing 
limb reductions. 
The study of reduced biosynthesis was investigated by the 
examination of the DNA synthesis rates for cell populations. 
A muta~enic agent may alter the base sequence of DNA dur ing 
the period of organoe;enesis leading to decreased r ates of 
DNA synthesis. If DNA synthesis is sufficiently inhibited 
to cause selective killing of the cells ru1d an inhibibion 
of proliferation, these prenat a l influences may lead to 
abnormal growth and development. 
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CHAPI'ER 4. 
DETECTION OF 'l'HE ' INITIAL ' AND ' SECONDARY ' EFFECTS OF 
A TERATOGENIC AGENT 
4.1 DETECTION OF A MUTATION ( 'INITIAL EVENT ' ) 
Considerable attention has been focused on the development of 
new techniques for detecting potential mutagenic substances 
involving the measurement of' DNA damage ( see Figure 3 • ) 
Screening tests have been developed which utilize bacteria, 
yeast and Drosophila as well as other lower orgru~isms. 
Although t hese tests have been highly successful in detecting 
agents which are mutagenic and/or carcinogenic in higher 
organisms, it is .vital to develop complementary systems for · 
detecting agents that may be mutagenic only in mammalian cells 
( Nakanishi and Schneider 1979 ). Cytogenetic methods have 
therefore come to play an important part in mutagenicity 
detection. As means to examine mutation inductivity and 
teratogenicity, these methods using chromosome abnormalities 
as an index are considered a useful screening test ( Matsushima 
et al 1981 )., 
DNA AND CHROMOSOMES 
The structure of mammalian chromatin is based upon a repeating 
unit called the nucleosome which is comprised of 200 base pairs 
of DNA coupled with one pair each of the four types of histones , 
H2, A, H2 B, H3 and H4. Some nucleosomes contain another 
histone molecule H1. The ' core ' of the nucleosome is 
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complexed with about 1L~Q highly conserved DNA base pairs 
and a ' linker' DNA segment of variable length. During 
differentiat i on or cellular specialization, some portions 
of DNA are permanently inactivated. Certain segments of 
DNA may be temporarily utilized more extensively during 
transcription. There is clearly strong biologic pressure 
for maintenance of the structural integrity of chromosomes 
in which the DNA resides ( see Figure 4. ). 
Figure 4. HYPOTHETICAL RELATICNSHIP BETWEEN DNA, NUCLEOSOMES-, 
CHRONOrlERES , G-BANDS , AND SPI".1ILIZED CHROMO~OMES . 
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At certain times in the cell cycle and during differentiation, 
structural changes in chromosomes are correlated with post-
synthetic modifications of histones, particularly 
phosphorylation of H1 and acetylation of H3 and H4, the former 
probably controls the packaging of coils of DNA during the 
cell cycle. 
In cell division ( Figure 5 • ) , the chromatin becomes 
condensed into deeply-staining rod~like structures called 
chromosomes ( chroma = stain, soma == b.ody ) which are present 
in specific numbers in each species. This process of forming 
chromosomes during division is necessary for the parcelling 
of chromatin into daughter cells. 
Figure 5. CELL DIVISION ( Shaeffer Hack and Lawce 1980) 
Prometapliase 
INTERPHASE +-PROPHASE--. METAPHASE 
ANAPHASE TELOPHASE CYTOKINESIS 
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The mitotic .chromosome as seen by the light microscope 
consists of two strands called sister chromatids which are 
held together at a light-staining region called the centromere. 
The areas above and below the centromere are called the arms 
of the chromosomes. After cell division, the chromatids are 
again referred to as chromosomes, having separated from their 
sisters during anaphase. Chromosomes come in pairs,called 
homologues, one maternal and the other paternal in orgin. 
They appear in several shapes depending on where the centromere 
is located . If the centromere is at.the end of the chromosome, 
the chromosome is called telocentric. This shape is found in 
the mouse~ the entire complement of chromo somes in mice is 
telocentric. If the centromere is just below the end of the 
chromosome, it is called acrocentric. If t he centromere is 
not located at the centre or the end of the chromosome, it is 
called submetacentric. When the centromere is directly in 
the centre of the chromosome, it is called metacentric. The 
term acentric is used for chromosomes with no centromere. 
In addition to the centromere or primary constriction, some 
chromosomes contain other regions which appear constricted and 
lightly-stained c·alled secondary constrictions. They have 
been shown to be the nucleolus organizing area of the 
chromosome. Some chromosomes have thin stalks above the 
centromere which usually ends in knobs called satellites. 
These stalks are actually secondary constrictions ( Shaeffer 
Hack and Lawce 1980 ) • 
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4.13 CHROMOSOME ABNORMALITIES AND CONGEN"ITAL l'1ALFORMN.1'IONS 
The contribution of gross chromosomal anomalies to human genet~c 
disease burden has been well documented ( Jacob 1972 ). 
Aneuploidy and structural chromosome anomalies hav.e been shown 
by various estimates and surveys to have a very significant 
impact on human feta~ wastage as we ll as on congenitally defective 
live births ( Holden 1982 ). In humans, it is estimated that 
approximate ly 50% of all conception products have 1:3. gross 
chromosome aberration ( Carr 1971 . ). Many of these are so 
severely abnormal that they fail to impl~~t and are thus lost 
without the mother realizing she was pregnant. However , the 
great majority of chromosomally defective conceptions are 
lost during pregnancy as a result of s pontaneous abortion .. 
( Carr 1967 ). Even so, a significant number of fetuses with 
chromosome abnormalities survive to term and beyond. Extensive 
surveys have set this incidence at one per 200· live births 
( Lubs and Ruddle 1970 ). All are associated with marked 
phenotypic dis abilities ranging from relatively mild in TIY, 
Down 's and Klinefelter's syndromes to severe in Pateau 's and 
Edward's syndrome ( Yunis 1974 ). 
Recongnition has recently been given to t he possibility that 
many of these alterations may be due to exposure to genetically 
active agents, and this present ptudy examines this possibility for 
DPH and its metabolic products . 
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.. 
4. 14 ANTICONVULANT DRUGS AND CHROMOSOME ABERRATIONS 
.Analysis of chromosollie aberrations has been the most commonly 
used method of detecting DNA damage in mammalian cells 
( Shaw 1 9 7 0 ) • For a diagrammatic illustration of 
the formation of chromosome aberrations see Figure 6 • 
Figure 6. THE FORMATION OF HUMAN CHROMOSOME ABERRATIONS 
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As many, if not all, chromosome breaking agents are teratogenic, 
and as these properties have been connected with each other, 
there has for some time been interest in the study of the 
cytogenetic effects of DPH ( Alving 1977 ). Conflicting 
reports about the cytogenetic effect of DPH have appeared in 
the literature and have been tabulated as follows:-








A.NTICONVULSA~{T DRUGS AND CHROMOSOM.E ABE~RATIONS 
POSI'rIVE RESULTS 
EXPERIMENTAL DETAILS 
DPH added to human· lymphocytes 
in cell culture. 
Intoxication dose of DPH. 
RESULT 
'Chromosome 
aberrations ' found. 
Exchange-type of 
abnormalities. 
Studied cultured leukocytes 'Chromosome 
from children born to epileptic aberrations' found. 
et al 1969) mothers. Results observed 
Human 
(Marquez-
probably caused by direct 
effects of the anticonvulsant 
drugs on the fetal haemato-
poietic system. 
Blood samples from users of 
anticonvulsant drugs, and 





Lymphocyte cultures of blood 
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Continued/ .. .. 
EXPERI:MENTAL DETAILS 
Human The chromosomes of epileptic 
(Neuhaliser mothers and their children were 











The authors examined bone 
marrow cells of rats treated 
with DPH. 
The chromos omes of 32 women 
suffering from epilepsy and 
treated with anticonvulsant 
drugs were examined, and those 
of their children ( aged O -
3 years) who had been exposed 
to the drugs during pregnancy. 
RESULT 
A high-level of 
chromos ome defects 
was detected in both 
cases. 
No congenital defects 
recorded. 
There was a high-
level of abnormal 
metaphases . This 
anomaly recovered 
to the normal level 
seven days after 
withdrawal of DPH. 
Chromosome aberrations 
were found. The 





correlation was found 
between the aberration 
rate of mother and 
child. No congenital 
defects obse r ved. 















AN·rICONVULS.t\.NT DRUGS AND CHROMOSOME ABERRATIONS 
~ NEGATIVE RESULTS 
EXPERIMENTAL DETAILS 
The chromosomes of lymphocytes 
taken fr9m seven patients with 
epilepsy and treated with DPTI 
were examined and found to be 
normal. 
The chromosomes of lymphocytes 
from epileptic patients 
receiving therapeutic doses of 
DPH were found to be normal. 
The authors investigated the 
chromosome breaking effects 
of various anticonvulsants 
(including DPH) in peripheral 
blood lymphocyte cultures a...~d 
found that there were no 
apparent chromosome defects 
(breaks, rearrangements, etc. ) 
produced by these drugs at 
the concentrations used (DPH 
10 to 70_rg/ml), although 
mitosis was inhibited at 
concentrations above these. 
RESULT 
There were no 
chromosome abnormaJ.j_ties 
in lymphocytes after 
in vivo exposure to 
DPH. 
The therapeutic dose 
of DPH does not cause 
chromosome abnormalities 
in lymphocyt es in vivo. 
Exposure of peripheral 
blood lymphocytes 
in vitro to DPH and 
other anticonvulsants 
did not c aus e the 
production of chromosome 
abnormalities. 
However, the authors 
make the important 
point that me tabolites 
of DPH produced in vivo 
and not in culture, may 





















The authors were unab le to confirm 
the results found by Muniz et al 
(1969) using human l ymphocytes 
with DPH added in cell culture. 
Peripheral blood l ymphocytes from 
ten patients with epilepsy and 
their bone marrow cells were 
examined for possible chromosome 
abnormalities resulting from 
in vivo treatment vii th DPH. 
RES ULT 
No chromosome 
abn ormalities were 
fou nd • 
There was no 
significant evidence 
of chromosome damage 
in either samplese 
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4.15 SISTER-CHROMATID EXCHANGE 
Sister-chromatid exhchanges ( SCEs ) have been utilized to 
detect DNA damage in eukaryotic cells ( Abe and Sasaki 1977; 
Kato 1974b; Latt 1974; Perry and Evans 1975; Popescu et al 
1977; Stetka and Wolff 1976, and Wolff et al 1977 ). 
A SCE is the cytological manifestation of an event occurring 
at the DNA level; its formation is dependent upon a four-
stranded exchange. The exchange can be observed cytologically 
in metaphase chromosomes ( Figure 7. ) following two cycles 
of DNA replication in the presence of the thymidine analogue 
5 - bromodeox-Juridine ( Br~U) ( Carrano 1980 ). 'rhese 
events were first observed by Taylor et al ( 1957) with 
tritiated thymidine labelling and autoradiography. A SCE 
is derived from the breakage and the repair of chromosome 
·fibres~ which . is now generally considered to concern the DNA 
molecule responsible for the linear continuity of the · 
chromosome ( Figure 7. ). 
Figure 7. FORMATION OF .SISTER CHROMATID EXCHANGES 
CORRECTION 
The interchange of a complete interstitial "block" of chromatid 
within a replicated chromosome requires 2, not 1, SCEs. Although 
this alters the basal level of SCEs stated and the SCE results . , 
since all treatments were analysed in the same way, the observation 
of no difference between control and treatments remains valid with 
DPH causing no increase in the number of SCEs detected. 
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These aberrations are the result of mi.srepair of DNA, the 
chromosome being considered as the visualized DNA molecule 
( Br¢gger 1979 ). The initiation of DNA damage in 
proliferating cells by a chemical agent is likely to delay 
DNA replication and may lead to post replication repair and 
possibly mutagenic errors in repair ( misrepair ). A high 
rate of cell turnover will be more susceptible to the effects 
of chemical exposure than non-dividing _tissues due to 
insufficient time for repair and a higher frequency of 
persistent DNA damage. In theory, DNA repair should impose 
a threshold on the dose-effect relationship for a g iven agent, 
that is,provide an absolute defence mechanism if all the DNA 
damage induced by that agent was repaired by an error-free 
process, but this is not the case. Therefore, the property 
of an agent to stimulate DNA repair in a test system, obser'red 
as SCE s , should be taken as an indication of its ability to 
induce DNA damage ( Lambert and Harper 1979 ). 
In mammalian cells, a SCE rate of 7 - 18 per cell seems to be 
the normal range with moderate amounts of BrdU ( Latt 1981; 
Kato 1974b; Wolff: and Perry 197L~; Wolff et al 1975; Galloway 
and Evans 1975; Latt 1974b; Latt et al '1975; Tice et al '1975, 
and Changanti et al 1974 ) • 
If SCE s are used to assess in vivo or in vitro chromosome 
damage by drugs, then information on the basal level of SCEs 
in the cells, that is, without drug treatment, must be obtained. 
The possible sources of variation due to external factors 
affecting the SCE rate would also have to be assessed . 
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4.16 BIOI_OGICAL AND PHYSICAL FACT0:1S AFFECTING THE SCE RI\.TE 
Work by Waksvik et al ( 1981 ) examined the effects of age, sex, 
and genetic factors on the SCE process as analysed by the 
occurrence of SCEs in cultured lymphocytes of human twin pairs. 
The age difference was statistically significa."TJ.t but not sex d.., fferenc.e. 
The analysis of variance did not reveal any significant 
differences in the total or within pair variance. It was 
concluded that genetic variance does not have a major influence 
on the between-subjects variation in the mean SCE value. 
However, an investigation of inherent inter-individual differences, 
which may be genetically influenced, has been performed i.n a 
study of familial patterns of SCE frequencies in complete 2-
or 3- generation family units ( Cohen 1982 ). There were 
significant differences among, but not within, families in the 
SOE rates. Therefore, a genetic contribution to the SCE 
frequency was suggested by the observed pattern of f amilial 
correlations, in contrast to the report by Waksvik et al ( 1981 ) . 
It is meaningful to refer to the differences in in vivo and 
in vitro SCE frequencies. The in vitro SOE frequency is 
generally higher than that in vivo in animals, suggesting 
that SCEs observed in vitro involve a fraction of SCEs -
induced by various physical factors such as the components 
of the media, including sera ( Kato and Sandberg 1977 ) 
and antibiotics, pH, temperature ( Kato 1980 ), light 
( Ikushima 1977 ), BrdU concentration ( Kato 1974a, and 
Tice et al 1976b ) , the change of original ·in vivo c ellular 
characteristics as well as other unknown factors ( Tsu and 
Kato 1981 ). 
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4.17 CHEMICAL MUTAGENS AND SCE FORMATION: INITIATING LESIONS 
There is no unique initiating lesion that leads to the formation 
of SCEs , rather their induction appears to arise from a wide 
spectrum of lesions , with varying efficiencies. w·ith few 
exceptions, an agent that induces mutation also induces SCEs. 
This may be due to the sensitivity of mammalian mutagenicity 
assays for detecting weak mutagens, or may indicate 
in fact, that the. lesions that form a mutation may be a subset 
of the l es ions that form SCEs ( Carrano 1981 )o . 
Although the exact mechanism of SC:S f ormation is not known, it 
is well established that the frequency of SCE is increased by 
exposure of cells in vivo and in vitro to known mutagens 
( Perry and Evans 1975; Abe and Sasaki 1977; Al len et al 1977, 
and Stetka and Wol ff 1976 ). Therefore, the SCE index has 
come into use as a sensitive means of detecting DNA damage 
and the bioassay has already been used to monitor the exposure 
of humans to potentially harmful chemicals ( Funnes - Cravioto 
1977 ) • 
4 .18 ANTICONVULSANT DRUGS AND SCE FORMATION 
Recent studies on the mutagenic potential of anticonvulsant 
drugs have centred on t he analysis of SCE frequency rates 
and have been tabulated as follow.s: 














ANTICONVULSANT DRUGS AND SCE FORMATION 
EXPERIMENTAL DETAILS 
The frequency of SCEs 
for human l ymphocyte cultures 
treated in vitro with v arious 
concentrations of DPH (10 to 
100 f-g/ml) was determined. 
The SCE frequency was 
determined f or lymphocytes 
in culture from six control 
subjects and ten patients 
undergoing monotherapy with 
DPH for an average of 
2.6 years. Serum DPH 
levels ranged from 3.8 to 
29 • 5 ./l'g/ml • 
RESULT 
Positive -
The SCE frequency 
increased with 
increasing DPH 
concentration in vitro. 
A decline in the 
mitotic index was also 
noted at higher 
concentrations. 
Negat ive -
There was no significant 
difference between the 
frequency of SCEs of 
the DPH treated ( in vivo) 
lymphocytes and controls. 
Human These experiments were Negative -
( Seshadri performed to see whether SCE Al l the infants born t o 
et al analysis of mothers and their the epileptic mothers 
1982) neonates would detect in utero were congenitally normal 
exposure of the fetus to DNA- with normal SCE rates . 
damaging agents (including 
DPH and otlier anticonvulsants). 
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4.190 THE BIOLOGICAL SIGNIFICANCE OF CHROMOSOME ABERRATIONS 
AND SCEs 
Whatever the nature of the lesions in the chromosome that 
ultimately lead to the formation of SCEs , because SOE induction 
differs in very many ways from the induction of ordinary 
chromosome aberrations , it is likely that the lesions wil l be 
quite different from those that lead to aberrations ( Wolff 1977: ) • 
SCEs for instance, are induced at high frequencies by 
concentrations of chemicals that induce very few aberrations 
( Latt 1974a; Perry and Evans 1975, and Solomon and Bowbrow 1975 ) , 
and they are not markedly increased by low doses of ionizing 
radiations, whereas aberrations are ( Perry and Evans 1975, and i,,tilff 
et al 1974 ). Cytogenetic analysis in patients following 
adriamycin treatment ( Nevstad 1978) have provided in vivo 
confirmation of the observation, first made in vitro, that 
mutagenic agents are more readily detected by SOE analysis than 
by conventional analysis ( Perry and Evans 1975 ). 
SCEs react differently to treatments with caffeine tha.n do 
chromosome aberrations ( Kato 1973, and Kihlman 1975 ), and 
they are not correlated in any consistent fashion with the 
increased ab'errations seen in human diseases; Bloom's syndrome 
( Chang anti et al 1974 ),ataxia telangiectasia ( Galloway and Evans 
1975) and Fanconi ' s anaemia ( Latt et al 1975 ), since the 
SOE levels are very high in Bloom's syndrome, normal in ataxia 
·and reportedly low in Fanconi' s anaemia. 
It therefore appears that SCEs may be the result of fundamentally 
different cellular lesions and processes from those that cause 
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chromosome aberrations ( Wolff et al 1977 ). It has been 
postulated, tha t although the majority of SCEs are probably 
genetically neutral because equal amounts of sister chromatid 
are exchanged, some unequal exchange could occur leading to 
deletion, insertion or frameshift mutation ( Wolff 1977 ). 
Nevertheless, the actual biological sign ificance of SCE remains 
obscure. 
4 .. 191 ADVANTAGES AND DISADVANTAGES OF CHROI'10SOME ABERRATION 
AND BCE ANALYSIS .TECL~TIQUES 
Biologically, aberrations are associated with cell death, 
whereas. SCEs _·do not seem to be so, thus making it likely that 
SCEs are more representative of events compatible with cell 
survival, such as mutagenesis ( Wolff 1977 ). 
The methodology for performing the SCE assay is relatively 
simple, the data quantitative and rapidly collected . 
Statistically significant results can be obt ained when only 
twenty cells are scored, as contrasted with the tedious 
lengthy scoring r ·equired to observe significant differences 
with ordinary chromo some aberrations ( Wolff and Carrano 1979 ). 
SCE is an extremely sensitive indicator of D:l'TA damage and it 
is possible to detect SCEs at far lower concentrations of 
compounds than are needed.to produce chromosome aberrations 
( Latt 1974a; Perry and Evans 1975, and Wolff 1977 ). 
However, the SCE assay may be more prone than chromosome 
aberrations to false positive results due to sensitivity 
of the actual technique to physical factors. Another 
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disadvantage lies in the technique itself: by the necessity of 
adding BrdU, in no case is the activity of the test agent alone 
measured, but always the co-activity of the test agent and BrdU. 
Theoretically, this could lead in some cases to the observation 
of a co-mutagenic rather than mutagenic activity ( Gebhart 1981 ). 
False negative results may also be apparent with the SCE assay 
since it is thought that the SCEs may reflect only a very small 
proportion of the DNA damage that has occurred after the exposure 
to a DNA damaging agent ( Latt et al 1981 ). 
SCE analysis is a method which allows a sensitive investigation 
of part of the spectrum of activity on DNA by mutagens ( Gebhart 
1981 ), although as described, there are some serious arguments 
against a general appl ication of this method for the screening 
of mutagens . 
4.19 .2 1.,ffiICH TECHNIQUE SHOULD BE USED TO INVESTIGATE POSSIBLE 
DPH MUTAGENICITY ? 
Several investigators tended to replace the ' painful 'classical 
cytogenetic analysis of mutagen treated cells with the simple 
i 
SCE test. The fact that the molecular mechanisms of SCE 
formation were , and are even now, large ly unknown, was apparently 
not considered as too disturbing. Not enough attention was 
paid to the fact that most of the steadily increasing number 
of agents contributing to the high correlation observed between 
break and SCE induction have the same mechanism of action 
( i.e. alkylation ) , thus rendering a high similarity of their 
cytogenetic effect s fairly probable. Chemicals which react 
with many different sites on DNA structure and/or metabolism, 
could probably induce both chromosome aberrations and SCEs , 
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whilst agents with a small and sometimes highly specific 
spectrum of activity may induce one or the other ( Gebhart 1981 ). 
It has been suggested that the SCE technique should be considered 
as a valuable additional method for cytogenetic mutagenicity 
testing, which however :is ~not adequate to replace the classical 
methods of analysis of structural chromosome damage ( Gebhart 
1981 ). 
4.2 DErECTION OF THE' SECONDARY EVENT 'OF REDUCED 
BIOSYNTHESIS: DNA SYNTHESIS 
The amount of DNA sythesized by a proliferating cell can be 
assessed by measuring the amount of a radioactive precursor 
incorporated into DNA. 3H- thymidine incorporation into DNA 
would thus be a measure of the amount of newly synthesized DNA 
and can be assessed by liquid scintillation counting, the 
results ofwhich c an be expressed as disintegrations per minute 
( dpm) of the incorporated radioactivity. 
It has been shown that O. 2 rM/ml concentration of DPH in the 
culture medium of whole mouse embryos caused a significant 
reduction in DNA synthesis ( Beyers 1981, MSc Med Thesis, UCT ). 
Resear,ch_ by Hassel in 1980 showed that DPR applied for two days 
to cultured human fibroblasts at concentrations of up to 5.14g/ml 
did not appear to affect protein, coll agen , or DNA synthesis 
in normal fibrob l asts . However, cells obtained from DPH -
enlarged g ingiva contained higher quantities of DNA , incorpor~ted 
3H- leucine into protein more rapidly, and produced a higher 
percent of collagen. At concentrations of 10 )'-g/ml or greater, 
DPH inhibited cell growth and synthesis of protein. 
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4. 21 DETECTION OF THE EFFECTS ON CELLULAR DEVELOPMENT 
Much work in this area has been concerned with the direct 
observation of the whole embryo or animal embryonic tissue 
using the light microscope or scanning and transmission 
electron microscopy ( Sulik et al 1980 ), or with the examination 
of post mortum material by histological techniques, 
( Livingston 1957; Utterback" 1958, and Kokenge et al 1965 ) . 
The effects on cell development included, 1) increased 
or decreased cell proliferation (mitosis), 2) reduction 
in cell size, and 3) changes in cell morphology with effects 
on cell migration and differentiation. 
Embryonic cells that undergo differentiation in culture 
have also proved an appropriate system for detecting 
teratogenic activity ( Wilk et al 1980 ). _ Alterations in growth 
or differentiation of the teratogen-treated chick limb 
mesenchyme cells and neural crest cells included detachment 
of the cells from the substratum, decre ased cell proliferation 
and changes in cell morphology with failure to develop into 
the expected phenotype. 
These alterations of cell growth in cultur~ are thought to be 
similar to those effects on cell development already mentioned(see 
3.2) and it is thought that similar events can cause 
abnormalities in the fetus exposed to teratogens ( Wilson 1977 ). 
Teratogens acting through the se mechanisms would be de·tected 
in cell culture and this system might al.so be effective for 
screening teratogens that interfere with interactions between 
cells and matrix, and with migration ( Wilk 1980 ). Using 
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this cell culture testing model, Wilk (1980) observed that 
DPH at 50 µg/ml caused 25% chick neural crest detachment 
when compared with controls, and als o caused a large reduction 
in limb bud mesenchyme cell differentiation which was less severe 
when DPH was incubated with the S-9 mixture required for 
metabolic activation, indicating that perhaps the parent compound 
caused most teratogenicity. 
4 . 3 SUM:MARY 
Methods for detecting potentially mutagenic substances usually 
involve measurement of DNA damage. As lower organisms are 
usually used in mutagenicity tests (viz. bacteria etc.), there 
needs to be developed systems which detect mutagens which are 
mutagenic and consequently teratogenic to mammals only. Cyto-
_genetic studies using mammalian cells would seem appropriate . 
Chromosomes are the highly organised structures in which DNA 
resides and can be examined microscopically during the metaphase 
of cell division. There is a huge contribution of gross chromo-
somal anomalies ~o fetal wastage and congenital defects which 
may be due to in utero exposure to genetically active agents . 
Chromosomal defects which can be detected by light microscopy 
includes gross chromosomal aberrations (dicentrics, acentrics, 
breaks, deletions, inversions and ring chromosomes) and sister 
chromatid exchanges (SCEs). 
The mutagenic effect of DPH on human chromosomes has been 
studied and conflicting reports ensued . In vivo studies have 
shown positive results with regard to the examination of leuko-
cytes taken from the children of epileptic mothers who had 
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been administered DPH during their pregnancies. No increase 
in the incidence of congenital defects was observed. The 
mothers also displayed chromosomal aberrations including exchange-
type defects and a high incidence of tetraploidy was found to 
occur, On the other hand, investigators have shown no chromo-
some aberrations to bccur in the leukocytes or bone marrow cells 
of epileptic patients treated with DPH in vivo . However, rat 
bone marrow cell analysis has shown a high level of abnormal 
metaphases due to in vivo exposure to DPH with recovery on 
withdrawal of the drug. In vitro exposure of human leukocyte 
cultures resulted in exchange-type chromosome aberrations in one 
instance but negative results in anothe~ which may be due to 
the lack of; metabolic activators in the medium during cell 
culture,or prior metabolic activation of the drug. 
The ability of an agent to cause DNA damage and stimulate repair 
in a test system has been estimated with the investigation of 
SCEs (the result of mi~repair). In mammalian cells, the normal 
basal SCE rate is 7-18 per cell with variation due to external 
physical factors during cell culture having some effect, giving 
a generally higher rate for in vitro exposure in comparison 
with in vivo drug exposure . With few exceptions, an agent 
that induces a mutation also induces SCEs although the exact 
mechanism is unknown . The technique would provide a sensitive 
means of detecting DNA damage with low drug concentrations and 
only 20 cells needs to be scored per treatment in order to obtain 
statistically significant results. 
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The in vitro exposure of human lymphocytes to DPH has been 
found to result in an increased SCE rate and a decrease in 
the mitotic index however, the examination of the leukocytes 
from epileptic mothers and their children exposed to DPH 
in vivo has shown no increase in the frequency of SCEs from 
normal and there w~s no increase in the incidence of congenital 
malformations. If DPH acts on many different sites of DNA 
structure, it could possibly induce both chromosome aberrations 
and SCEs which probably result from fundamentally different 
processes. If there is highly specific activity, the agent 
may induce only one or the other and so an examination of both 
is necessary. Mutagenic agents are thought to be more readily 
detected by SCE analysis than by conventional chromos ome 
analysis which tends to lead to cell death whilst SCEs are 
compatable with cell survival. 
Detection of reduced biosynthesis (DNA) has been made possible 
by measuring the amount of DNA precursor (3H-Thymidine) incor-
porated into DNA. DPH has been shown to cause a significantly 
decreased rate of DNA synthesis in whole mouse embryos exposed 
to DPH in vitro. In humans with enlarged gingiva, DPH has been 
shown to cause a decreased rate of DNA synthesis and conse-
quently reduced protein synthesis and cell growth, although 
the drug has been shown not to affec t the DNA synthesis rates 
of human fibroblasts in cell culture. 
Examination of DPH affects on whole embryos, embryonic tissue 
and post mortem material has shown changes from normal in the 
cell proliferation rates, size, morphology and differentiation. 
Embryonic cells undergo ing differentiation in culture, such as 
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chick limb mesenchyme cells and chick neural crest cells has 
led to cell detachment and al l of the other changes mentioned 
above which could eventually lead to congenital malformations . 
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CHAPrER 5. 
THE MONITOR.ING OF CONGENITAL ABNORMALI'rIES 
TERATOGENICITY TESTING AND SCRSEJ\TING MErHODS : 
HUMAN STUDIES 
The use of pregnant women to test agents directly for 
teratogenicity is fraught with moral and ethical implications 
that make such studies impossible to perform ( Chenoff and 
Lyons Jones 1981 ). The study of prenatal losses however 
may provide a sensitive index of the response to a teratogenic 
agent ( Shepard 1979 ). The 3% of neonates with congenital 
defects represents only the tip of the iceberg when compared 
to the total number of embryonic/fetal los ses. By studying 
embryos and fetuses from spontaneous abortions in the first 
trimester, an earlier indication of the trouble might be noted, 
which could provide epidemiologic information some six months 
before a teratogenic effect would otherwise be'detected in 
newborns. Another advantage of this early monitoring is a 
short period from the teratogenic exposure to the interview 
and examination of the mother. This could be less than a 
week as compared to the seven to eight month interval when the 
history is taken from the mother of a neonate. There may 
however be some difficulties in obtaining an unbiased account 
of the case history. 
Monitoring facilities for defects in neonates exist in many 
countries but these facilities probably fail to detect minor 
chane;es in bl:'.ain function or long-term carc.inogenesis. 
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Generally, only easily recognized physical defects are recorded; 
the larger portion of congenital disease ( 60% ) is identified 
after the newborn period and so is not included, als o artifacts 
may be associated with data collection. However~ ·. a continuous 
recording and registry of congenital defects could perhaps 
provide an important warning of teratogenic action by a new 
drug ( Shepard 1979 ). 
The majority of attempts to identify teratogens in human beings 
have however been retrospective epidemiologic studies on the 
malformed chi ld which has very serious flaws when applied to 
teratogen identification. For example, it seems to concentrat e 
on the easily recognizable malformations, whilst the patterns of 
less obvious malformations may never be identified. These 
studies also rely heavily on maternal history which may have 
been inaccurate. While epidemiologic studies have been 
successful in identifying ' epidemics ' of particular major 
malformations, such as limb reductions, . they generally ( an 
exception is thalidomide) have not been successful in 
identifying any probable cause for these' epidemics ' 
( Chernoff and Lyons Jones 1981 ). 
The monitoring of human populations is a retrospective study 
the damage has been done. The most important thing would 
be to prevent a drug from ever being allowed to be administered 
to the pregnant woman ( except in extreme exigency) and 
causing damage to the unborn child. Therefore, teratogenicity 
testing should be the first step in the line of defence and 
monitoring the second ( Shepard 1979 ). 
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In contrast to human population studies, inwhich extremely 
large numbers of pregnancies must be analysed to provide 
statistically significant data relative to the teratogenicity 
of a drug , appropriate animal model systems which approximate 
the human situation can readily provide v aluable information. 
Unlike human studies, variables can be well controlled and 
the effects of the drug more easily delineated (Sulik . 
et al 1980 ) • 
5-12 TERATOGENICITY TESTING AND SCREENING T1ETHODS: 
ANIMAL STUDIES 
The U.S. Pharmaceutical Manufacturers Association established 
in 1962 founded a Subcommittee on Teratology which was involved 
in activities which culminated in the publication in 1966 of 
" The Guidelines for Safety Evaluation of Drugs for Human Use 11 , 
more familiarly referred to a the II FDA Guidelines of 1966 "• 
Modest extensions and changes have been made , but still the 
FDA guidelines of 1966 r emain as the prototype for teratological 
testing procedures ( Wilson 1979a). 
The standard teratogenicity testing in pregnant laboratory 
animals was created only after the devastating effects of 
thalidomide in the early 1960's ( Shepard 1979 ). The FDA 
instituted legislation which required t hat no drug for human 
consumption,which may be administered to pregnant women,will 
be released for sale without first having been tested in at 
least three non-human animal species, that is, at least two 
rodents and one other of the dog, rabbit, o.r cat ( Wilson 1979a ). 
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Recommendations given for testing drugs during the reproductive 
cycle of animals . were the conventional six week chronic 
toxicity tests in male and female animals; these were followed 
over two pregnancies, and fetal survival was the main parameter 
measured in this so-called 'litter - test 1 ( Schardein 1976 ). 
However, this test was criticized since the test could keep 
valuable and teratogenically innocuous compounds ( in humans) 
off the market while permitting teratogens to reach the public 
( Wilson 1979 ). 
Besides being time consuming, inefficient and costly, animal 
studies give no guarantee that a given agent, tested in the 
legal minimum of animals and found free of side effects, will 
be equally innocuous in humans. Although animal studies have 
played a major role in elucidating the principles and 
mechanisms of teratogenesis, they have not been successful 
in identifying human teratogens ( Chernoff and Lyons Jones 1981 ). 
The reason for this failure can be found in the principle of 
teratology that states that susceptibility to teratogens depends 
on the genotype ( strain and species) of the conceptus 
( ·\.iilson 1973 ) • Therefore, an important question arises as 
to which species should be used for these tests. 
While the only true model for human DPH - induced teratology 
is clearly the human, other animal species, particularly the 
mouse may be valuable for investigating the teratogenic effects 
of DPH and elucidating the possible mechanisms involved. 
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5. 2 THE FET AL HYDANTOIN SYNDROME I N THE MOUSE 
A valid animal model of the Fetal Hydantoin Syndrome ( FHS) 
has been developed called the II Quaker w mouse model ( Finnel 
1977 ). Mouse neurological mutant quaking is a mouse strain 
predisposed to spontaneous seizures. The model was designed 
• 
to assess the overall teratogenicity of DPH, with the resulting 
malformations duplic ating many of the fe atures of the FHS as 
it appears in man. It helps to confirm the aetiologic role of 
DPH rather than maternal seizure s as a cause of congenital 
malformations and shows that mice are susceptible to its 
teratogenic effects. DPH is also clearly teratogenic both in 
A/Jax mice, a strain spontaneously susceptible to fetal anomalies 
( Massey 1966) and in Swiss-Webster mice ( Harbison and 
Becker 1969 ). This illustrates the important point that 
experimental results in the mouse may have validity when 
extrapolated to man~ perhaps even more so than the much 
more costly and elaborate methods using subhuman primates, 
since in the monkey only slight teratogenic effects of DPH 
have been observed ( Nakan. 1980 ) • 
5.31 IN VIVO ANIMAL TERATOGENICITY TESTING ADVANT AGES AND 
DISADVANT AGES 
In vivo teratogenicity testing in.._trinsically allows for the 
activation of those drugs which cause their effects by a 
product of their metabolism and also allows for all other 
factors which may affect the actual dose of the agent, including 
maternal metabolism and placental barriers. However, an 
inherent problem of animal in vivo testing of teratogenic agents 
on the pregnant female and the later examination of the fetus 
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for possible pathological effects is that there is little 
control over what precise form the applied drug is being 
presented to the fetus, and in what concentration it is being 
delivered. The pharmacok~netics of the experiment cannot 
be fully defined and the pharmacodynamics of a teratological 
effect are also difficult to establish ( Williams 1982 ). 
Futhermore, these experiments are time consuming and expensive 
since currently approved tests on drugs for possible teratogenic 
effects on the human fetus generally include the examination 
! 
for m9rphopathology and for histopathology of a large number of 
rodent fetuses, at various ages, obtained from pregnant females 
injected or fed with the substance in question, at different 
stages of pregnancy and at different dose levels ( Williams j982 ). 
IN VITRO ANIMAL TERATOGENICITY TESTING: ADVANTAGES AND 
DISADVANTAGES 
The use of in vitro methods and organ culture techniques using 
differentiating embryonic tissues in particular, allows for 
the investigation of the embryotoxic potential of an agent while 
excludi~g the complicating pharmacokinetic factors. It makes 
possible the study of the direct effect of the original agent 
or its defined metabolites on the developing and differentiating 
system ( Barrach 1978 ). 
Whole explanted embryos, organs or their parts in culture require 
many growth measurements, histological and biochemical 
investigations which are time consuming. Cell culture-based 
assays however, can assess the effect of a teratogenic substance 
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on differentiation 1n a relatively short time. Cell cultures 
are generally more homogeneous and so can be exposed to the 
pos s ible tera togenic agent in a more controlled fashion. 
These cultures are also more suited to biochemical and 
·chromosomal assays, although cell-cell recognition properties . 
histiotypic assembly and cell replication may also be me asured 
accurately. Using ultrastructure techniques, neurotoxic 
effects may also be studied by assessing the effect of a 
suspected substance on neural outgrowths and synaptic 
connections ( Clayton and Zehir 1982 ). The confounding 
factors of maternal, nutritional and hormonal considerations 
are excluded. The exact drug concentration and time of 
exposure and the developmental stage _can be defined. In 
addition, cell cultures are relatively inexpensive and simple 
to maintain. 
A serious limitation of in vitro techniques is that the drug 
concentration in the culture dish derived directly from the dose 
per body weight of the mother does not allow for the effects 
of maternal - fetal partition or for rapid elimination by the 
mother, which would reduce fetal dose. The more serious 
problem of whether the drug exerts its teratogenic effect 
directly or through a toxic or persistent metabolite can 
be approached by culturing in the presence of an activating 
system which is capable of the biotransformation of the 
drug ( Ames et al 1975 ) . There is much support for the 
idea that in vitro testing should play a more important role , 
along with in vivo €><.periments, in the campaign against 
teratogenic agents ( Barrach 1978 , and Shepard 1979 ). 
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Recently, the preparation and properties of whole liver cell 
cultures have been reported, both as isolated hepatocytes and 
as cultures of liver slices ( Liddiard et al 1978 ). Their 
advantages over microsomal preparations include a long life-
span, an independence of cofactors and the retention f !:tie 
total cellular metabolism of the drug. However, it has 
not been possible to decide which of the in vitro methods 
is most appropriate for purposes of prediction of teratogenicity 
( Merker 1978 ). In the present study, rat liver micro s omal 
fractions were used because they were prepared elsewhere and 
kindly made available to the authoro 
were not available. 
! 
Other preparations 
Much valuable information about human fetal drug metabolism 
has been gained by using human fetal liver for metabolic 
activation ( Nau and Neubert 1978 ), since the human embryonic liver 
c.an metabolize a wide variety of xenobiotic substances as 
early in gestation as during the period of late organogenesis . 
The use of human fetal liver tissue would allow much better 
extrapolation of results to the human situation than is 
possible with rat liver tissue. 
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5.4 METABOLIC ACTIVATION: LIVER P~EPARATIONS 
Numerous teratogenic agents may require metabolic activation 
before their effect s may be manifest. In contrast to the 
in vivo system, activation products cannot be formed by 
embryonic tissue in vitro ( Kittel et al 1978 ) . Therefore, for 
the assessment of indirect teratogens with mammalian cell 
cultures, several eArperimental systems have been developed. 
The incubation of chemicals with liver microsomes allows for 
metabolic activation ( Uehleke 1973 ). Liver microsomes 
can be obtained using the r e latively convenient and simple 
method of Ames et al 1975. The incubation of DPH with rat 
liver 9,000 X g supernatant and with rat liver microsomes 
has demonstrated that NADPH - dependent mixed function oxidases 
are involved i n the production of p-HPPH ( Kutt and Verebely 1970? 
and kutt and Fouts 1971 ) the major metabolite in the rat ( Chang and 
Glazko 1972). Hepatic micro soma-1- enzymes ··are _probably 
involved in the conversion of DPH to the DHD metabolite ( Lu 
et al 1.977 ) and hep atic soluble enzymes are likely to be 
responsible for the conversion of the DHD metabolite to 
catechol ( Jerina et al 1970a ). 
The disadvantages of this cell-free method include the changes 
in the organelles during preparation, the absence of influences 
caused by other organelles such as mitochondria, the changes 
in the level of cofRctors and the inevitable neglect of 
permeability factors and metabolic processes taking place 
in other cellular components. 
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5.5'1 CELL CULTURE AND I N VITRO TERATOGENICITY TEST ING 
Ideally, the study of the effect of a possible teratogenic 
agent should be performed on differentiating embryonic cells. 
:Mouse limb buds in organ culture have already been tested as 
indicator organs for identifying teratogenic compounds 
( Kochhar '1975 ). The potential of this system was extended 
to the us e of chick limb mesenchyme cells and neural crest 
cells ( Wilk et al '1980; Section 4.2'1 ), where the teratogenic 
effect was judged by alterations in cell morphology. 
The rapid teratogen screening method of cell culturing may not 
detect biochemical changes that occur in the absence of 
morphological alterations, although these cell cultures would 
allow easy applic ation of techniques for biochemical 
investigations such as the analysis of the rate of DNA synthesis 
in control and treated ( drug present) cultures. Therefore, 
this syst em would be sensitive to teratogens that specifically 
alter tis sue development and to agents that inhibit overall 
growth processes. Another dis advant ag e of this in vitro 
animal model is that the differentiating cells have to be 
excised from the developing chick embryo at particular stages 
of early development, depending on which stage of differentiation 
is to be studied in vitro ( Wilk et al '1980 ). 
Differentiating cells in culture can therefore provide a rapid 
means of identifying potential teratogens and as such should 
be be a practical adjunct to animal testing. 
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The in vitro model of differentiating cells in culture would 
lend itself well to the application of cytogenetic techniques 
and the investigation of mutagenic effectse Cells to be used 
for cytogenetic testing should possess the following qualities; 
1) long-term monolayer cell lines that are not fastidious in 
growth requirements or handling, 2) short cell cycle for easy 
propagation with high mitotic rate, and 3) favourable chromosome 
characteristics including low diploid number. 
Several murine embryonal carcinoma cell lines seem very similar 
to early embryonal cells by having the capacity to differentiate 
in vitro into some derivatives of the three primary germ cell 
layers ( Martin 1975 ), and for these reasons such cell lines 
may be of· value in studying the teratogenicity of potentially 
embryotoxic agents. These cells are also suitable for 
cytogenetic analysis since they possess all of the desired 
qualities mentioned above. One of these cell lines, PC13, 
was used in this investigation as the in vitro animal model. 
5.52 NORMAL EMBRYONIC CELLS AND EMBRYONAL CARCINOMA CELLS 
It is clear that numerous similarities exist between the cells 
of the early embryo and embryonal carcinoma cells 
or the stem cells of a teratocarcinoma ( Martin 1975 ). 
Pluripotency, or the ability to proliferate in the undifferentiated 
state and to give rise to differentiated somatic cell types, is 
displayed by both cell types. Differentiation of the embryonal 
carcinoma cells occurs by a process similar to normal 
embryogenesis. The fact that endoderm is the first differentiated 
cell type formed by embryonal carcinoma cells in vit r o suggests 
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that on a functional level, all embryonal carcinoma cells 
resemble the cells of the inner cell mass of the four day· 
embryo. 
Ultrastructurally, they both have the morphology of the 
undifferentiated cell type. They share biochemical properties 
such as alkaline phosphatase activity, which is present at 
high levels. The two cell types have at least one specific 
surface antigen in common, which has so far not been found 
in any other cell type except sperm ( Martin 1975 ). 
Murine PC13 embryonal carcinoma stem cells or EC cells were used 
in this investigation and therefore the problem r emains of 
extrapolation of results of any teratogenicity to the human 
situation. 
' 
5•61 MORPHOLOGICAL CHARACTERISTICS OF THE UNDIFFERENTIATED 
PC13 EMBRYONAL CARCINOMA CELLS 
PC13 EC cells are small, Epithelial-like cells that have 
indistinct cell boundaries and their nucleocytoplasmic ratio 
is high ( Nicholas et al 1976 ). Their cytoplasm as seen by 
electron microscopy contains few organelles, some .mitochondria, 
a large number of free ribosomes, little endoplasmic reticulu~, 
and the occasional Golgi complex. The characteristic . ·paucity 
of organelles is a characteristic of most EC stem cells 
( ~e Chalain and Falb 1981 ). 
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5.62 THE ORIGIN OF PC13 EMBRYONAL CARCINOMA CELLS 
PC13 is one of a number of clones isolated. from a tumour 
OTT6050 by Stevens in 1957 and originated from the grafting 
of a six day old male embryo ( strain 129/S.1. C ~) to a host 
(A/Hex 129 - SL Cf) F1 hybrid adult . testis in 1967. The 
stem cells have since been maintained intraperitoneally in 
the 129/ Sv strain of mice by the serial transfer of ascitic 
fluid ( Bernstine et al 1973 ). 
Tumours of the OTT6050 A teratoma contain predominantly nervous 
tissue, although other types of differentiated cells have been 
observed. The OTT6050 B teratoma initially contained cells 
able to differentiate into many cell types, it was pluripotent 
and perhaps totipotent. The PC13 cell line is from this 
teratoma and these stem cells are thought to be mainly neuronal 
in nature ( Stevens 1981, personal communication). This 
cell line was supplied to the University of Cape Town ( Dept., 
of Pharmacology) in 1981 by Professor Fabian(University of the 
Wi tswatersrru1d). 
THE DIFFERENTIATION OF EMBRYONAL CARCINOMA CELLS IN 
CULTURE 
In culture it is possible to grow EC cells in relatively large 
numbers and this .. ' controll ed environment allows the cells to 
be subjected readily to various biological and biochemical 
manipulations . It appears that cultured EC cells are highly 
stable with regard to the retention of developmental 
potentialities even after months of rapid proliferation in 
an undifferentiated state ( Finch and Ephrussi 1967 ). 
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O:::casionally , cell lines maintained in culture often undergo 
phenotypic and genotypic ch?D-ges with the cons equence that 
eventually the cells bear little resemblance to the starting 
population ( Nicholas 1976 ). This phenomenom will be 
assessed for PC13 stem cells. 
The discovery of physical and chemical means to induce specific 
differentiation in EC _stem cell cultures and the characterization 
of the differentiated progeny has established the relevance of 
this system to normal development ( Strickl.and 1981 ) , and 
suggested that this in vitro model represents useful material 
for the study of teratogenic agents which affect differentiating 
cells. The process of cell determination, that is, the process 
by which a pluripotent cell becomes restricted in its possib.le 
determination may also be studied ( Martin and Evans 1974 ). 
5. 72 DIFFERENTIATION INDUCTION 
Aggregation was first used by Martin and Evans ( 1974) to induce 
differentiation of EC cells in culture. It is also possible to 
induce EC cells to differentiate by low density plating ( Burket 
al 1978, Pfe:i,ffer et al 1981 , Speers 1979, and Ilgren and 
Littlefield 1981 ). 
Hexamethylene bisacetamide treatme1:1t of ·an EC cell line resulted 
in the formation of differentiated cells with epithelial or 
fibroblast morphologies depending on whether or not the cells 
are aggregated during drug treatment ( Speers et al 1979 ). 
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It was established in 1925 ( Wolbach and Howe), that vitamin A 
compounds could influence differentiation and retinoic acid a 
vitamin A analogue induces differentiation of EC cells in culture 
( Strickland and Madhavi 1978 ). The effects of retinoic 
acid reported by Hogan et al ( 1981 ), are also dependent on 
cell aggregation. The effects of cell aggregation may result 
from inside - outside interactions similar to those hyp.othesized 
in other mammalian developmental processes ( Herbert and 
Graham 1974 ). 
Efforts must be made to solve the problem of achieving 
unidirectional differentiation with cultures yielding largely 
or exclusively one cell type inorder that cytogeneti c or 
biochemical analysis may be made on a differentiating homogeneous 
cell population ( Mintz and Fleischman 1981 ). Conditions must 
be defined in which a certain type of differentiation occurs 
preferentially ( Andrews et al 1982.). 
The present study involved the differentiation of the PC 13 EC 
cell line, a cloned cell line which can differentiate readily 
in vivo but requires the presence of retinoic acid for in vitro 
differentiation. The study by Strickland and Madhavi in 1978 
showed that retinoic acid is increasingly effective as the 




THE MECHANISM OF RETINOIC ACID INDUCTION OF CELL 
DIFFERENTIAT ION 
The structural requirements for the effect of retinoic acid 
are stringent ( Strickland and Mahdavi 1978 ). The carboxylic 
acid group is essential for activity as an inducer of 
differentiation. The structure can be modified in the 
cyclohexenyl ring system with retention of effectiveness. 
Figure 8 • THE ST;tUCTUR:S OF :EE'TIIK·IC ACID 
COCH 
' 
The intracellular consequences of retinoic acid treatment may 
be similar to t~e normal developmental signals which initiate 
differentiation ( Jones-Villeneuve 1982 ). The process of 
normal cell differentiation involves selective transcription 
of different regions of the DNA to produce the messengers for 
the protein characteristics of the different cell types. 
Developmental processes require a succession of activity and 
inactivity of groups of genes. It is thought that binding 
proteins, similar to steroid hormones, may mediate the action 
of retinoic acid and that the effect is probably on the process 
of gene activation or ina.ctivation which controls cell 
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differentiation by affecting cytoplasmic as well as cell 
surface components ( Linder et al 1981 ). The biochemical 
mechanism of retinoic acid action however., is not. yet 
understood ( Strickland and Madhavi 1978). 
The stimulus to differentiate appears to be indiscriminate: 
retinoic acid promotes whatever development the cells are 
capable of but does not influence the direction of differentiation 
( Mintz and Fleischman 1981 ). The time-course of the response 
by the cells shows that the amount of diff~rentiation is 
proportional to the duration of treatment and suggests that 
retinoic acid facilitates formation of the differentiating cell 
type at each division. The continued presence of retinoic 
acid is not required for maintenance of the differentiated 
state and so is thought to act as a' trigger' ( Strickland 
and Sawey 1980 ). The retinoic acid induced effects on F9 EC 
cell growth do not occur immediately but seem to manifest 
themselves afer a lag period of some twenty four hours(Linderetal1981) 
·s. 73. 1 THE EFFECTS OF RETINOIC ACID ON CELL PROLIFERATION 
Time - lapse cinematography has clearly shown that F9 EC cells 
with retinoic acid induced morphology continue to divide but 
that the rate of multiplication was considerably slower than 
that of untreated EC cells ( Linder et al 1981 ). The number 
of cells grown in the presence of retinoic acid ( 10-6 to 10-8 M) 
has been shown to be similar to that of the control cells up to 
day two in culture. However, longer exposure to retinoic acid 
resulted in growth inhibition with increased time, thus, 
inhibition of cell growth occurred only after the cells were 
exposed to retinoic acid for more than two days ( Ogiso et al 1982 ). 
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Differentiation of F9 EC cells induced by retinoic acid has 
caused a reduction in DNA synthesis levels as is·evident from 
~ 
the measurement of the rate of /H-thymidine incorporation into 
cells. No decrease was observed during the first twenty four 
hours, but with futher culture,incorporation decreased. 
Futhermore, growth cultures revealed a slowing of the rate of 
cell proliferation ( Linder et al 1981 ). The effects of 
retinoic acid on cell proliferation and rate of DNA synthesis 
would need to be established for PC13 EC cells used in this 
study and distinguished from those effects_. caused by exposure 
to DPH. 
THE EFFECTS OF RETINOIC ACID ON THE SCE RATE 
Retinoic acid has been found to neither induce an incre as e of 
SCEs nor cell cycle delay in Chinese hamster V79 cells with 
or without the metabolic activation using a S-9 mixture. 
However, it inhibited SCE increases and cell cycle delay in 
V79 cells induced by the indirect mutagen cyclophoshamide or 
aflatoxin B1. The inhibition was found to be dose and time 
dependent. These results suggest that retinal itself may 
have no direct effect on the genetic materials but rather 
exert its effects possibly by inhibiting the metabolic activation 
of an indirect mutagen or carcinogen ( Huang et al 1982 ). 
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5. 74 INDUCED DIFFERENTIATION AND CELL' TYPES 
When retinoic acid was applied to cell lines with very little 
capacity to differentiate, for example F9, endoderm-like 
development occurred with associated biochemical changes 
( Strickland and Madhavi 1978 ), and this has been seen to 
occur in the PC13 EC cell line ( Adamson et al 1979 ). 
This first cell type to differentiate from aggregated EC cells 
in culture resembles the endoderm cell layers which develop 
from the inner cell mass in the intact embryo and may contain 
a mixture of parietal and visceral endoderm-like cells 
( Adamson et al 1979 ). Since the normal embryonic equivalent 
of these cells is unknown, they are called END cells. They 
have also been referred to as' giant 'because of their large 
size ( Ilgren and Littlefield 1981, and Lo and Guila 1980 )~ 
The term END or endoderm-like was used primarily for 
morphological distinction, but also based on biochemical 
criteria such as the production of plasminogen activator, a 
marker enzyme of parietal endoderm ( Speers 1979 ). The 
END cells sometimes display II stress fibres 11 ( .Lo and Guila 1980) 
and numerous II thread-l ike extensions 11 ( Linder et al 1981 ) • 
Retinoic acid at 10-6 Mand low density plating ( 105 
cells in a 25 cm2 gelatin-coated tissue culture flask) caused 
large flat END cells to appear after juBt three days exposure. 
Binucleate endoderm-like' giant' cells are occasionally found 
in retinoic acid treated PC13 E'C cell cultures ( Ilgren and 
Littlefield 1981 ). 'Big flat cells' were also observed with 
low cell density plating of EC cells by Papaioannou et al ( 197_9. ) • 
' 
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Retinoic acid induced the differentiation of EC cells into 
a restricted spectrum of tissue t:ypes, namely, fibroblast-
like cells, glial cells and neurones ( Speers ·et al 1979 and 
' 
Jones-Villeneuve 1982 ). Glial cells and neurone-like cells 
have been observed in retinoic acid treated cultures of the 
EC cell line . P19, which does not differentiate into neurones 
in the absence of the drug. The morphology of these glial 
and neurone-like cells was also strikingly similar to the 
morphologies of cells in cultures of central nervous system 
and peripheral nervous system tissues ( Jones-Villeneuve 1982 ). 
! 
It is well known that repeated transplantation can result in 
tumours that either do not differentiate at all and consists of 
EC cells ( multipotential) or form predominantly neural tissue 
from EC cells and are called neuroteratomas ( Stevens 1970, and 
Bernstine et al 1973 ), and this latter phenomenom may be the 
case for PC13 EC stem cells in culture upon stimulation of 
differentiation by retinoic acid. 
BIOCHEMICAL MARKERS OF DIFFERENTIATION 
A number of embryonic activities known to vary during embryonic 
development have been studied as biochemical markers. High 
alkaline phosphatase activity has been associated with EC cells 
but during differentiation it disappears very quickly and low 
levels of alkaline phosphatase have been shown to be properties 
of parietal endoderm. Other properties include the secretion 
of plasminogen activator and type IV collagen, and low levels 
of lactate dehydrogenase ( Strickland et al 1980 ). 
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5.81 CYTOGENETIC CHARACTERISTICS OF EMBRYONAL CARCINOMA 
CELLS: UNDIFFERENTIATED CELL TYPE 
There is evidence that teratocarcinomas at their inception tend 
to be chromosomally normal. It is particularly impressive that 
although chromosomal changes, including Y chromosome loss from 
X/Y lines may occur in these tumours, transplant lines have 
retained euploidy for very long periods ( Mintz and 
Fleischman 1981 ). The basis for the exceptional karyotypic 
stability in teratocarcinoma cell in vivo remains unknown. 
It may be that in the teratocarcinoma transplant lines there 
is relatively little selective pressure favouring more rapidly 
proliferating variant cells ( likely to be increasingly aneuploid) 
because a large percentage of the cells, when serially 
transferred in the host, are differentiating and are declining 
in mitotic activity during this limited period of residence 
of usually three to four weeks . The pool of dividing stem 
cells thus remains fairly small ( Mintz and Fleischman 1981 ) o 
There is a large body of evidence indicating that cbromosom.al 
abnormalities in mammals result in failure or impairment of 
development. Therefore, in considering any teratocarcinoma 
cell line as a possible candidate as a differentiating 
"embryonic II model in teratogenicity testing and chromosome 
analysis, it is necessary to ascertain _its karyotype before 
treatment application ( Cronmiller and Mintz 1978 ). 
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Developmental pluripotency is accompanied by karyotypic 
normalcy or near-normalcy whilst aneuploidy has not yet 
given evidence of totipotency ( Cronmiller and Mintz 1978 ). 
Karyotypic normalcy may therefore have predictive value for 
choosing teratocarcinoma lines with relatively high developmental 
prospects. However, slight deviations from euploidy need not 
impair the developmental potential ( Cronmiller and Mintz 1978 ). 
Guenet et al ( 1974) found normal or near normal karyotypes 
in their pluripotent EC cell lines but found many chromosomal 
anomalies in the F9 karyotype ~ these cells are no longer 
pluripotent. Although an abnormal ·karyotype is not inconsistent 
with the pluripotentiality of EC cells. The conclusion seems 
to be that EC cells with changed patterns of differentiation 
are always chromosomally abnormal, yet EC cells with abnormal 
karyotypes can remain pluripotent. It is cert ain that abnormal 
karyotypes by themselves do not prevent the expression of 
differentiated function since the EC cell karyotypes contain 
at least one copy of each pair of chromo s omes and it is unlikely 
that the cells lack any gene that is present in the normal 
diploid cell. r't seems probable that unbalanced karyotypes 
slightly alter the rate of various processes, and so change 
the apparent range of differentiation ( Graham 1977 ). 
The reason for the observed departure from karyotypic normalcy 
in EC cells in culture is probably due to the long-term culturing 
conditions where perhaps the nuclear material of the cell is 
suffering considerable disturbances which disrupt the mechanism 
of genetic control which may re sul t in chromosome abnormalities 
( Guenet et al 1974 ). 
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Most EC cell lines are nea.rly diploid, having a modal chromosome 
number of 39 to 42, and a missing Y chromosome, whilst some 
carry one biarmed chromo s ome. This biarmed chromo s ome has 
been shown to occur with PC13 ( Bernstein et al 1973 ), and 
may be termed a' marker' chromosome which describes any 
morphologically distinguishable abnormal chromosome that cannot 
be fully characterized. When markers in different cells are 
known or thought to be the same, they may be indicated by MAR, 
for example, MAR 1, MAR 2 etcetera ( Schaeffer Hack and Lawce 1980). 
An isochromosome is a chromosome inwhich the arms on either 
side of the centromere are morphologically identical by G-
banding. Isochromosomes may be formed by two means; 1) by 
11 centric fusion 11 , where two homologous chromoso:::nes fracture 
at the centromere and the two similar short arms unite with 
each other and the other fragments are usually lost, and 
2) a transverse fission through the centromere of a chromosome 
( perpendicular to the axis) in which the chromatids have 
formed. If the fractured chromatids unite with their adjacent 
(sister) strands,isochromosomes will result, where in 
subsequent metaphases the two joined chromatid arms act as a 
biarmed chromosome ( Schaeffer Hack and Lawce 1980). 
Isochromosomes of chromosome 8 have been detected in EC cells 
of the OTT6050 teratocarcinoma ( Cronmiller and Mintz 1978 ). 
Two biarmed chromosomes, also termed the :i metacentric 11 
markers have been observed by McBurney and Adamson ( 1976 ). 
They also observed in the EC cell line C17S1 ( of strain 
C3H/HE mouse ) an elongated telocentric chromosome which could 
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be distinguished from the normal mouse chromosomes on the 
basis of length. 
Many of the abnormal karyotypes of transplantable teratocarcinomas 
are trisomies ( Iles and Evans 1977) which appear to be a 
heterogeneous collection, although trisomy 17 was common and 
a subline inwhich the EC cells formed mainly neural tissue 
had a modal chromo s ome number of 41, with trisomy for chromosome 11 
( Graham 1977 ). Trisomy of chromosome 19 has been observed 
( Bernstine et ·a.1 1973 ) and of chromosome 8 .t ·· ~Burney 
and Adamson 1976 ). 
In teratocarcinoma cell lines, there has been found both 
additions to and deletions of chromosomes such as a 20% 
addition to the distal end of chromosome 1 an.d a 30% deletion 
from the distal end of chromosome 14 ( thought at first to 
mimic a Y chromosome) ( Graham 1977, and Papaioannou et al 1979 ). 
A deletion of chromosome 18 was observed by Guenet et al (1974) 
who also noted translocations of chromosomes 8 , 11, 13 and 14. 
Intra-chromosomal rearrangement . of chromosome 11 and others 
of the OC15 EC stemcell line of tumour OTT6050 was observed by 
McBurney and Adamson ('.1976 ) , who also noted the addition of 
an extra band to chromosome 2, just below the centromere. 
A submetacentric marker chromosome has also been obs erved by 
McBurney ( 1977) in the C17S1 and C10681 murine teratocarcinoma 
cell lines, thought to be formed by centromeric fusion of 
chromosomes 7 and 11. 
PC13 EC . stem cell. cultures have also been reported to contain 
a small ( >6% ) subpopulation of polyploid cells ( Ilgren. and 
Littlefield 1981 ). 
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5.82 CYTOGEiIBTIC CHARACT ERI STICS OF EMBRYONAL CARCINOMA 
CELLS : DIFFE~ENT I ATED CELL TYPE 
Linder et al 1981 showed that retinoic acid induced differentiation 
in F9 EC cell cultures which was accompanied by a slowing down 
of the rate of cell multiplication. Strickland and Sawey 
( 1980) concluded that the generated cell types of retinoic 
acid induced differentiation appear to be capable only of limited 
cell division in most cases. Ilgren and Littlefield ( 1981) 
suggest ed that the END or' giant ' cells do not appear to be 
termi nal cell types since they can occasionally enter , renewed 
cell di vision inspi te· of their large size. 
In some case s , so few of the differentiated in vitro progeny 
undergo mitosis, that it has been impossible to perform 
cytogenetic studies on them ( Lehman 1974 ). However, it has 
been reported that the k:aryotypes of the differentiated derivatives 
of EC cells range from apparently normal to highly aneuploid 
( Lehman 1974, and Martin 1975 ). It is possible that the 
majority of the differentiated cells are arrested in the diploid 
stage and that the cells contributing to a proliferating 
tetraploid population are either specific cell t ypes of 
differentiated cells or spontaneously transformed cells. It 
may be that an increase ,· in chromosome number from diploid to 
tetraploid may be a necessary prerequi~ite for the differentiation 
of EC stem cells ( Swartzendruber et al 1976 ). 
Primitive endoderm has been found to become polyploid during 
the course of normal embryonic development ( Ilgren and 
Littlefield 1981 ). Polyploid is the na.."Ile for multiples of 
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the ~aploid numb.er of chromosomes other than diploid, for 
example triploid, tetraploid, etc. Treatment of PC13 EC 
cell cultures with 10- 6 M retinoic acid and low cell density 
plating (10 5 - 5 x 10 5 cells per 25 cm2 flask) produced large 
END cells and polyploidation was about 16% of each cell 
culture. This net shift toward polyploidy resembled that 
which occurred during growth of visceral yolk sac endoderm 
by seventeen days post conception. As differentiated cells 
appeared in culture, cells in the near-tetraploid range 
appeared (Swartzendruber et al 1976). It · should be noted that 
polyploidization involves an increase in DNA content of the 
cell, which has been found to correlate with an increase in 
cell size (Ilgren and Littlefield 1981). 
5.9 SUMMARY 
For obvious reasons it is not possible to use pregnant women 
and their conceptus for the direct screening of a drug and its 
teratogenic effect. Instead early monitoring systems have 
been used to study prenatal losses and are sensitive indicators 
of the response to a teratogenic agent. The monitoring of 
neonates with congenital abnormalities however has failed to 
detect minor changes in brain function or long-term carcino-
genesis with only the major recognisable congenital malforma-
tions being recorded. Retrospective epidemiological studies 
on the malformed child have only been able to recognize easily 
observable abnormalities resulting in the identification of 
epidemics but not their causes (thalidomide an exception). 
With this type of retrospective monitoring the damage has 
already been done. Rather, prevention using teratogenicity 
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testing a s the first step in defence followed by monitoring 
as the s e cond ·step would be a much be tter app r oach to the 
prevention of teratogenic exposure. 
In vivo an i mal systems have be en developed which approximate 
the human situation. Here the variables are more easily 
controlled and the effects better indentified, however they 
have proved costly, time consuming and inefficient with no 
guarantee of protection from teratogenic exposure. In vitro 
animal systems (for example organ culture) have been devised 
which solve some of these problems but are not without their 
restrictions . Cell cultures have been proved of great value 
and can be used to monitor alterations in cell morphology, 
inhihition of the overall cell development and mutation 
induction. For the assessment of indirect teratogens with 
mammalian cell cultures, several experimental systems have 
been developed, such as liver microsomal and whole hepatocyte 
cell culture preparations. Differentiating cell cultures 
have been shown to have considerable potential in terato-
genicity testing and may prove a very important adjunct to 
animal testing in the campaign against teratogenic agents. 
It is thought that experimental results on teratogenicity in 
the mouse may have validity when extrapolated to man, 
and perhaps even more so than the costly and elaborate methods 
using subhuman primates. 
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Embryonal carcinoma (EC) cells have similar qualities 
to early embryonic cells in that they are pluripotent, 
structurally, biochemically and even immunochemically similar 
to some extent. A differentiating murine embryonal carcinoma 
cell culture would lend itself well to general microscopic 
morphological examjnation and cytogenetic analysis. 
There are many physical and chemical means of inducing · 
differentiation of EC cells and alterations in the charac-
teristics of the differentiating progeny can be used to test 
for teratogenic agents. Retinoic acid as the inducer of 
differentiation may mimic the normal signals to differentiation 
which probably either activates or inactivates cell differen-
tiation,however the precise biochemical mechanism is not yet 
understood. Retinoic acid promotes what development the cells 
are capable of and does not interfere with the direction 
of differentiation. The amount of differentiation is propor-
tional to the duration of treatment,however the continued 
presence of retinoic acid is not necessary for the maintenance 
of the differe~tiated state. There is a lag period of about 
twenty four hours before differentiation is seen to occur 
after the "triggering" effect of retinoic acid administration. 
It should be noted that treatment with retinoic acid itself 
causes a slowing down and reduction of cell division after 
about fourty-eight hours and this would have to be distin-
guished from any similar toxic effect to the drug applied 
(in this instance DPH). In addition to this effect observed 
- 95 -
at a morphological level, effects on DNA synthesis would 
have to be similarly evaluated. It should be noted that 
retinoic acid prevents SCE induction by the indirect mutagen 
cyclophosphamide upon chinese hamster cells in culture 
and could possibly have a similar effect on DPH mutagenic 
activity. 
PC13 EC cells in culture are thought mainly to differentiate 
eventually into neuronal cells. They appear to be highly 
stable with regard to the retention of d~velopmental poten-
tialities after proliferation in the undifferentiated state. 
The first differentiating cell type _ appears after two to three 
days in cell culture and is endoderm-like resembling the four 
day inner-cell mass (endoderm) of normal embryonic develop~ 
ment. These cells have been referred to as (Giant) because 
of their large size and possess "stress fibres" within their 
cytoplasm and "thread-like" cellular extensions. Fibrobast-
like cells then make an appearance in differentiating cell 
cultures along with Glial-like cells and later Neuronal-like 
cell types. The morphologies of the latter cell types show 
a striking resemblence to cell cultures of tissues from the 
central and peripheral nervous systems. 
Teratocarcinomas at their inception t~nd to be chromosomally 
normal and maintain exceptional karyotypic normality throughout 
their cell culture propogation. The more normal the karyotype, 
the less affected is the EC cell differentiation potential, 
however slight deviation from aneuploidy need not impair this. 
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Abnormal karyotypes have been shown not to prevent the 
expression of differentiative function but instead to alter 
the rate of the various processes and so limit the range of 
differentiation . EC cells may become karyotypically abnor-
mal because the cells suffer from being in cell culture 
which disrupts the. mechanism of genetic control resulting 
in chromosomal abnormalities . The fewer number of chromo-
somal anomalies found , the less would be this disruptive 
influence . This study examined PC13 EC cells in' culture 
with regard to their normal (basal) level of chromosomal 
anomalies and any changes in frequency in response to the 
various treatments . In general, EC cells in culture show 
slight aneuploidy with biarmed chromosomes, elongated 
telocentric chromosomes, etc. and the chromosome count 
ranging from 39-42 per metaphase (normal mouse chromosome 
number per metaphase is 40} . 
In normal embryonic development, the primltive endoderm 
has been found to become polyploid, and the great increase 
in cell size (Giant) is due to the increased DNA content 
as a result of polyploidation. 
Increased aneuploidy, structural aberrations and SCEs from 
the basal levels established for the PC13 murine EC cell 
line following particular cell culture treatments would be 
indicative of an (embryotoxic) effect and could possibly lead 




EQUIPMENT/MATERIALS, METHODS AND EXPERIMENTAL PLAN 
6 .10 E1UIPMENT/MAT ERIALS 
6.10.1 CELL CULTURING 
Dry Incubator ( set at
0
37°C HERAEUS 
and 60 C ) 
Centrifuge HERAEUS o-IRIST QvffiH 
Vortex Mixer ROTAMIXER DE LUX 
Gas Bottle (5% CO 2 in air) AFROX LTD,. 
Air Filters F~OW LABORATORIES . 
Sartorius Balance ZEISS 
pH metre ( model 601A) ORION RESEARCH 
Tissue culture flasks (25mm2)- GREINER 
Capped (sterile) conical GREINER 
plastic tubes (10ml) 
Plastic test tubes ( 5ml GREINER 
sterile) 
Glass Media Bottles ( 100 HOLPRO ANALYT ICS (PrY)LTD,. 
and 500 ml) 
Plastic Surgical Syringes CPA HOSPITAL SERVICES. 
( sterile, 5,10 and 20 ml) 
Pa~t eur Pipettes (plugged) HOLPRO ANALYTICS(PrY)LTD,. 
Gelatine DIFCO 
stock - powder 
working solution- 0.1% 
( w/v H20) 
Hanks Balanced Salt FLOW LABORAT ORIES. 
solution (HBSS )(10-331-26) 
Trypsin/EDTA s9lution(1:10) HOLPRO ANALYTICS(FTY)LTD,. 
Dulbecco's Modification of FLOW LABORATORIES. 
Eagles Medium(10-331-26) 
Eagle's Minimum Essential FLOW LABORATORI ES . 
Medium(10-101-26) 
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Table 10 • CONSTITUENTS OF EMEM AND DMEM CUL'l'URE MEDIA 
( Flow Manua 1 1981 ) . 
INGREDIENT 
L-Arginine HCl 
L-Cystine disodium salt 
L-Glutamine 
Glycine 



















CaC1 2 2H20 
Fe(N0
3







Sodium phenol red 
Sodium pyruvate 
* with Earle's salts 





































1. 900ml of deionized water was measured and the 
contents of the packet of powdered media (13.65g) 
were added ( at room temperature) and mixed to 
dissolve. 
2. 3.7g of Sodium Bicarbonate were added (as a buffer). 
3. The pH was adjusted to 7.3 using either 1N HCl 
or 1 N Na OH. 
4. The final volume of 1 litre was reached by adding 
more deionized water. ' ·.~ .. ..... • .. C 
5. Using positive pressure to minimize the loss of 
co2 , the media was filtered through a sterile 
membrane filter ( O. 22 µm porosity ) • 
6. Sterile powdered antibiotics were reconstituted with 
sterile distilled water and used at the following 
amounts in the prepared culture media. 
benzylpenicillin 100 units per ml. 
streptomycin sulphate - 100 p,g per ml. 
neomycin sulphate - 100 p. g per ml. 
These antibiotics afford a good protection against 
a wide range of bacteria ( gram positive and negative). 
7. Sterile lyophilizecl · Arnphotericin B, reconstituted with 
sterile distilled water, 1.oQS added to the culture 
media at 2. 5 µ,g/ml. 
8. Heat inactivated ( 56°c for 30 minutes to destroy 
complement activity) mycoplasma and virus free 
Foetal bovine serum ( FBS) was added to constitute 
10 % of the now' complete ' culture media, providing 







Fetal Bovine Serum (FBS) 
6.10.2 FREEZING/THAi:fING CELLS 
Freezing Ampoules (1ml) 
Dimethyl Sulphoxide(DT1SO) 
6.10.3 CELL COUNTING 
Naeuber Haemocytometer 
Coverglasses 
Trypan Blue (vital stain) 
stock - powder 
working solution- 0.1% 












HOLPRO ANALYTICS (PIY) LTD;. 
MERCK 
6.10.4 MORPHOLOGIC.AL, HISTOLOGICAL A..~D CYTOGENET IC OBSERVATIONS 




'Ordinary' Light Microscope 
LEITZ 
LEITZ 








Glacial Acetic Acid BDH 
Giemsa stain 
stock - liquid 
working solution- 10% v/v 
with PBS 
MERCK 
6.11 DIFFERZNTIATION INDUCTION 
.6.12 
Retinoic Acid (R-2625) 
stock - powder 
working solution-10-3!1 
prepared in subdued 
light with absolute 
Ethanol, then diluted 
futher using medium 
with FBS.(Strickland 
and Sawey 1980) .• 
SIGMA CHEMICAL COMPANY 




stock - powder 
Final dosage · .5,50 and 





NaOH ( 1N): 
Hater 
Phenytoin, m- hydroxy 
metabolite*-
Phenytoin, p- hydroxy 
Metabolite*-
(* metabolites added to 
a Final dosage of 50 )'g/ml ) 








This analysis involves a 
homogeneous immunoassay 
technique used inter alia for 
the microanalysis of DPH in 
biological fluids, but could 
also be used for culture media. 
A drug can· be labelled with an 
enzyme then becomes bound to an 
antibo~y ~gainst the drug, with 
the activity of the enzyme 
becoming reduced. When the 
media is sampled, the drug 
present can compete with the 
enzyme-labelled drug for the 
antibody, thereby· decrease 
the antibody-induced inactivation 
of the enzyme. The enzyme 
activity can be correlated with 
the concentration of the drug 
introduced and is measured by 
an absorbance change. Results 
we re in f g/ml • 
MET ABOLIC ACTIVATION 
S-9 Mixture:-
S-9 Fraction 
MgC1 2 (10.67ml'1) 
Phosphate buff er ( 13 3 . 3 3mM)-
( titrated to ph 7.4 with 
- 1N HCl) 
KCl (44.0n!1) 
Dr . P . Thiel 




Disodium salt of NADP(5 . 33mI1)- MANHEIM BOEHRINGER 
Disodium salt of glucose-6 






6 .14 SOLVENTS 
~
Ethanol (for Retinoic acid 
and drug preparation) 
Propylene glycol (for drug 
preparation) 
NaOH (for drug preparation) 
6.15 CONVENT IONAL CYTOGENETIC ANALYSI S 
Colcemid 





0.6 jJ. g/ml 
·Fixative (4:1) 
Methanol:acetic acid 
Glass Slides (76mm x 25mm) 
Covers lips (22mm x 22mm) 
Mounting Media (DePEX) 
Phosphate Buffered Saline(PBS) -
stock - tablet form 
working- 1 tablet to be made 
solution to 100 ml with H20 
Giemsa stain 
stock - liquid 
working solution- 10% v/v 
with pH 6.8 buffer 
pH 6.$ Buffer 
stock - tablet form 
working solution- 1 tablet 
made to 100 ml with 
H20. 
/ 












HICKI'1AN & KLEBER LTD 
Trypsin: stock - 5% solution BACTO~DIFCO 
working solution 0.13% 
( 1ml of stock/39 ml PBS) 
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6.17 SISTER CHROI'IATID EXCHANGE 
5- Bromodeoxyuridine (BrdU) 10 pM - SIGMA 
( Shaeffer Hack and Lawce 1980) 
Giemsa stain (GURR 66) HICKMAN & KLEBER 
stock - liquid 
working solution- 2% v/v 
diluted in:-
0.3M Na2 HP04 HICKMAN & KLEBER 
(adjusted to pH 10.4 with 
6.1 8 PHOTOGRAPHY 
Enlarger 
Negative Holder 
1N Na OH) 
Negative developer(G14 7C) 
stock - liquid 
working solution- 75 ml of 
stock and 225 ml H20 
Negative Fixative (Hypam) 
stock - liquid 
working solution- 50 ml of 
stock and 240 ml H20 
Paper developer (Ilfospeed) 
stoQk - liquid 
working solution - 100 ml of 
stock and 900 ml H20 
Paper fixative (Hypam) 
stock - .liquid 
working solution - 500 ml of 
stock and 1500 ml H20 
Print Paper (Glossy No.3) 
Photographic Film 













6.19 DNA SYNTHESIS 
Spectrophotometer 
Liquid Scintillation counter ·- BECKMAN 
( model Ls 900 with automatic 
quench correction and DPM 
calculation facilities) 
3H- Thymidine - AMERSHMl, ENGLAND 
(specific activity= 5 Ci) 
stock - 250 El with activity 
of 250 J.lCi (9.25 
l""iEGAB Q) as an aqueous 
solution(sterile) 
working solution- dilution of 
1 in 10 to achieve an 
activity of 1 ;iCi per 
10 /"l. 
Diluent: Saline (0.9g)(sterile) - PETERSEN LTD, 
Millipore Media Filtering System - MILLIPORE 
..,. Filters (0.02 fl.ID 
porosity) 
Filter Holder 
(XX 100. 25 30) 
Glass Fibre Discs 
(AP 150 22 00) . 
Flask with side arm 
(XX 102 50 5) 
Trichloroacetic Acid (TCA) 
Scintillation vials (20 ml) 
(low potassium glass) 




Sodium Dodecyl Sulphate (SDS) 
0.5% solution with 
0.1% DNA (to aid 
precipitation of 
cellular DNA.) 
- MERCK PRODUCTS 
- BECKMAN 




Serum Albumin(1;g/1µ1 SDS) 
Solution X : -
A• 1% Copper sulphate 1ml -
B. c'/o Sodium/Potassium- 1ml -
Tartrate 
C. _-_2%· N a2co3 
-0.1 N Na OH 
Mix A. and B. then 
add to c. 
100ml 
Folin Ciscolteus Reagent 
stock - liquid 








6. 2 I'1Rl'HODS 
6.20.1 CELL CULTURING 
1. To each of two new culture flasks were added 2.0 ml of 
a 0.1% gelatine solution. The flasks were immediately 
closed and carefully rotated in one plane inorder to 
spread the gelatine and produce an even and complete 
film over the bottom surface of the new flasks. 
Excess was removed after 5 minutes and discarded. 
2. To each new flask was added 10 ml of fresh complete 
culture medium. 
3. The old medium was removed from the confluent stock 
cell culture flasks and discarded. 
4. 5 ml of HESS were added to the stock cell culture flasks, 
the cap replaced and the solution gently swirled inorder 
to wash the cells and dilute the residual media protein 
that was present. The HESS was then removed and discarded. 
5. 2.5 ml of the trypsin/EDTA solution were added to the 
stock cell culture fl asks which were then put into the 
37 °c dry incubator. 
6. After four minutes the flasks were removed and gently 
tapped to displace any cell patches adhered to the 
gelatinized surface. 
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7. The trypsin/ EJYfA solution was then diluted by the 
addition . of 5 ml of fresh complete medium, inorder 
to reduce the enzymatic action of the trypsin. 
8. The cell suspension was removed from the stock cell 
culture flask and put into 10 ml graduated capped 
conical plastic test tubes which were then centrifuged 
at 1500 rpm for 5 minutes. 
9. The supernatant was poured off and
1
the pellet of cells 
gently resuspended in 2 ml of fresh complete medium, 
afterwhich the tightly caped conical test tubes were 
vortexed inorder to thoroughly disperse the cells. 
10. To each new gelatinized culture flask containing the 
10 ml of fresh complete medium was added 1 ml of the 
well mixed cell suspension, and the flasks then 
' gassed' with an atmosphere of 5% co2 in air followed 
by incubation at 37°c in the dry incubator. 
Note: In the controlled experiments, 'old' flasks 
needing to be re-cultured were treated as 
'stock cell culture flasks' above. 
Sterile techniques were employed for all 
manipulations. 
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6.20.2 INCUBATION TEMPERA'IURE AND CELL GRCWI'H 
'Ihe incubation temperature for cell culturing was very important since 
lower temperatures ( such as 30°C) seemed to delay. cell growth when canpared 
with controls ( at 37°C ). Observations were made using the inverted 
phase contrast microscope and recorded in the following photographs ( Figure 9 ). 
Temperatures atove 42°C resulted in cell death with cells lifting off from 
the surface of the culture flask and floating freely in the media. It has been 
shown that cells grown at a temperature only slightly lower than optimum can cla.c.rease 
~ 5rodh ra.le and result in a lowered mitotic index and chrorrosomes with poor 
rrorphology ( Shaeffer Hack and Iawce 1980 ). 
Figure 9. INCUBATION 'l'EMPERA'IURE AND. CELL GROWI'H 
( initial cell density of 5 x 107 cells/ flask 
a. after 24 hours 
at 37°C 
( X 80 ) 
b. after 24 hours at 30°C c. after 24 hours at 44°C 
( X 80 ) ( X 80 ) 
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6. 20. 3 FREEZING CELLS 
The PC13 cell line was preserved in this laboratory by the 
continuous freezing of stock cultures. In a frozen state 
they may keep for a long time without significant loss· of 
viability ( Flow Manual 1981. ) • 
Freezing cells without cell death is possible due to the 
discovery that Dimethyl Sulfoxide ( nnso) protects cells 
from ice crystal formation during freezing. A concentration 
of 5% DMSO in fetal calf serum was used. Cells were kept 
at -90°c to -196°c ( the temperature of liquid nitrogen) 
to prevent cell loss. Freezing units were used to cool 
cells at an optimal programmed rate, and special freezing 
ampoules were used which held about 1 ml of cell suspension each . 
6. 20. 4 THAWING CELLS 
When required, cells were thawed by removal of the ampoule from 
the storage freezer and immediate immersion into a 37°c waterbath, 
and agitated until defrosted. Cells were removed and added to 
a 5 ml tube with screw cap along with fresh complete medium, 
inorder to dilute the cryoprotective agent. Cells were then 
centrifuged, resuspended in 2 ml of fresh complete medium and 
plated into prepared culture flasks. 
6. 20.5 CELL COUNTING 
Cells were counted using a haemocytometer chamber which is 
divided into 9 large squares by triple white lines. The centre 
large square is divided into 25 small squares which, in their 
turn, are sub-divided into 16 smaller squares ., whilst the four 
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corner large squares are divided into 16 squares. The large 
squares have each an area of 1 mm2 • The haemocytometer 
counting chamber was loaded as follows:-
1. The coverglass was placed dovm over the grid so that 
interference patterns appeared, giving the chamber a 
-4 depth of 0.1 mm and each large square a volume of 10 ml. 
2. A dilution was made of the cell suspension in vital stain 
( 0.1 ml of cell suspension in 0.9 ml of Trypan blue 
solution), and a small drop added to the side of the 
coverglass. The chamber was filled by capillary 
action and care was taken not to overfill the chamber. 
3. Under the low power objective of the light microscope, 
the cells were counted in the centre square and the four 
6.20.6 
large corner squares. Cells touching the upper and 
right hand perimeter lines were ignored; those touching 
the lower and left hand perimeter lines were counted. 
Dead cells stained blue. 
CALCULATION FOR THE NUMBER OF CELLS PER ML OF CELL SAMPLE 
If the total number of cells counted was n and the 
solution was diluted y - fold in Trypan blue, 
n the number of cells in one large square= 5 , 
the number of cells per ml of diluted suspension Lt-= ~o n, 
-
and the numb.er of cells per ml of 




6. 20.7 THE ESTIMATION OF PC13 EC CELL GR0 1,/TH RATE 
( Method adapted from Priest 1977 ). 
1. Cells were plated at an initial density of 106 cells 
per culture flask ( in 8 replicate culture flasks), 
then gassed with 5% co2 in air and incubated at 37°c. 
This was taken as day 1, time O hours. 
2. The cell count was performed on duplicate flask cell 
cultures at 24 hour intervals from the time of the 
initial plating for a total of 4 intervals ( the entire 
analysis taking 5 days). 
3. The average of the duplicate cell count for each 24 hours 
was plotted ( on the vertical log scale) against time 
in culture in hours ( horizonatal scale). Including 
the initial number of cells at O time, 5 intervals 
were plotted on the semi-log paper ( Results, page 175 ) • 
6.20.8 :MCRPHOLOGICAL OBSE~VATIONS 
Culture development was monitored on day 12 of 
Experiments A, B, C, and D. 
were measured,-
The following parameters 
i. CEIJ.i DEATH - This was confirmed by the observation 
of floating cells in the medium which 
had lifted off from the flask surface 
and appeared as s mall round refractile 
bodies. Quan ti tati vely, a ·broad 
description o~ cell death was employed 
which with cell count determinations 
was used to estimate cell culture growth. 
ii. GROWTH RATES 
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Cell culture growth rates were 
compared for each treatment by an 
estimation of eel] density for which 
cell counts were performed in 
Experiments A and B, and protein 
determinations made for Experiments 
D and E ( correlating with cell 
density) ·! Both measurements were 
an indication of the rates of cell 
proliferation. 
iii. CELL MORPHOLOGY- The general appearance of cell 
cultures was noted and a comparison 
made with controls. Normal EC cell 
morphology ( illustrated by the 
controls) was distinguished from 
differentiating cells arid a··. 
quantitative estimation of each type 
present was made using the tech...-riique 
described in Section 6.21. 2. 
6.20.9 HISTOLOGIC ~L PREPARATIONS 
1. Media was removed from the culture flasks and the 
bottom layer of the flask was quickly cut with a hot 
scalpel blade into approximately 20mm x 40 mm sized pieces. 
2. These preparations were then fixed with Methanol:acet:Lc 
acid ( 3:1) in a glass petri dish for 30 minutes. 
3. Fixative was removed and Giemsa stain added for 4 minutes. 
4. The stain vms poured off and a wat.er rinse followed. 
5. The preparations were left to air dry. 
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6.21 . DIFFERENTIATION INDUCTION 
Retinoic acid was used to induce in vitro differentiation of 
PC13 stem cells. .. In experiments A, B, C and D, retinoic acid 
was added on Day 1 and DfH or its metabolites were added on 
Day 7. In some treatments, retinoic acid was added for a 
futher five days ( until Day 12) afterwhich the cell cultures 
were terminated and the analyses performed ( see Table 13.). 
6. 21. 1 REI'INO IC ACID CONCENTRATION 
The concentration of retinoic acid used in this laboratory to 
induce PC13 EC cell differentiation prior to this investigation 
. -6 was 1.33 x 10 M. It was decided upon to test three retinoic 
. . 10-5 -6 o-7 ac±d concentrations, viz M , 10 M , and 1 I1. The 
10-6 M concentration was that used by Strickland and Mahdavi 
( 1978 ) for inducing the differentiation of F9 EC cells. 
The higher concentration was used to test for toxicity and effect 
on differentiation, whilst the 10-7 M concentration was used to 
examine the potential of retinoic acid to induce differentiation 
at low concentrations. 
Chronic exposure . to retinoic acid was employed as this would 
ensure adequat e inducement of differentiation in the rel atively 
short period allowed for an exper i ment al run. 
Direct observation of growing cell cultures ( Day 12 of cell 
culture) using the phase contrast microscope revealed that 
with a retinoic acid concentration of 10-6M there was a large 
number of easily visible differentiating cells after 12 days 
of mainly fibroblast-like character ( Section 6.21.2 ) surrounding 
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clumps of undiff erentiated EC cell s ( junction between two 
cell types indic ated by the arrow in Figure 10.b.). Lower 
retinoic acid concentration ( 10 -7M) resulted in much less 
differentiation of an earlier stage, indicated by the presence 
Figure 10. RETINO IC ACID CONC ENT~tAT ION : CELL GRO~-!TH 
AND DEVELOPMENT 
b. 
(initial cell density of 5 x 106cells/flask) 
a. 10-7M retinoic 
10-6M retinoic acid 
Day 12 
( x 80 ) 
Day 12 
c. 
( X 80 ) 
10-5:M retinoic acid 
Day 12 
( X 80 ) 
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of small granular Fndoderm-like cells ( ~dicated by the arrow in Figure 10 a.) . 
'Ihe relatively low level of differentiation in this instance was inappropriate 
for the time scale planned fer experimental runs. 'Ine highest retinoic acid 
concentration employed ( 10-5.M) resulted in rapid differentiation of cells 
many ofwhich were in the large Endoderm or END - like fonn . (indicated by the 
arrow in Figure 10 c. ) surrounding large clusters of undifferentiated EC 
cells many cf which in the top layers had lifted off due to cell death and 
were floating arounq. as small refractile bodies in the media. A retinoic acid 
concentration of 10-6M was employed for further experimental work. 
6.21.2 ANALYSIS OF DIFFERENTIATION 
Differentiation c,f EC cell cultures was qualitatively analysed by the direct 
" 
observation of morphological changes in the cells following differentiation 
il).duction. 'Ine descriptions and nomenclature employed. here closely follows 
that used by the authors referred to in Section 5.74. 
types were observed ·: -
'Ine f'Dllowing cell 
Undifferentiated EC cells ( 10-12~m) 
Small granular Endoden11-like cells ( 20-30;tm ) 
Glial-like cells ( 30-60/'m) 
Fibrcblast-like cells,( 50-200,µm) 
Large Endoderm-like cells ( 100-200 ;irn ) , with " Stress fibres " 
and" Thread-like extentions 11 • 
Large multi-processed Neuronal-like cells ( 100-200µm) 
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Differentiation of monolayer cultures of cells was quantified 
by a point counting method ( Hennig et al 1968, and Speers et al 
1979 ). Growing cultures in tissue culture flasks were 
examined using an inverted phase contrast microscope with a 
reticule grid in one ocular lens. The flask was positioned 
at random and each of 121 points of intersection was scored 
for the underlying cell type. The frequency of" hits" 
was directly proportional to the area covered by each cell 
type. The relative areas covered by EC ( undifferentiated 
embryonal cells) and DIFF cells ( differentiating embryonal 
carcinoma cells), was estimated by photographing confluent 
areas of each at the same magnification and counting the 
nuclei in these pictures. The average for several determinations 
was 3.5 EC cells per Diff cell. 
The relative proportion of EC cells in a mixed EC/DIFF cell 
culture was computed using the following formula:-
EC hits x 3.5 x 100 
== % DIFF cells 
EC hits x 3.5 + (DIFF hits) 
= % Differentiation 
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6. 22.1 DPH ( PARENT COMPOUND) 
DPH, thought to be responsible for the set of congenital 
abnormalities commonly referred to as the Fetal Hydantoin 
Syndrome, was here tested for toxic effects. 
DPH was initially added to cell cultures at a concentration 
of 5, 50 and 500;tg/ml and its effects on chromosome aberration 
induction, DNA synthesis and genera l morphological appearance 
determined. These concentrations were chosen because 50.Jlg/ml 
of DPH was used by Wilk et al ( 1980) whe{i examining the 
effects of DPH on chick mesenchymal and neural crest cells in 
culture with regard to changes in cell morphology, differentiation 
inhibition and cell death. DPH at a concentration of 50~g/ml 
caused effects on these parameters, and so it was decided upon 
to use t his concentration as the intermediate ' dose ' of DPH 
used in this study. This concentration of DPH was in the range 
of blood lev~ls that have been associated with congenital 
malformations. ( Wilk et al 1980 ). The two other concentrations 
of 5 and 500)"-g/ml were included in the present study to give an 
indication of a dose response relationship to DPH exposure. 
The development of the cells was assessed by phase contrast 
microscopy for 5 days after the addition of DPH to cell cultures 
( after Wilk et al 1980) and represented chronic exposure in 
relation to the observed rate of cell differentiation. 
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6.22.2 CHEMIC ALLY SYNTHESI ZED METABOLITES OF DPH 
Two of the main DPH metabolites in man, p- HPPH and m.- HPPH, 
were available chemically in small quantities and were 
included in Experiment D. as positive controls for the 
metabolic activation treatment involving the S-9 Mixture. 
A concentration of 50 fg/ml was used and the development of 
cells assessed by phase contrast microscopy for 5 days after 
the addition of the metabolites. 
6.23 M~"'TABOLIC ACTIVATION OF DPH 
Metabolic activation of DPH using liver microsomal preparations 
should result in the production of intermediates of metabolism 
and various end metabolites. These metabolites were not 
(_ 
identified qualitatively or quantitatively, however, it was 
possible to measure quantitatively the disappearance of 
DPH using EMIT ( refer to Section 6.12 .1 ). 
The metabolism of DPH by the S-9 Mixture was monitored, as a 
function of time by measuring the decrease in DPH conc entration 
at hourly intervals in the sample having an initial DPH 
concentration of approximately 52 I g/ml . It was found 
( Taple 11; Figure 11. ) that the drug concentration diminished 
to about only 10% of its original value- after 2 hours of 
incubation with the S-9 Mixture. It was therefore assumed 
that met abolic activation had indeed occurred and that 
metabolites were present in the highly centrifuged ( 50,000 g) 
supernatant of the S-9 Mixture with the drug added. 
As di s cussed in Section 2.5 an end metabolite of DPII metabolism 
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may be able to revert back to the reactive arene oxide intennediate which 
may be the teratogenic canponent. All futher 'If.Ork with the S-9 Mixture 
( Elq>eriments A., B., C., and D. ) involved the incubation of the S-9 Mixture 
with DPH for 4 hours prio~ to centrifugati6n, to ensure that all activity had 
stopped due to lack of enzyme or substrate and that the DPH added 'lf.Ould have 







DPH AND METABOLIC ACTIVATICN WI'IH S-9 MIXTURE 
TIME (hours) 









DPH (;tg/ml ) 
(1) (2) AVERAGE ! 
50.4 53.4 51.9 
38.4 40.2 39.3 
· 24.4 23.3 23.9 
15.5 16.1 15.8 
10.8 10.9 10.9 
6.6 6.2 6.4 
7.3 9.3 '-,. 8.3 
8. 1 7.0 7.6 
Figure 11. DISAPPEARANCE OF DPH UPON INCUBATION 







6,23.1 PREPARATION OF RAT LIVER MICROSOMAL FRACTIONS 
The S-9 fraction was kindly supplied by Dr. P. Thiel~ 
Medical Research Cow1cil, 
Institute for Nutritional Diseases, 
Tygerberg, CAPE. 
The liver microsomes were obtained principally after the 
method developed by Ames et al ( 1975 ), as follows:-
1. Ten BD 1X male rats of about 200g body weight each 
were fed on rat cubes and five days before they were 
killed, 0.1% sodium phenobarbital was added to their 
drinking wa.ter in order to cause liver enzyme induction. 
On the fifth day the rats were· killed and the livers 
excised aseptically, and processed at O - 4°0. 
2. The livers, with an approximate weight of 10 - 15 g each 
were divided into two groups of five each and transferred 
to pre-weighed 250 ml glass beakers containing 0.15 M 
KCL ( 1 ml/g ·wet liver ) • 
3. The weighed livers were then transferred to glass beakers 
containing 0.15 M KOL ( 3 ml/g wet liver), and blended 
in a Sorvall - Omni - mixer for 30 seconds at full speed. 
4. The mixture was filtered throug~ cheese cloth into a 250 ml 
glass beaker and homogenized in a Daunce homogenizer using 
10 strokes with a tight plunger. 
5. The homogenate was centrifuged in a Sorvall SS-34 rotor for 
10 minutes at 9000 g and the supernatant ( S-9 fraction) 
was transferred in 3 ml quantities into test tubes with 
metal caps and stored at -ao0 c until required. 
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6.23.2 PREPARATION OF THE S-9 MIXTURE 
The rat liver microsomal samples ( S-9 fractions) were 
supplemented with certain cofactors and salts forming the 
S-9 mixture reqired for the metabolic activation of DPH. 
The S-9 mixture was prepared at 4°c and contained ( per 1 ml 
of complete media) the following:-
0.2 ml of S-9 fraction, and 
0.025 ml of 10.7 mM MgC12 , 
133.0 mM phosphate buffer, 
4L~. 0 mI'1 KCl, 
5.3 mI1 disodium salt of NADP and 
6.7 mM disodium salt of glucose-6-phosphate. 
The volume of S-9 fraction, salt solution and cofactors used 
per ml of culture media was the same as that used by Wilk · · 
et al ( 1980 ), whilst the addition of KCl and phosphate buffer 
and the molarity of all components used follows the method of 
Ames et al ( 1975 ). Due to the instability of NADP when in 
solution, the S-9 fraction was prepared on the day of use and 
the components ( other than the S-9 fraction) were made up in 
10 ml of distilled water. 
S-9 fraction added directly to the medium is toxic to cell 
cultures and so the S-9 mixture was initially incubated with 
the drug to be tested ( DPH) or vehicle control ( 5jil per 
0.225 ml of S-9 mix) and then highly centrifuged ( 50,000 g 
or 27,000 rpm ) for 1 hour • 0.23 ml of the supernatant 
was added per ml of medium .which was then sterilized by 
filtration . Prepared in this way the S-9 fraction would not 
be toxic to cells in culture ( Madle and Obe 1977 ). 
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6.24 SOLVENTS 
Solvents used in this investigation included ethanol, propylene 
glycol and sodium hydroxide. Equal amounts of the various 
solvents were tested in all experimental runs inorder to examine 
any differences from the negative controls. If the solvents 
had no effect then their usage would only be limited by toxicity 
' 
at high levels ( Latt et al 1981 ). 
All three of the above mentioned solvents, ., used at similar 
concentrations to those used in this investigation, had no 
effect on developing cells ( chick me_senchymal and neural crest 
cells) according to Wilk et al ( 1980 ). 
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6.25 CONVENT IONAL CYTOGENET IC ANALYSIS 
Although there are many published methods for cytogenetic 
analysis of teratocarcinoma cells ( Evans 1972; Lehman et al 1974; 
Papaioannou et al 1979; Cronmiller and Mintz 1978, and 
McBurney and Strutt 1980 ), these techniques are only giossed 
over in this literature. Detailed knowledge of these 
techniques is however critical for obtaining good metaphase 
preparations. Various differences in experimental conditions 
exist ( such as different brands of reagents employed , different 
environmental climates etc,. ), therefore , investigators need 
to establish specific cytogenetic procedures for their laboratory 
conditions and for the actual cell line used. 
The treatments involved in the harvesting procedure, although 
mostly routine cytogenetic techniques, had to be specially 
adapted for the murine teratocarcinoma cell line used in this study. 
Harvesting of the cells according to the exact methods of the 
Human Cytogenetics laboratory at the University of Cape Town 
Medical School did not afford good chroTiosome preparations, due 
probably to the inherent characteristics of the cell line used. 
It was necessary to establish eacl:;l. stage of the Harvesting 
procedure, such as colcemid concentration and exposure time, 
KCl exposure time, and fixative exposure time, before 
proceeding to the main experimental work with specific drug 
treatments. Eventually, a harvesting and slide making 
procedure was established which gave relatively good and 
consistent results. 
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6•2~1 COLCEMID ~ EXF0SURE TIME AND CONCENTRATION 
The first step in the harvesting procedure is the addition of 
the mitotic inhibitor which accumulates metaphases and prevents 
the formation of the spindle apparatus by blocking assembly of 
microtubule monomer units into polymeric spindle fibres. 
Colcemid was added . 0.06, 0.1 and 0.6f-g/ml to culture flasks 
after the cells were plated at 106 cells/flask. Cultures were 
incubated for f, f, 1, 2, 3, and 4 hours, then harvested. 
Observation of conventionally stained slides under oil-immersion 
lens of the · iight microscope showed that better and adequate 
numbers of metaphase plates occurred at O .1 p. g/ml colcemid 
concentration and exposure time of 3 hours. Many of the 
chromosomes appeared well spread out and at the length which 
allowed adequate examination of their morphology. Be.fore this 
time and with lower colcemid concentration metaphase plates 
were fewer in number and the chromosomes were long and not well 
spread out, with . a residual cytoplasmic background. Increasing 
exposure time beyond 3 hours and increasing colcemid concentration 
I 
seemed to cause most of the many metaphase plates observed to be 
too_ compact, and chromosomes too short. 
6.25.2 KCl ( 0.075 M ) EXPOSURE TIME 
During mitosis, one of the changes that takes place in the cell 
is the disintegration of the nuclear membrane. The chromosomes 
are then held together by the cytoplasmic membrane and the spindle 
apparatus. The addition of this hypotonic solution causes water 
to enter the cell and the cytoplasmic membrane stretches and the 
cell . swells. 
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Six exposure times ( 5, 10, 20, 30, and 60 minutes) were tested 
using pre-warmed· Kcl ( 0.075 M) and incubation in the . dry 
incubator at 37°c. Centrifugation time of 5 - 7 minutes ·was 
included as part of the exposure times. It appeared that a 
total exposure time of 20 minutes ( which later also included 
an initial rinse in KCl to dilute any media still present) , 
proved to have the best effect, producing many well spread but 
apparently complete metaphase plates. Times less than 20 minutes 
resulted in underspread metaphase plates and crossed chromosomes 
with visible cytoplasm. Beyond this time . many of the metaphase 
plates appeared incomplete with many scattered chromo s omes present 
and poor chromosome morphology. 
6 • 25. 3 FIXATIVE 
Prior to fixation, cells are alive, metabolizing and continue 
to be affected by the mitotic arresting agent. The fixative 
preserves the swollen cells, stopping all cell functions, 
preventing futher cell swelling and making the cells less 
fragile ( although the cells must still be treated gently as 
they are sensitive to the first fixation). 
The addition of a few drops of fixative at the end of KCl exposure 
seemed to help the cells centrifuge out of hypotonic suspension 
and make them less fragile during the fixation steps ( Shaeffer Hack 
and Lawce 1980 ) • It appeared that the more times the cells were 
fixed, the more distinct and better spread out the chromosomes 
looked after qtaining, although, if left in fixative for too 
long before spreading, the chromosomes appeared fuzzy. 
Insufficient fixation resulted in many crossed chromosomes, 
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visible cytoplasm, holes in the chromosomes and poor morphology. 
An increase in methanol concentration to achieve a ratio of 
4: 1 with acetic acid was found to help prevent overspreading 
and allowed better clearing of cellular residues, giving 
' cleaner 'metaphase preparations than with the 3: 1 ratio 
usually employed. 
Cell . storage in fixative overnight (.. for_ convenience) as a 
pellet instead of a loose suspension , was thought to protect cells 
I 
from overfixation and so helped to keep them from becoming 
trypsin-resistant and perhaps aided SCE differential staining 
( Shaeffer Hack and Lawce 1980 ) • 
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6.25.4 THE HARVESTING PROC EDURE 
1. At the appropriate time, 0.1)'g/ml Colcemid was added 
to the cell cultures which were then gently shaken and 
reincubated for a futher 35 minutes at 37°c. 
2. Instructions 3. to 7. of the method for cell culturing 
( section 6.20~) were performed with the exception 
that the old media or HBSS were not discarded but put 
into the centrifuge tubes and centrifuged at 2,000 rpm 
I 
for 7 minutes. The supernatant was then removed down 
to the 1 ml mark and discarded. 
3. The cell suspension was removed from the culture flasks 
and put into the centrifuge tubes already containing the 
1 ml old media/HESS rinse cell solution. 
4. The remainder of the procedure did not require aseptic 
conditions, continuing with centrifugation of the cell 
suspension at 2,000 rpm for 7 minutes. The supernatant 
was carefully pipetted off down to the 0.1 - 0.5 ml mark 
depending _· upon the size of the cell pellet~ 
5. The cells were gently but thoroughly resuspended with the 
addition of 0.5 - 1.0 ml of warmed KCl ( 0.075 M ). 
Warmed KCl was then added up to the 8 ml mark, whilst 
working as rapidly as possible with the pasteur pipette 
inorder to thoroughly mix the solution. 
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6. The tubes were vortexed for 10 seconds and then immediately 
centrifuged at 2,000 rpm for 7 minutes. 
7. All but 0.5 - 1.0 ml of the supernatant was carefully 
removed from the tubes and the cells gently resuspended. 
Warmed KCl ( 0.075 M) was added, mixing constantly, up 
to the 8 ml mark ( less if the cell density was low). 
8. Tubes were vortexed for 10 seconds and put into the 37°c 
dry incubator for 6 minutes. After 3 minutes, the 
cells were agitated by tapping inorder to prevent the 
cells from settling out and es_caping from the KCl (0.075 M) 
concentration gradient. 
(, 
9. The cells were removed from the incubator and a few 
drops of fresh cold fixative were added to each tube 
which was then centrifuged at 2,000 rpm for 5 minutes. 
10. 1 First Fixation' - the critical step in the procedure. 
The supernatant was carefully pipetted off to the 0.5 -
1.0 ml mark, depending upon the cell pellet size, and 
the cells gently mixed. More cold fixative was 
vigorously added to the 8 ml mark and mixed well. 
11. Tubes were vortexed for 10 seconds and left at room 
temperature for 15 minutes. The cell suspension was 
then ce~trifuged at 2,000 rpm for 7 minutes. 
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12. ' Second Fi xat i on' 
Instructi"ons 10. and 11. were repeated. 
13. The cells were refrigerated ( about 4°c) as a pellet 
for 24 hours, then the following day the settled cell 
suspension was centrifuged at 2,000 rpm for 7 minutes. 
14. The supernatant was removed down to the 0.5 - 1.0 ml 
mark and the cells gently resuspended in this volume, 
which when necessary was adjusted inorder to obtain a 
slightly opaque solution. This was followed by 
slide ' spreading'• 
6.25.S MITOTIC' SHAKE OFF ' 
•J 
In an attempt to increase the number of metaphase plates for 
cytogenetic examination, mitotic ' shake off 'was employed 
to synchronize cell division by replating the mitotic cells 
which were detached from the culture layer by tapping the 
flask , since the cells in metaphase had been loosely attached 
to the growth surface. However, this led to cell differentiation 
(Figure 12.a. b. and c. where arrows indicate a differentiating 
cell.), probably due to the ' low cell density effect ' ( Section 
5.72 ). This method did not prove to .be a way of increasing 
the mitotic index, and it helped to confirm the phenomenom of 
differentiation induction due to low cell density plating. 
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Figure 12. MI'IUI'IC I SHAKE OFF I 
a. 3 hours after plating 
( X 250 ) 
b. 8 hours after plating c. 24 hours after plating 
I 
( X 250 ) ( X 250 ) 
6.26 
- 132.;. 
SLIDE SPREADING ( CONVENTIONAL ANALYSIS, G- .. BAN:;)ING 
AND SCE ) 
The method of air - drying chromosomes spread on pre-cleaned 
glass slides allowed the fixative to be lost quickly due to 
its property of quick evaporation from around and under the 
swollen cells which then flatten completely, forcing the 
chromosomes to spread out. This occurred after the cells 
were dropped onto the cold slides by the" bonsai" technique 
which involved dropping the cell suspension from a height. 
Different methods of making slides and the environmental climate 
may speed up or slow down the process of evaporation, causing 
a greater or lesser spreading effect ( Shaeffer Hack and Lawce 1980). 
Neither fast nor slow evaporation is ideal, since either can 
result in poor spreading , scattered chromosomes, or visible 
cytoplasmic background around the metaphase. 
In this study, the method involved dropping the cell suspension 
onto cold wet slides lying on a wire rack over a bowl of hot 
water to allow the slides to dry more slowly in the rather hot 
climate. \fr1en the slides were dried incorrectly, the chromosomes 
tended to look indistinct or fuzzy. 
l 
One slide was prepared initially and examined for cell density 
and if the quantity and quality of mitotic plates were 
satisfactory, all of the cell suspension was spread onto slides. 
The quality of the metaphase plates could sometimes be improved 
by re-fixation or by using fixative composed of Methanol and 
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Acetic acid in a 1 : 1 ratio instead of the usual 4- : .. 1 ratio, 
this would tend to prevent underspreading. Slides were 
~ 
stored in a 6o0 c · dry incubator until ready for use, this was 
thought to' age' the slides and afford better staining. 
Chromosome spreading and morphology,and therefore banding quality 
are completely dependent upon how slides are made and a very 
important end point in cytogenetic analysis is reproducibility 
inorder to obtain consistent results, however this is quite 
difficult to achieve. 
- 6.27. 1 SLIDE STAINING : C01'1"'V:2NTIONAL ANALYSIS 
. ;. 
1. The slides were put into 10 % Giemsa stain in a pH 6.8 
buffer for 4 minutes. 
2. Slides were then removed and rinsed under running tap 
water • 
Tissue paper was then used to blot the slides which were 
left to dry at room temperature. 
4. Slides were mounted with a coverglass using mounting media. · 
6.27 . .2 SLIDE SCANNING : C01"'VENTI0NAL .AJLf\.LYSIS 
A uniform method was followed when scanning with a low power 
objective on the light microscope, to ensure that the slide was 
totally examined. 
( see Appendix). 
All results were recorded on a tally sheet 
Slides were analysed' blind ' and all 
metaphases, ofwhich chromosome morpholoey could be definitely 
distinguished were analysed. Photographs were taken where 
necessary using the x 100 oil immersion objective. 
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6.27.3 G- BANDING 
G - banding results from the digestion of chromosomes with a 
proteolytic enzyme (Trypsin) and then staining with Giemsa 
stain. This technique reveals detailed information, the 
banding pattern, which could afford identification and 
classification of the karyotype of the cells studied. The 
optimal resolution of bands is obtained from early metaphase 
chromosomes which are longer. In contracted chromosomes, 
the finer bands tend to merge together so that only the main 
bands are apparent . 
1. It was necessary to 1age'the slides in a dry oven at 60°c 
for · 24 hours inorder to eliminate fuzzy banding and to 
enhance the contrast of the bands. 
2. The slides were then dipped into the working solution 
of freshly prepared Trypsin ( 0.13% ). Timing was 
critical, about 30 seconds for the preparation recorded 
in this study. Ove.rtrypsinized chromosomes appeared 
bloated and undertrypsinized chromosomes stained uniformly 
with little evidence of banding. 
3. Slides were then rinsed thoroughly in a PBS rinse. 
4. Slides were stained in 10% Giemsa stain, diluted in pH 6.8 
buffer, for 3 minutes by flooding the horizontal slide. 
5. Slides were then rinsed in g ently running tap water and 
blotted dry, and lastly,mounted in the usual way. 
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6. 28 .1 SI STER CHROMAT ID EXCHANGE 
Detection of SCEs in non-ring chromos omes requires some means 
of differentially labelling sister chromatids. This was initially 
accomplished with the use of tritiated thymidine ( Taylor et al 
1957 ), although recent studies employ halogenated nucleosides 
such as 5-bromo-2'-deoxyuridine ( BrdU ). BrdU has largely 
supplanted 3H- thymidine for the purpose of differentially 
labelling of sister chromatids since when . incorporat ed into DNA 
the BrdU can quench the fluorescence of DNA binding dyes such 
as 33258 Hoechst ( Latt 1973 ), acridine orange ( Dutrillaux 
et al 1973; .Kato 1974b, and Perry and Wolff 1974 ), and under 
appropriate conditions 4'6- diamidino-2- phenylindole ( Lin and 
Alfi 1976). Fluorescence methods for SCE detection do not 
provide permanent preparations and rapid fading of stained · 
specimens makes even initial photomicroscopy difficult. Giemsa 
methods ( Goto et al 1978; Ikushima and Wolff 1974; Korenberg 
and Freedlender 1974; Perry and Wolff 1974; Sakanishi and 
Takayama 1978, and Scheres et al 1977 ), many utilizing 
a BrdU - sensitive prestain for photosensitization, have thus 
in many laboratories replaced fluorescence techniques for routine 
SCE analysis. 
In this study, a direct technique was used for the selective 
staining of BrdU - substituted DNA and -involved treatment with 
salts at a high pH to enhance the staining when Giemsa stain alone 
:was employed ( Alves and Jonas son 1978 ) •. 
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1. Brdu was added ( 10 µ. M ) to cell cultures 40 hours before 
harvest • . Thereafter, the cultures were kept in 
complete darkness. 
2. After harvesting by the usual method , the slides were 
stained 45 minutes at room temperature. 
3. The preparations were tl;len rinsed in distilled water, 
blotted dry and mounted. 
As with all chromosome banding techniques, slides may respond 
differently to the staining procedure. However, altering the 
pH between 10.2 and 10.6 and the phosphate concentration 
between 0.2 and 0.4 M, could generally achieve satisfactory 
results. 
The metaphase chromosomes of cells grown in the absence of 
BrdU are refractory to Giemsa staining with the present 
technique. After two rounds of replication in the presence 
of BrdU, the fully-substituted chromatid stains an intense 
magenta, whereas the half-substituted chromatid remains pale -
.( Figure 13.). After three rounds of replication, chromosomes 
appear with both chromatids staining intensely. 
This method of differentially staining sister chromatids was 
used because it was relatively quick and simple to perform, 
giving permanent preparations. 
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Figure 13. SISTER CHROJVIATID EXCH..\NGE 
6.28.2 SLIDE SPREADING AND SCANNING 
The same methods as used for conventional analysis were 
employed ( 6.27.1 and 6.27.3 ). Latt et al ( 1981) 
reported that a minimum of 25 cells should be scored per 
replicate and at least 50 per treatment. In this study, 60 
cells were scored per replicate (120 per treatment). SCEs 
were expressed on a per metaphase bas is as suggested by 




6.28.31 FILM DEVELOPMENT 
1. In complete darkness, the film negative was wound 
around the :p l astic spool of the light-tight negative 
holder. 
2. In the light, negative developer was added and left 
for 6 minutes, during which the container was agitated. 
3. The developer was :poured off and Fixative added then 
left for 3 minutes with frequent agitation. 
! 
4. Tap water rinse for 30 minutes. 
5. The film was removed from the container and spool, 
then hung to dry. 
6.28.32 PRINT DEVELOPMENT 
1. Following the exposure of the developing :paper on the 
enlarger, the :print was dipped into Paper Developer 
until an image appeared. 
2. Sto:pbath of tap water. 
3. The print was then dipped into Fixative and remained 
there for 10 minutes. 
4. The :prints were then placed in a water tank and washed 
for 30 minutes, then left to dry. 
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6.29 DNA SYNTHESIS 
3H- Thymidine incorporation into DNA measured quantitatively gives 
an indication of the comparable rate of DNA synthesis between two 
samples. In this study two such methods were employed, the 
latter being an improvement on the former, with regard to 
experimental accuracy. 
The first method employed used whole EC cells which were rinsed 
to remove any' hot' media which had remained after incubation 
but before scintillation counting. The second revised method 
improved on this technique by breaking down the cell and nuclear 
membranes with sodium-dodecyl sulphate ( SDS ), thus allowing 
the nucleic acids to be thoroughly washed, preventing an 
inaccurate result due to trapped radioactivity in the cytoplasm 
and not incorporated into DNA. 
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METHOD 1. 
1. On day 12 of the experiment, instructions 3. to 8. 
the Cell Culturing method was followed ( see Section 6.20.1) 
2. The supernatant was poured off and the pellet of cells 
gently resuspended in 1 ml of fresh complete medium, 
afterwhich, the tightly capped conical test tubes were 
vortexed inorder to thoroughly disperse the cells. 
3. A cell count was performed on this cell suspension 
( Section 6.20.5 ·6 ),and the cell suspension diluted, 
if necessary, to contain 5 x 105 cells per ml. 
4. The 1 ml of cell suspension containing 5 x 105 cells 
was then added to the old culture flasks now held in an 
upright position to reduce the surface area to 80 mm2• 
5. To each flask ( control and treated) was added a futher 
1 ml of complete fresh medium. 
6. To each 2 ml in the old culture flask was added 1.0,ci 
of 3H- Thymidine, and the suspensions incubated for 
four hours in the dry incubator at 37°c. 
7. To the culture flasks were added 50 ml of cold ( 4°C) 
PBS in an effort to terminate thymidine incorporation, 
and culture flasks were then stored overnight in the 
refrigerator ( 4°c for 14 hours). 
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8. The culture flasks were removed from the refrigerator 
and placed in an ice bath until the contents were emptied 
into the funnel of the millipore filtering system connected 
to a suction inlet at the water tap. The cells remained 
behind on the filter disc whilst the liquid was discarded 
into the flask below. 
9. The old culture flask was rinsed with 20 ml of cold PBS 
and this suspension also slowly poured into the funnel. 
10. The cells on the disc were then washed with 2 x 10 ml volumes 
of 10% TOA. 
11. Two washes of absolute Methanol ( 2 x 20 ml) followed, 
to remove all traces of the TOA. 
12. The glass-fibre discs were removed from the filter holder 
and put into the labelled scintillation vials then dried 
in a drying oven at 60°0 for 1 hour. 
13. To each vial was added 10 ml of scintillant and after 
30 minutes, each sample was put through the Beckman 
Scintillation counting system. 
METHOD 2. 
1. On day 12 of the experiment, the 10 ml of old medium was 
removed from the culture flasks and replaced with 5 ml of 
' hot ' media ( 2. 5 ;"Ci of 3R- Thymidine ) then re-incubated 
at 37°0 for 4 hours. 
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2. At the end of incubation, the ' hot 'medium was removed 
and the cell layer rinsed three times with 5 ml of cold 
( 4°c) PBS. 
3. 2.0 ml of 0.5% SDS ( containing 0.1% DNA) was added to 
the culture flasks which were then left for 5 minutes 
inorder to allow the cells to lyse. 
4. 2 x 100 _pl aliquots of the flask contents were removed 
for protein determinations ( Lowry Method see section 6.29.2 ). 
5. 2.0 ml of 20% TCA was added to the culture flasks and 
left for 5 minutes. 
6. The contents were poured into the funnel of the millipore 
filtering system attached to a negative (suction) pressure 
source. 
7. To the flasks was added 5 ml of 5% TCA, the contents then 
added to the funnel of the filtering system. 
8. The filter discs were washed with a futher 10 ml of 5% TCA. 
9. 2 x 10 ml washes of 96% Methanol ( Absolute ) . 
10. The filter disc with cell' debris ' was then removed 
from the filtering ·.system and put into the labelled 
scintillation vial ( 20 ml capacity) using small forceps , 
and the vials put in the dry oven at 60°c for 1 hour. 
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11. Dimilum-30 liquid scintillation cocktail with 
chemiluminescence inhibitor was added and liquid 
scintillation counting performed using a counter with 
an automatic quenching correction factor. 
6.29.1 PROTEIN DETERMINATION : LOl.·lRY 1'1ETHOD ( Lowry et al 1951 ) . 
The method involves the formation of a copper-protein complex 
in an alkaline solution. This complex then reduces a 
phosphomolybdie-phosphotungstate reagent ( Folin ), to yield 
a blue colour the intensity · ofwhich is pr'oportional to the 
amount of protein present which can in turn be related to the 
cell density. 
I STANDARD CURVE I 
1. In duplicate, microlitre amounts ( 20, 40, 60, 80, and 
100 p.l )of a 1,-glfl solution of a serum albumin solution 
in 0.5% SDS were added to small plastic tubes. 
2. These volumes were made up to 100f-l with 0.5% SDS 
( 100 .f"l of SDS used as the blank). 
3. 400 _rl of distilled water was then added and 2 ml of 
solution X ( see section 6.19 ). 
4. 200p-l of F~lin reagent was added and the samples mixed 
and left for 30 minutes before the absorbance 
measurements were made using a spectrophotometer at 750 nm. 
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6~29.2 DETERMINATION OF THE SAMPLE PROTEIN CONTENT 
1. 2 x 100;tl aliquots of each treatment proc e dure and controls 
( Section 6.29.1 : Method 2, Instruction 4. ) were placed 
in small plastic tubes to which was added 400/-1 of 
distilled water. 
2. 2 ml of Solution X was added to each tube. 
3. 200 f-1 of Folin reagent was then added. 
4. The samples were mixed thoroughly and left for 30 minutes 
before absorbance readings were determined at 750 nm 
using a spectrophotometer. 
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6.29.3 STATISTICAL ANALYSIS DNA SYNTH:SSIS 
The distribution - free or non parametric techniques were used· 
here because conclusions could be drawn about results which 
required fewer qualifications than parametric testing. The 
former techniques of inference do not make numerous or stringent 
assumptions about a normal distribution or otherwise, of the 
population from which the sample was drawn. 
Non parametric tests focus o~ the order of ranking of scores, 
not on their actual II numerical II values. Various ranking 
tests have been designed to test the significance of this type 
of information and the one used in this study to d·etermine if 
the DNA synthesis results of one treatment were different from 
the results of another, is the Wilcoxon Signed - Rank Test. 
-This test was developed by Wilcoxon ( 1945)~ 
although it is sometimes called the Mann-Whitney Test. The 
particular procedure used here involved the ranking of unpaired 
measurements as follows:-
1) All observations of both treatments were put into a single 
array ( with each group still being distinguishable from 
each other). 
2) Ranks were then assigned to the combined array. 
3) Finally, the sum of the ranks for each treatment was 
calculated, and when the value for the one treatment 
( usually the control) fell outside a specified range 
( Documenta Geigy, Statistical Tables), the null hypothesis 
of II No difference between groups II was rejected. 
- 146 -
Table 12. ANALYSES PERFORMED 
EXPERIMENT 
ANALYSES . A B C D 
Morphological 
+ + + + 
Examination 
Conventional 
+ + + + 
Chromosome Analysis 
Sister Chromatid - - + + 
Exchange Analysis 
DNA Synthesis - + + + 
Analysis 
+=performed: - = not performed 
Table 13. EXPERIMENTAL PLAN 
Y,..EY TO T~ble 13. 
RA = Retinoic Acid 
S-9 Mix = S-9 Mixture 
DPH = Diphenylhydantoin 
+ = Performed 
= Not Performed 
® ... = Actual DPH values as measured by EMIT 
( µg/ml ) in prepared culture media. 
** = Approximate amount of metabolite ( )'G/ml ) 
added during media preparation. 
Continued/ ••• 
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Table 13 • u'l'ER IMENT AL PL AN ( DPH OOSAGES ) 
C EXPERIMENT 0 
B C D d TR:SATI"i:~NT A 
0 
1 Control + + + + (no RA or druµ;) 
2 RA (10-
6M) + + + + 
3 S-9 Mix + + + -
4 RA (10-6M)and S-9 Mix + + + -
5 Solvent only + + + -. 
6 DPH (High dose) + 492.6* - - -
7 DPH (Intermediate dose) + 52.2• + 42.6* + 49.0* + 50.s• 
8 DFH (Low dose) + 5.3• - - -
DPH (High dose) · 
+ 516.0* - - -9 and RA (10-6M) 
10· DPE (Intermediate dose) + 54.0* + 53.4* + 45;6• + 49.2* and RA (10-6M) 
11 DPH (Low dose) + 4.5* - - -and RA (10-6M) 
DPil (High dose) 
+ 504.2* - - -·12 and S-9 Mix 
DPH (Intermediate dose) 48.4* + 52.s• + 54.0* + 5r ?,.. 13 + V•-and S-9 Mix 
DPH (Low dose) 
4.8* 14 + - - -and S-9 Mix I 
15 DPH (High dose), + 486.0* - - -RA. (10-6M) and S-9 Mix 
DPH (Intermediate dose), 
+ 48.2* + 48.8* + 52.2• + 50.6* 16 RA (10-6M) and S-9 Mix 
DPH (Low dose), 
17 RA (10-6M) and S-9 Mix + 5.9• - - -
18 
DPH m-hydroxy metabolite - - - -to 50.0• • 
DPH m-hydroxy metabolite 
19 and RA (10-6M) 
- - - + 50.0•• 
20 DPH p-hydroxy metabolite - - - + 50.0•• 
DPH p-hydroxy metabolite - - - + 50 .o • • 21 I+ RA ( 10-6M) . -
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A Stmmary of the culture programne involved in Experiments A, B, C, and D 
now follows. Each experiment was over a 12 day period, with chronic drug 
exposire for 5 days ( days 7. - 12 ). 
Table 14 • CULTURE PROGRAM!'IE FOR ~XPERIMENTS A,B,C .AND ·D·. 
DAY P~OCEDURE 
1 Cells plated-initial cell density per flask:-
Experiment A = 107 cells 
II B = 107 cells -
II C = 5x106 cells 
II D = 5x106 cells 
2 Media change 
3 Subculture 
4* Media change / 
5· Subculture 
6* Media change 
7• Subculture- Drug added (where necessary) 
8 Media change 
9 Media change 
10 Media change- BrdU added for SCE analysis 
11 Media change 
12* Culture termination 
Note: Morphological examination using phase contrast 
microscopy was performed daily to check on 
cell culture development and photographs taken on 
days indicated•. 
Number of culture flasks employed:-
i) Morphological observations- made on all culture 
flasks. 
ii) Conventional chromosome analysis and SOE- were 
performed in duplicate. 
iii) DNA synthesis measurments were made on six 
flasks for each treatment. 
The p-hydroxy metabolite ·was in short supply, 
and so a single flask was used for ii) and 




7 .1 NORMAL MORPHOLOGY OF PC13 EC CELLS IN CULTURE 
Cell cultures of ·PC13 EC cells differentiate minimally, 
although occasional Endoderm-like, Fibroblast-like, and 
Glial-like cells may be seen but routinely represent less 
than 1% of the total population. Phase contrast microscopy 
of the normal cell cultures reveals ( Figure 14 a. b. and c. ) 
the general morphology of the PC13 EC cells, which is futher 
supported by a photomicrograph ( Figure 15. ) of a 
histologically processed slide preparation of the fixed cells. 
The cells were seen to be small ( about 10 /- m ) , rounded, 
~ 
with scant cytoplasm and often indistinct borders, giving the 
appearance of a syncytium. These cells usually have a large 
central nucleolus and little in the way of cytoplasmic 
structures. Mitotic figures were common ( Figure 15. arrows). 
Figure 14. NORMAL CELL MORPHOLOGY: CELL CULTURES 
( X 80) ( X 250) 
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Figure 14. Continued/ .•. 
c. 
( X 500 ) 
( X 1500 ) 
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Figure 16. T.£:M CELL DENSI'IY PIATING ( 7 ~ 105 CELLS/ FLASK) 
AND THE INDUCTION OF CELL DIFFERENTIATION 
a. I:MEM : D3.y 3. b. EMEM : D3.y 3. 
( X 250 ) ( X 250 
C. I:MEM D3.y 5 • d. EMEM D3.y 5. 
( X 250 ) ( X 250 ) 
Figure 16. Continued/ ... 
e. LMEM : D:ly 7 • . 
( X 250 ) 
g. I:MEM D:ly 21. 
( X 80 -) 
i. LMEM : D:ly 21. 
( X 250 ) 
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f. EMEM 
( X 250 ) 
h.. EMEM : D:ly 21. 
( X 80 ) 
j. F.MEM D:ly 21. 
( X 250 ) 
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Figure 17. LO.fl CELL DENSI'IY PIATING ( 5 x 105 CELIS/ FIASK) 
AND THE INDUCTION OF CELL DIFFERENTIATION 
a. r:MEM Day 21. b. EMEM : Day 21. 
.. 
,;. • 







( X 80 ) ( X 80 ) 
c. r:MEM : Day 21. d. EMEM Day 21. 














7. 2 CELL DENSITY AND .DIFFERENTIATION INDUCTION 
In an attempt to culture PC13 EC cells at lower cell densities 
( initial cell densities of 5 x 105 and 7 x 105 cells per flask) 
in both DMEM and EI'1EM culture media so that growth could be 
observed for a longer period before confluency, the phenomenom 
of differentiation was observed ( Figure 16. a. b. c. d. e. f. 
g . h. i. and j. and Figure 17. a. b. c. and d. ). Cell 
culture plated initially with 106 cells per flask retained the 
normal growth pattern and did not differentiate as such. 
1,.,rith initial dens{ty 7 x· -10 5 , the cells did not proliferate very 
rapidly ( when compared with controls) due to the induction of 
differentiation and when the cultures were · examined on Day 21, 
the lower cell density cultures had become well differentiated 
with mainly Fibroblast-like cells ( Figure 16. i. arrow) and 
Giant Multiprocessed (Neuron-like) cells ( Figure 16 j. arrow). 
l ~ 
On Day 3 of the experiment, the differentiating cells took the 
form of small granular Endoderm-like cells( Figure 16 a. and b. 
arrows) . By Day 5, Fibroblast-like cells could be seen 
( Figure 16 c . and d. arrows ) and on Day 7 the large Endode.rm-
like cells were apparent ( Figure 16. e. and f. ) with Glial-
like cells ( Figure 16 f~ lower arrow). 
These observations were also observed when an initial cell 
density of 5 x 105 cells per culture flask was plated ( Figure 17.) 
~ . . . 
and by day 21, .very large multiprcx::essed Neuronal-like cells were present 
( Figure 17 c • · and ·a· arrows ) • - Results were the same for ooth types of 
culture media employed. 
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DIFFERENTIATION INDUCTION \.!ITH RETINOIC ACID ( 10-SM) 
The PC13 EC cells in cell culture normally tend to form sheets 
of closely adherent polygonal cells and so have been termed 
Epithelial- like due to their mosaic-like appearance. When 
cell cultures become confluent, they lose their monolayered 
appearance, with the cells having a tendency to pile up as 
there is no contact inhibition, a phenomenom associated with 
teratocarcinoma cells. 
Following the application of 10-6M retinoic acid to PC13 stem 
cell cultures, small granular Endoderm-like cells began to 
to appear by Day 2 and were very .apparent by Day 4 ( Figure 
18. a. and b. arrows). These early cells seemed to become 
replaced by two main cell types: Glial-like cells which 
appeared after about 5 days ( Figure 19 a. and b. arrows) 
becoming more differentiated with time ( Figure 19 c. and d.Day 6. 
arrows), also Fibroblast-like cells were observed ( Figure 
20 a . and b. Day 8. arrows) which seemed to develop into or 
become intimately involved with the larger Endoderm-like cell 
i 
type. These larger cells May fail to develop the large cell 
processes and form the large Squamous epithelium-like cell 
type ( Figure 21 a. and b. Day 14.) The cell in Figure 21 a. 
exhibits the " stress fibres " mentioned in Section 6.21. z and 
Figure 21 b. illustrates the" thread-like extentions" also 
mentioned. Alternatively, the larger Endoderm-like cell type 
may go on to develop into the large multiprocessed neuronal-like 
cell type ( Figure 22 a. b. c. and d. Day 18 ). The elongated 
neuronal type cells usually make contact with many neighbouring 
cells ( Figure 22. a. and b. arr ows). 
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Figures 18. to 24. are photographs representative of similar morphology 
observed in 8 replicate culture flasks over a period of 18 days. Initial 
. 6 
cell density was 10 cells per culture flask. 
Figure 18. SMALL GRANUIAR ENOODERM-LIKE CELLS 
a. CMEM Day 4. 
( X 250 ) 
b. EMEM Day 4. 
( X 250 ) 
- 157 -
Figure 19. GLIAL - LIKE CELIS 
a. a-1EM 03.y 5. b. EMEM 03.y 5. 
( X 250 ) ( X 250 ) 
C. a-1EM 03.y 6. d. rMEM : 03.y 6. 
( X 250 ) ( X 250 ) 
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Figure 20. FIBROBLAST <;]LIKE CELLS 
a. DMEM : Day 8. 
( X 250 ) 
Figure 21. LARGE ENDODERM - -LIKE CELLS 
a. Ilv1Etv1 : Day 14. 
( X 80 ) 
b. EMEM : Day 8 • 
( X 250 ) 
b. EMFM Day 14. 
( X 250 ) 
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Figure 22. LARGE MULTIPRCCESSED NEURCNAL - LIKE CELIS 
a • I:MEM : D3.y 18 • b. EMEM : ray 18. 
( X 250 ) .' ( X 250 ) 
c. ™EM : D3.y 18. a. EMEM : ray 18. 
( X 80 ) ( X 80 ) 
- 160 -
The Fibroblast-like cells fonned distinct boundaries around the undifferentiated 
EC cells which tended to pile up ( Figure 23 b. arrow) due to lack of contac~ 
inhibition. The junction bebveen both cell types is indicated in Figures 23a. 
and 24. by the black arrows. 
Figure 23. JUXTAPOSITION OF UNDIFFERENTIATED AND DIFFERENTIATING PC13 EC 
CELLS IN CULTIJRE 
a. DMEM Day 8. b. EMEM Day 8. 
( X 80 ) ( X 250) 
( X 200 ) 
f 
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EXPERIMENTS A. B. C. AND D. COMBINED TREATMENTS 
For those cell cultures requiring differentiation induction, 
( Table 13. ), there was the treatment of cultures with 10-6M 
retinoic acid for a period of seven days, followed by specific 
culture treatments ( for example, drug added alone, drug added 
with retinoic acid, drug added with S-9 mixture) for 5 days, 
until Day 12 of the experimental run onwhich cell cultures 
were terminated and analyses performed ( Table 12. ). 
The medium used for these Experiments was DMEM because the 
cells grew well in this medium which did not tend to become 
acidic ( indicated by phenyl red colour change to yellow) 
quite as readily as EMEM under the same conditions, this 
was a reflection on the actual media composition ( Table 10.). 
In order to achieve optimum cell culture growth, cultures were 
subcultured on Days 3. 5. and 7. This necessitated the use 
of an initial cell density of 107cells per flask ( Experiments 
A. and B., later revised to 5 x 106 cells per flask (Experiments 
c. and D. ) inorder to overcome problems with low mitotic index 
due to confluency. 
The morphological results for Experiments A. and B. were very 
similar throughout the experimental run and therefore only one 
photograph has been included to depict the observations made, 
this also applies to Experiments c. and D. 
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Figure 25. CELL M)RPHOLCGY IN EXPERIMENTS A. B. C. AND D. 
( Pre-treatment with Retinoic acid at 10-6M 
for those treatments requiring differentiating 
cells - refer to Table 13. ) 
a. Experiments A. and B. 
ray 4. 
( X 250 ) 
c. Experiments A. and B. 
ray 5. 
( X 250 ) 
b. Experiments C. and D. 
ray 4. 
( X 250 ) 
d. Experiments C. and D. 
rays. 
( X 250 ) 
e. Experiments A. and B. 
lay 6. 
( X 250 ) 
g. Experiments A. and B. 
lay 7. 
( X 250 ) 
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f. Experiments C. and D. 
lay 6. 
( X 250 ) 
h. Experiments C. and D. 
lay 7. 
( X 250 ) 
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Cell morphology did not change from normal until about Day 3. and the small 
granular Endoderm-like cells became more apparent by Day 4. ( Figure 25 . a.- and 
b. arrows). By Day 5. the Glial-like cells were observable ( Figure 25 c. 
and d. 1 and Fibroblast~like cells by Day 6. ( Figures 25 e. and f. arrows). 
All the aforementioned cell types and the undifferentiated..:;EC: .cells were 
observed in the cell cultures on Day 7. ( Figures 25 g. and h. ) when the 
specific treatments were applied. 'Ibe relative proportions of the 
Undifferentiated and Differentiating cell types were estimated using the 
'point counting method' mentioned in' Section 6.21.2. 
Table 15. PERCENTAGES OF CELL DIFFERENTIATION AFTER TI-IE INDUCTION 
OF DIFFERENTIATION WITI-1 10-~RETINOIC ACID TREAn,,mNT IN 
EXPERIMENTS A. B. C. AND D~ ( Estimations made on Day 7) , 
Number of 11 hits 11 
EXPERIMENT out of 121 points % DIF~ 
. . Ee*; DIF~ 
A; 35 86 41 
B-~· 32 90 43 
c. 28 93 so 
D. 24 97 54 
47 
. (Average) - . 
Note: Results are of an average of data 
obtained on 8 culture flasks 
x = Undifferentiated PC13 EC cells 
xx = Differentiating PC13 EC cells 
Refer to Section 6.21.2 for foI111Ula. 
Photographs taken on Day 12, depicting the morphological appearance of cells 
in culture for all treatments in Experiments A/Band C::/D now follows where 
x refers to approximate DPH dosages ( see Table 13. ) :-
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Figure 26. C'ONTROL ( ~ Retinoic acid or drug present 
a. Experiments A/B. b. Experiments C/D. 
·~;.~.: .... , ..... _ .· . . ·- . ., .,. . .. , 
.fL' 0 •• J /'I-,•." • lj;; -~ ·' • . ..,. 
I"' • . ·- .. '' . "-'; · .. . , -· ".t . .. ' i ~ •. ,,. 
\ ,,1 '. ) .. :· tii; : .. -~ ) -·~ • .,.,• ; ~.:.~":. ~·11 r' ..... 1 ... ,. .,-. ·.~ .... 
tr~:;~~~, · -•::. :,>- V 
;1:.· . ..... · ~ . .. -:; .... : ,.-.. . , :>,·, ... .. ' #" '..~ ~,, ·• -
r.J :--..... . ~ .. .?"'I \ \ ·~ ,, , . i !'J( ,) l \ :·· ,., 
r-, • • 1,..· 'I--
~ .,v. 1 
~,.r\ "\ ··, f V _, • .. - \ ·, · ; . , 
~ :" .... ,'-.~ . , .:- {, . . . ' Vfi . (' 
.,;;, . ' . • \ ~ ..:. .... · ·., 4· · , 
f • • • \ \. J... . I • • ,· -·t· -,).•_ 
..... ~---.• , \ I . 
. ,( -.. ... ·'. 
"'.I -.._ ' • •. , ·, r .. " ~ ·.r,C...· e~. 
r .• { ' .> ' • • • : , , ' · .. : .. - • ~ ' .· . • • .• I, ........ ' # ! " • ,· ti, .,. -. ' ... ~ )" .. , . " '" . ' .. · ........ .. 
"' "i ~, • I\"' - J <o' ,I I ' •:.·. ···,- . ·v .~ '·\ \ ' . < .• - .• .,,., 
.<.J~" .t.,;. ,· y ·_::...' . ·<---:J 
I • • . • • .• • •, ... • \~ .I 
\ 
( X 250 ) ( X 250 ) 
Figure 27. RETINOIC ACID ( 10-6M) 
a. Experiments A/B. b. Experiments C/D. 
( X 250 ) ( X 250 ) 
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Figure 28. S-9 MIXWRE 
a. Experiments A/B. b. Experiment C. 
( X 250 ) ( X 250 ) · 
Figure 29. RRI'INOIC ACID ( 10-GM) AND S-9 MIX'IURE 
a. Experiment A/B. b. Experiment C. 
( X 250 ) ( X 250 ) 
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Figure 30. SOLVENTS 
a. EKperirnents A/B. -b. EKperirnents C. 
( X 250 ) ( X 250 ) 
Figure 31. DPH ( 500 pg/ml * ) 
a. Experiment A. 
( X 250 ) 
- 168 -
Figure 32. DPH ( 50 pg/ml * } 
a. Experiments A/B. b. Experiments C/D. 
( X 250 } ( X 250 } 
Figure 33. DPH ( 5 pg/ml * } 
a. Experiment A. 
.... 
• . , -., 
' ., ~· ,, --~ ~ I". ( 
' ' ' { .. .. I 
\.' • 
. 
, '. / .-~ ... .. .. 
' ,,. ' 
.. - ,. • \ I 
. ~' _J -·'. ~ ... 
,. 
),J "} JJ, ,. \' ·., -. . • • I, 
( X 250 } 
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Figure 34. DPH ( 500 ;t g/rnl * ) AND RETINOIC ACID ( 10-6M ) 
a. Experiment A. 
( X 250 ) 
Figure 35. DPH ( 50 p g/rnl * ) AND RETINOIC ACID ( 1 o-6M ) 
a. Experiments A/B. b. Experiments C/D. 
( X 250 ) ( X 250 ) 
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Figure 36. DPH (5 }'g/ml * ) AND RETINOIC ACID ( 1 o-6M ) 
a. Experiment A. 
( X 250 ) 
Figure 37. DPH ( 500 }'Lg/ml * ) AND S-9 MIX'IURE 
a. Experiment A. 
( X 250 ) 
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Figure 38. DPH ( 50 }lg/ml * ) AND S-9 MIX'IURE 
a. EKperiments A/B. b. Experiments C/D. 
( X 250 ) ( X 250 ) 
Figure 39. DPH ( 5 .,t1. g/ml * ) AND S-9 MIX'IURE 
a. EKperiment A. 
( X 250 ) 
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Figure 40. DPH ( 500)1.g/ml * ) , RETINOIC ACID ( 10-6M ) 
AND S-9 MIXTURE 
Figure 41. 
a. EKperirnent A. ' 
( X 250 ) 
DPH ( 50 ).lg/ml * } , RETINOIC ACID ( 10 ....:6M ) 
AND 5-9· MIXTURE 
a. EKperirnents A/B. b. EKperirnents C/D. 
( X 250 ) ( X 250 ) 
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Figure 42. DPH ( 5 µ g/ml * ) , RE'TINOIC ACID ( 1 o-6M ) 
AND S-9 MIX'IURE 
a. Experiment A. 
( X 250 ) 
Figure 43. DPH, m- HYDROXY ·Mfil'ABOLITE ( 50p.g/rnl * ) 
a. Experiment D. 
( X 250 ) 
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Figure 44. DPH, m - HYDROXY METABOLITE ( 50 ){ g/ml * ) AND 
RETINOIC ACID ( 10-6M) 
a. ~ ·- • 
. . . . ·-,.. ~-~ -21.. ~, ~ 
7 ,--;, ·• ~ ; \ ,. - ·- \., _/.~, .... - ~ ..... \. - . . ,.,,,. 
/I . _; ,-. .J",a;) Nf ~ 
.1.,l.. ~-7-.\,. l. · .. 
' ~ . ' '.... -· • " ' .• JI 
. ··-... - .... t,-.4.. /' ~ ' . •, ,-\.... ..~. ~ "· ·-~ .. 
& I - . ···-• \It • - , ~ . I,• . . 'I . 
r,' 7 --"I,.. . ' . ~' • V '\. ' t . -'"t. ; . ·~ .- - ,, , 1'f ,_ .~. I 
/ , ~ ... ~ ,jt· ;'/'• '~ ~~ ii. 'i ..... 'i' ,r l~"( 
r. ~-·: -.. ~.~. ~£~{.,. ~4 ..... ~·~1.v .. 1-;' ;; ; ~{~-. ,· . ' .... - . . • ~, . • . . ·.ly .. ,. • • ;, "' ,.. -·, . .,, ~-. -~ .. . ' 
• t ~ -'.\' . _ :• r-,. :J~· -~ . . ~. . . ·, ....... -.. . ~\.!t' ~r" . . , 
I \,, J&.t'._' ; ~' ~~ .... , ~ • • ._ , ~-"' •-.;· •~~-n. 
( X 250 ) 
Figure 45. DPH, p - HYDROXY METABOLI'IE ( 50){ g/ml * ) 
a. 
Figure 46. DPH, p - HYDROXY METABOLI'IE ( SO)tg/ml * ) AND 
REI'INOIC ACID ( 10-6M) 
a. 
( X 250 ) 
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7.5 PC13 MEAN CELL CYCLE TIME 
The cells were in logarithmic growth when a straight line could be drawn 
through 3 plots ( Figure 4 7. ) • The time was deteI1!1llled ( horizontal 
scale) for the cell number to double ( vertical scale) during log 
growth of the cells. This time approximated the mean population 
doubling time which in turn approximated the mean cell cycle time. For 
PC13 stem cells this was calculated to be between 18 and 20 hours. 
Table 16. DETERMINATION OF TI-IE GROWlli RATE OF PC13 EC CELLS 
IN CULTIJRE 
Replicate CELL COUNTS ( x 106 ): 
Hours 1 2 3 4 5 6 7 8 
0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
24 1.08 1.26 1.42 1.18 1.12 1.20 1.34 1.28 
48 1.56 1.92 2.20 1.88 1.96 1.68 2.24 1. 98 
72 4.06 4.36 4.60 4.42 4.78 3.76 4. 18 4.32 







Figure 47. ESTIMATION OF TI-IE MEAN CELL CYCLE TIME FRCJ.1 POPULATION 
DJUBLING TIMES DURING LOGARI'I11MIC GR.Own-I OF PC13 EC 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































7;8 DNA SYN1HESIS 
The DNA synthesis rates ( Table 20.) of each of the following treatments 
measured after a four hour period of incubation with 3H - thymidine did not 
differ from controls; Retinoic acid only ( 10-~ ) , S-9 Mixture only, 
Solvents only, and DPH only ( approximately SOJ(-g/ml ). This suggests 
that the above ,treatments did not have a toxic effect upon DNA synthesis. 
However, the following treatments were shown to differ significantly from 
controls; Retinoic acid ( 10-~) with S-9 Mixture, DPH (approximately 
SOj(g/ml) with Retinoic acid ( 10-~), DPH (approx~tely 50,µg/ml) with 
Retinoic acid ( 10-6M ) and S-9 Mixture, · ·DJ?H; . m- hydroxy metabolite 
(approximately 50µ.g/ml) and finally DPH, m- hydroxy metabolite (approx-
imately SO pg/ml) with Retinoic acid ( 10-6M ) • All but the last two 
treatments caused a significant decrease in the rate of DNA synthesis, 
whilst the latter two treatments actually caused a significant increase in 
the rate of DNA synthesis. DPH (approximately 50..,ug/ml) with S-9 Mixture 
gave conflicting results: in Experiment C. there was a significant decrease 
whilst Experiment D. showed the treatment not to affect the DNA synthesis 









































































































































































































































































































































































































































































































































































































































7.91 UfRCM)Sa&\L ANALYSIS: CONVENTIONAL 
Chromosomal analysis of PC13 EC cells revealed a chromosome count of 
between 38 to 42 chromosomes per metaphase (modal 41); the normal mouse 
chromosome complement is 40. This indicates that there has been a slight 
shift from normality during the development of these cells from a terato-
carcinoma and subsequent animal passage and cell culturing. 
The most frequent occurring chromosome number was 41 in virtually all 
treatments, except for; DPH only (5.3 µg/ml) in Experiment A, and DPH 
m-hydroxy metabolite (approximately 50 µg/ml) with Retinoic Acid (10-6M) 
in Experiment D where the most frequently occurring chromosome number was 
respectively 42 or 41/42 occurring equally~ However in these two instances, 
only between 60 and 100 metaphases were examined which was a relatively 
small sample size. Polyploidy was observed to a maximum of 4% of the total 
number of metaphases counted per treatment and the range for chromosome 
number recorded was 60 to 84 chromosomes per metaphase plate. 
Four marker chromosomes were demonstrated in controls (Figures 49 to 52) 
and were as follows; a metacentric chromosome (M1), a very elongated 
acrocentric chromosome (M2), a large submetacentric chromosome (M3), 
and a small submetacentric chromosome (M4). Markers M1 and M2 have been 
G-banded and M1 appears to be an isochromosome (Figure 54). 
Results were the same in all treatments and tnere was no increase in 
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C0.1BINED FREQUENCY TOTALS vs. rnRCJ..fJSCNE COUNT~ rnetanhase) 























S-9 Mix /'D DPH (50) + 10 DPH (5) + r1in DPH, p-hydroxy r->1"I 0 RA. 10- 6i,r S-9 Mix ® rnetaboli te (50) + ® 
DPH (5) (ID 
120 DPH (50) C1) 












38 39 40 41 42 p 
RA 10-6M 
DPH ( 5o) + DPH, p-hydroxy @ 
s-9 Mix © metabolite(SO) 
DPH (500) + 
S-9 Mix @ 
DPH (5) + ll 
RA 1 o-6M 1 
38 39 40 41 42 p 
DPH, m-hydroxy G]) 
metabolite (50) + 19 
RA 10-6M 
DPH, m-hydro:>-')' @ 
metabolite (50) 18 
.NOTE: 
_Olromosome count per rnetaphase 
( ) = approxlJ!late drug dosage in µg/ml O = treahn~ t d 
p = polyplo1d ' T bl w 1icD,:l co e 











































































































































































































































































































































































































































































































































































































































































































































































































MAR.KER CHRQ\10SCT-1ES~ M.1 · (METACENTRIC)_ AND M4 (SMALL 
. . SUBMETACENTRIC) 
Figure . SO. MARKER CHRQ\10SOMES: M1 (METACENTRIC) AND M2 (ELONGATED 
. ACROCEN'IRIC) 
/ 
Figure 51 . 
Figure 52. 
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MARKER CHRQ\10SOMES: M3 (LARGE SUBMETACENTRIC) 
MARKER CHROMOS01ES: M3 (LARGE SUEMETACENTRIC) AND 
M4 (SMALL SUBMETACENfRIC) 
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Figure 53 . POLYPLOIDY (61 CHROMOSCMES): MARKER CHROMOSCNES -
2 x Ml (!',ffiTACENTRICS) AND 2 x M4 (SMALL SUB~ffiTACENTRICS) 
Figure 54 . G - BANDING : MARKER CHROMOSOMES -
M1 (METACENTRIC) and M2 (ELONGATED ACROCENTRIC) 
t 
- 195 -
The SCE frequency was also analysed and the most frequently occurring · 
SCE number was 10 per metaphase (Figure 57) for all treatments including 
the controls, with two exceptions which were as follows; DPH (approximately 
50 µg/ml) with Retinoic Acid (10-6M), and DPH m-hydroxy metabolite 
(approximately 50 µg/ml) which had 9 and 11 respectively as the most 
frequent nwnber of SCEs per metaphase. This seems to indicate that neither 
Retinoic Acid, DPH, S-9 ~.fixture, Solvents, nor the chemically synthesized 
metabolites in the arr~unts tested, are capable of increasing the SCE 
frequency rate above 12, the maxirrn..un for the controls. 
BrdU has been shown to affect the SCE frequency (Bannigan and Langman 1979). 
Therefore a standard concentration of BrdU (10 µM) was used for controls 
and treatments which probably contributed to the baseline rate of SCEs 
which was round to range from 7 to 12 SCEs per metaphase. It was expected 
that an agent which could cause an increase in SCEs would be detected 
by causing an increase in the SCE frequency. A high number (18) of SCEs 
was infact observed when a cell culture was incubated in the presence of 
artificial light (Figure 56)_ and confirms the finding that physical factors 
such. as light do influence the rate of SCE formation. All other cell 
cultures were incubated with BrdU in complete darkness and so this pheno-
menon was avoided but it did indicate that SCEs were inducible in the 
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Figure 55. CDIBINED FREQUENCY IDI'ALS vs. SCE NUMBER (per metaphase) 
('.j 30 
z 



























FOR FA01 TREA'D1ENT OF EXPEJID1ENTS C A"ID D (HIS'IffiRN,1 OF TABLE 2?.). 
Solvents 
S-9 Mix 
RA IO -6M 
Control 
{J) 
~-CD DPH, m- hydroxF 
metabolite{50) 
DPH (50) & 
S-9 Mix 
DPH (50) & 
RA IO -6M 
© 
G) (j) 
DPH, p hydroxy 
metabolite(50)@ 
& RA fO- 6M 21 
DPH, p-hydroxy @ 
metabolite 
@ 
DPH (50) DPH, m-hydroxy 
metabolite ~50) 
& RA ( - IO . - t1) 
7 8 9 10 11 12 7 8 9 10 11 12 7 8 
SCEs per metaphase 
9 10 11 12 
NOTE: ( ) = approxl.J!lcite drug dosap,e in µg/ml, Q 
P = polyplo1d. RA = Retinoic l'cid 
I DPH 
= treatment code (Refer to 




















































































































































































































































































































































































































































































































































































































































































SISTER CHROMATID EXCHAl~GE ANALYSIS: EXPOSURE TO ARTIFICIAL 
LIGHT DURING INCUBATION WITI-1 BrdU - 18 SCEs 
MODAL SISTER CHROMATID EXCHANGE RATE FOR ALL TREATMENTS IN 
EXPERIMEl'-J'IS C AND D AFfER INCUBATION WITI-1 BrdU IN COMPLETE 
DARKNESS - 10 SCEs 
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·QIAPTER . 8 
DISCUSSION AND CONCLUSIONS 
8. 1 DISCUSSION 
8. 11 PC13 EC CELL DIFFERENTIATION IN CUL1URE 
A reproducible patteTil of PC13 embryonal carcinoma cell differentiation 
was found to follow induction by low cell density plating (7 ·x 105 cells/ 
culture flask) and exposure to Retinoic Acid (10-~. 1he sequence was as 
follows: the appearance of small granular Endoderm-like cells (20-30 µm) 
on days 2 to 4, Glial-like cells (30-60 µm) on days 4 to 5, Fibroblast-
like cells (60-100 µm} from day 5, large Endoderm-like cells (100-200 µm) 
and multi-processed Neuronal-like cells (up to 900 µm) by day 18 to 21. 
Low cell density plating of 5 x 105 cells/culture flask gave similar 
results on day 21. The sequential and apparently limited patten1 of 
differentiation was monitored by direct observation using phase contrast 
microscopy. 
A comparison can be drawn between these differentiating cell types and the 
cell derivatives o~ the early endodermal germ layer which initially fon:ns. 
the epithelial lining of the primati ve embryonic gut, etcetera ~d the 
appearance of the large Endoderm-like cells similar to squamous epithe-
liUin would. seem to confirm this (Langman 1981). The Fibroblast-like cells 
_; 
may represent a neuroectodermal derivative by analogy to early differen-
tiation of the inner cell mass of the developing embryo. The Fibroblast-
like cells may represent further glial differentiation, with glial tissue 
being a corrnnon component of well-differentiated murine teratocarcinomas 
in vivo (Kleinsmith and Pierce 1964) and Fibroblast-like cells have been 
described as resembling differentiating glial tissue of embryoid body 
differentiation in vitro (Van den Berg et al 1976). Focal neuronal 
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differentiation has been occasionally found associated with Fibroblast-
like cells, which further suggests the possibility and it seems likely 
that these Fibroblast-like cells are analogous to cells of similar 
morphology in explants of embryonic brain tissue (Jones-Villeneuve 1982). 
However, it may be possible that these cells are a mixed population of 
morphologically similar cells representing more than one germ layer 
(Speers et al 1979). TI1e reproducible sequence of differentiation after 
Retinoic Acid (10-6M) treatment, with Glial-like and Fibroblast-like 
cells appearing early on followed by what appears to be large Neuronal-
like cells is· identical to that seen in explants of brain from 10-day old 
rat embryos (Jones-Villeneuve 1982}. 
Confinnation of the presence of a neuronal cell type requires data on 
neurotransmitter activity, neurite ultrastructure and sodium transport 
characteristics in response to certain neurotoxins (Pfeiffer et al 1981). 
Irmrruno£luorescent staining of these neuronal type cells with antitubulin 
antiserum may reveal varicosities on some neuronal processes, a charac-
teristic of some types of neurons. Tiie Glial-like cells may be positive-
. ly identified by staining with dye coupled with antibody to glial fibrillar 
protein (Jones-Villeneuve 1982). Tiie identification of the biosynthetic 
product(s) of the giant cells in the future may help to clarify the rele-
vance of t~is differentiation process to normal mouse embryogenesis in 
vivo (Lo and Guila 1980). 
/ 
In summary, a definite identification of the cell types observed in this 
investigation was not made although the fact that undifferentiated EC 
cells appeared morphologically to be differentiating into more advanced 
cell types seemed to afford the criteria of 'embryonic-like development' 
required for teratogenicity testing& 
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The observations made on cell morphology after differentiation induction 
(Retinoic Acid 10-6M) in experiments A, B, C and D confirmed the above 
sequence of events and the percentage of differentiating cells was on 
average 47% by day 7. '!he cells were then subjected to various treatments 
for the next five days which each affected the percentage of differentiation 
achieved, the degree of proliferation and the morphological appearance 
of cell cultures by day 12 (culture termination}. '!he control cultures 
proliferated normally and did not change morphologically. In cultures 
where only retinoic acid (10-6M) was present throughout, approximately 
· 69% of the culture population was differentiating by day 12, with large 
Fibroblast-like cells (60-100 µm) predominating. Moderate cell death 
and density were recorded, indicating that Retinoic Acid (10-6M) had a 
toxic effect, a result similar to that found by Linder et al (1981) and 
Ogiso et al (19821 using different cell systems. '!he other substances 
tested (viz. DPH. and the S-9 mixture) did not cause the induction of 
cell differentiation when monitored by phase contrast microscopic analysis 
of cell morphology. 
8. 12 PC13 EC CELL EXPOSURE 1D DPH (PARENT COMPOUND) AND ITS METABOLIC 
PRODUCTS (~ffiTABOLICALLY DERIVED USING S-9 MIX'IURE AND CHEMICALLY 
SYNTHESIZED). 
DPH at approximately 500 µg/ml had a very toxic effect upon undifferentiated 
/ 
and differentiating cells in culture, leading to a high rate of cell death 
and consequently to a lowered cell density (Table 18). '!he cells appeared 
granular and were surrounded by adherent debris, therefore it was not 
possible to observe their f-ull morphology. DPH at 50 and 5 µg/ml caused 
low cell death and high cell density with normal cell morphology was 
therefore recorded for undifferentiated cell cultures. However, in 
differentiating cell cultures the degree of differentiation was reduced to 
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an average of 57% and 49% respectively instead of the expected 69% 
by day 12. There was also marked cell death, and consequently lowered 
cell density. 
The addition of the S-9 mixture had no apparent effect on undifferentiated 
cell cultures ·except to cause the abnormal feature of cell retraction 
which. is probably an indication of a toxic effect. Differentiating 
cells could not be assessed for this feature due to the inherent change 
in cell morphology with time, but there was a reduction in the percentage 
of cells differentiating to 42% instead of the expected 69% by day 12, 
implying some interference with the initiation of cell differentiation. 
It was found that the S-9 mixture added to undifferentiated cells with 
DPH at approximately 500 µg/ml appeared to provide protection against the 
expected drug toxicity, resulting in low cell death .and consequently 
high cell density. DPH at SO and 5 µg/ml with the S-9 mixture also 
led to a normal cell density and the only apparent effect on morphology 
was to cause cell retraction. 
Differentiating cells (10-6M Retinoic Acid induced) exposed to DPH at 
approximately 500 µg/ml in the presence of the S-9 mixture were however 
sensitive to DPH effects, although the effect was not as toxic as that 
which occurred with differentiating cells in the presence of DPH (approxi-
mately 500 µg/ml). This suggests that the conversion of DPH to_its 
metabolites reduced toxicity similar to that .with the same dosage of 
DPH and undifferentiated cells. It has similarly been found that DPH 
parent compound (SO µg/ml) once incubated with the S-9 mixture to induce 
the fo11nation of metabolites has a much reduced toxic effect upon chick 
limb bud mesenchymal differentiation (Wilk et al 1980)a It was concluded 
that the parent compound was the more toxic agent and that the S-9 mixture 
was possibly "protective" in converting DPH to its metabolites. 
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However in this investigation, the lower doses of DPH (SO and S µg/ml 
approximately) in the presence of the S-9 mixture had a more toxic 
effect (increased cell death, decreased cell density and reduced cell 
differentiation to 26 and 23% respectively) on differentiating cells 
than when no S-9 mixture was added. 
1be chemically synthesized metabolites, DPH m-hydroxy metabolite and 
DPH p-hydroxy metabolite had apparently no effect on undifferentiated 
cells but with differentiating cells they caused an increase in cell death 
and consequently lowered cell density. 1be morphology of the differentia-
ting cells did not appear affected by the addition of these metabolites 
but they both caused a slight increase {to 72 and 76% respectively instead 
of 69%) in the degree of differentiation by day 12 when compared with 
the treatment of 10-6M Retinoic Acid alone. It should be noted 
that an increase in_ protein synthesis and cell growth of cells obtained 
from enlarged rat gingiva resulted from prior treatment in vivo with up 
to 10 µg/ml of DPH but above this level, synthesis and growth were decreased 
(Hassell 1980). 1be significance of this result is not known and much 
thorough testing is required be~ore firm conclusion can be made about the 
toxicity of these ~PH metabolites. 
8.13 'IHE EFFECT OF DPH ON DNA SYNTI-IESIS BY PC13 EC CELLS 
DPH (approximately 50 µg/ml) was found not t9 cause a change from nonnal 
in DNA synthesis rates when administered as the parent compound to undifferen-
tiated cells. 1be same result was found for Retinoic Acid (10-6M) and the 
S-9 mixture when each was added alone . DPH (approximately 50 µg/ml) 
and S-9 mixture added together in Experiment C caused a significant decrease 
in the DNA synthesis rate but in Experiment D the results were not 
significantly different from those of the controls and therefore the initial 
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result suggesting DPH metabolic products caused some toxicity were not 
confinned. 
Retinoic Acid (10-~) and DPH (50 µg/ml) the parent compound caused a 
decrease in the DNA synthesis rate probably due to the toxic effect of 
Retinoic Acid mentioned previously or due to the fonnation of differen-
tiating cells which may be more susceptible to DPH parent compound 
toxicity. These results were also observed when the S-9 mixture was 
included in the treatment, suggesting that both the parent compound or 
metabolites may be toxic to differentiating cells. Alternatively,it may 
be the Retinoic Acid (10-~1) and S-9 mixture Khen added together which 
causes the toxicity in the presence of DPH since the S-9 mixture and 
Retinoic Acid (10-~) when added toget~er ~~thout DPH caused a toxic 
effect which led to a decrease in the DNA synthesis rate. 
The chemically synthesized DPH, m-hydroxy metabolite increased the DNA 
synthesis rate in undifferentiated and differentiating cells, implying 
that metabolites are toxic. 1he DPH, p-hydroxy metabolite was not 
available in an amount large enough to allow full analysis of its effect 
on the DNA synthesis rate . 
8. 14 DPH (PARDff CCMPOUND A,\ffi MET.ABOLIC PROOOCTS) EFFECTS ON CHR(M)SOME 
ABERRATION MTI SCE INDUCTION IN PC13 EC CELI.S 
The nodal chromosome cm.mt was 41 per metaphase and the various treatments 
did not cause a significant change in this result and did not induce any 
chrorrosomal aberrations in addition to the four marker chromosomes already 
present in this cell line when analysed by conventional chromosomal methods . 
Therefore it is concluded that DPH doses of 50 µg/ml do not cause a ITil.lta-
genic effect on PC13 EC cells in culture when monitored by chromosomal 
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analyses of aberration induction. This was the finding when DPH was 
administered as the parent compound, after being metabolically activated, 
and when two ch~nically synthesized metabolic products were added 
individually. Presumably, DPH acts at another level of DNA structure 
in order to exert its toxic effects and subsequent teratogenicity. 
In addition , the SCE frequency was not increased above 12 SCEs per meta-
phase in all of the treatments suggesting that DPH, parent compound or 
metabolites does not cause a teratogenic effect by inducing SCEs. 
8.2 . CONCLUSIONS 
1. 'Ine formation of possible neuronal components from PC13 EC cells was 
a protracted and more or less fortuitous process which has also been 
experienced by other investigators using a different clone of 
embryonal carcinoma cells (Kuff and Fewell 1980). A more suitable 
embryonal carcinoma cell line (such as PCC7} would provide a better 
test organism for the investigation of neuronal differentiation. At 
low cell densities, these cells preferentially differentiate into 
.cholinergic neurons, making up at least 90% of the total cell popu-
lation, the other cells being EC cells (Pfeiffer et al 1981). Such 
a cell. line would be useful for the analysis of the process involved 
in the terminal differentiation of neurons~ especially neurite 
outgrowth. 
2. a) Results supporting the suggestion that the DPH parent compound 
is responsible for DPH toxicity are as follows:-
i) DPH at approximately 500 µg/ml was toxic to undifferentiated 
cells in culture (increased cell death and decreased cell 
proliferation with abnormal cell morphology), however lower 
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doses (approxnnately· SO and 5 µg/mll had no observable 
toxic effect. DPH at SO µg/ml also had no effect on the rate 
of DNA synthesis~ 
ii). DPH appeared very toxic (increased cell death, decreased 
proliferation and decreased degree of differentiation) to 
differentiating cells at all three doses tested (approximately 
500, SO and S µg/mll. However, · the 10-6M Retinoic Acid used 
to induce differentiation may infact be responsible for some 
of the toxicity observed (especially at low DPH doses) even 
though the differentiating cells were thought to be more 'vulnera-
ble', since Retinoic Acid alone causes increased cell death and 
decreased cell proliferation when compared wi~h controls. 
DNA synthesis by differentiating cells had decreased with a 
DPH dose of approximately SO µg/ml, whilst Retinoic Acid (10-6M), 
was not found to cause a decrease in the DNA synthesis rate when 
tested alone. 
iii) Incubation of DPH {parent compound at approximately 500, SO and 
S µg/ml) ,. with the S-9 mixture presumably led to the formation of 
metabolic products which had no apparent toxic effect (cell 
death. and proliferation similar to controls) on undifferentiated 
cells, although 'cell retraction' was observed which can be 
attributed to the S-9 mixture sin~e it occurs with S-9 mixture 
alone. This infers that at the higher DPH dose (approximately 
500 µg/ml) especially, the S-9 has a protective effect in 
converting DPH to its metabolites and avoiding toxicity due to 
the high dose of the parent compound. 
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Conflicting results were found with regard to DNA synthesis 
rates and therefore will not be stated here. 
iv) With differentiating cells (10-6M Retinoic Acid induced), the 
DPH metabolic products formed in the presence of the S-9 
mixture and DPH at approximately 500 µg/ml caused toxicity 
(increased cell death, decreased proliferation and decreased 
degree of differentiation (to 36%)). However, there was less 
toxicity when compared with the effect of DPH (approximately 
500 µg/rnl) on differentiating cells without the S-9 mixture, 
suggesting that the metabolic products are less toxic than the 
parent compound at high doses or alternatively, the S-9 
mixture may not have caused adequate metabolic activation of 
the parent compound and the DPH parent compound may have been 
responsible for all the toxicity actually observed. 
b) Results supporting the suggestion that DPH metabolites (resulting 
from metabolic activation of DPH or chemically synthesized) are 
responsible for DPH toxicity and not the parent compound are as 
follows:-
i) With differentiating cells (10-6M Retinoic Acid induced), 
the DPH metabolic products formed in the presence of the S-9 
mixture and DPH at SO and 5 µg/ml (compare with 1(iv) above) 
were found to be more toxic (increased cell death, decreased cell 
1 
proliferation and a decrease in the degree of cell differentiation 
to 26 and 23% respectively) than the parent compound at similar 
concentrations. 
This implies that provided there was adequate metabolic acti-
vation of the DPH, the metabolic products are the cause of 
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DPH toxicity. In addition, a decreased rate of DNA synthesis 
by differentiating cells was observed with SO µg/ml DPH 
in the presence of the S-9 mixture although this also occurred 
without the S-9 mixture, and also without the d111g itself. 
ii) 1he chemically synthesized metabolic products only (approximately 
SO µg/rnl) affected differentiating cells with regard to toxicity 
monitored as an increased in cell death, decreased cell prolife-
ration and in increase in the degree of cell differentiation, 
however the DPH m-hydroxy metabolite was also found to cause 
.increased level of DNA synthesis in both undifferentiated and 
differentiating cell cultures. 
Overall, these results may therefore support the theory that 
DPH parent compound at therapeutic doses is able to cause 
toxicity to differentiating cells which can lead to terato-
genic effects, although the experiment would need to be repeated 
using a larger sample size and perhaps a more controlled 
system of differentiation induction, metabolic activation of 
DPH and .an improved sequence monitoring, before these con-
clusions can be made definite. 
A positive control such as cyclophosphaJnide with the S-9 
mixture has been recommended (Hsu .et al 1977) as an additional 
treatment which would ensure that metabolic activation was 
adequate and exclude inadequate activation of DPH where 
activated intermediates (arene oxides) or other metabolites 
were not formed leading to a negative result •. If DPH, the 
parent compound, is responsible for toxic effects it should 
be tested with a chemical not requir:i,ng metabolic activation, 
'--
- 211 -
for example, methylsulfonate which readily induces SCEs. 
Alternative positive controls may be required if the above 
two are not adequate to mimic the effect of DPH. 
3. The negative response of tllldifferentiated and differentiating PC13 EC 
cells to the effects of DPH with regard to chromosome aberrations and 
SCE induction may be due to the possibility that EC cells are unable 
to respond due to various causes. 
Fabricant and Hofnung (1979) who tested the effect of Mitomycin C 
(a known SCE inducer) on CBR2 EC cell cultures and due to a negative 
result concluded that the EC cell cultures may have been less permeable 
to the drug or defective in particular pathway of DNA repair. Further 
cytogenetic and biochemical analysis and the inclusion of definite 
positive and negative controls would probably resolve the problem of a 
possible false negative result in this investigation. 
4. Some strains of mice have been shown to be more susceptible than others 
to the teratogenic effect of DPH (Mirkin 1971). Therefore as discussed, 
a more suitable .Jlillrine teratocarcinoma cell line which may be more 
susceptible to DPH, and one in which, for example, definite neuronal 
differentiation predominates without chemical inducement should be 
examined. However, a htnnan teratocarcinoma cell line with the above 
features would be the most appropriate . 
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APPENDIX 
The disappearance of DPH incubated with S-9 mixture (Refer to Table 11). 
DPH ihi'tial amount = approximately SO µg/mL 
PHEHYTO!t~ 
FOR ·LAST STD CURUE, 
STD DEI..J = 
DATE= 
LOT#= 







.··· ... ·. -;·· .•. .·. . ... · ... ··· ...... .... < .... · -~;. ... , (.;, -: ... -: .. •(,·~·· ...  . 
RUH SAMF'LE # . 3 
RUt~ SAMPLE # 5 
Time = 0 (with S-9 mix) 
A,:,= 66::5 . 
RATE = 293. 1 
(i) COtK: ( UG/t1L) -:: 6. 4 (x6) 
RUt~ SAMPLE # 6 
Time = 0 (wi tl-i S-9 mix 
A,:,= 644 
RATE = 300.1 
(ii) COMC ( UG./ML) = 6. 7 (x6) 
. . . . . . . . . . . . . . . . . . . . 
RUt-~ SAMPLE # 9 
A,:,= 7l~ 
Time= 0.25 hrs 
RATE = 340.1 
(i) CONC (UG/ML) = 24.4 
• • • • • r • • • • • • 
RUN SAMPLE#······;; 
A,:,= 724 
. RATE = 338. 7 
(ii) COt·4C ( UG/ML) = 23.3 
I 
Time= 0 (no S-9 mix) • • • • • • • • • • • • • • • • • • • • 
RUN SAMPLE# A.:,= 635 
RATE= 307.1 
(i) COt~C CUG/ML >. = 
RU~~ SAMF·CE # 
ID#? 
·. A.:,= 692 
· 'Ra.TE -= 308. 9 
8.4 (x6) 
4 
(ii) COHC < UG/ML) = 8. 9 (x6) 
. . . . . . . . . . . . . . . . . . . . 
Ao= 729 
RATE= 326.l 
(i). CONC ( UG/ML) = 
13 
Time= 0.5 hrs 




(ii) CONC < UG/ML) = 16. 1 
. . . . . . . . . . . . . . . . . . . . 
RUN SAMPLE# 4 
Time = 1. 0 hrs 
A,:,= 628 
RATE= 31~.0 
(i) COt·4C < UG.··'ML > = 1 (1. 8 
.................... 
RUN SAMPLE# 5 
Ao:,= 649 
RATE= 31':i.1 
(ii) COt·K: ( UG / ML ) = 10. 9 
PUt-~ ~;AMPLE # 19 
Time= 2.0 hrs 
A,:,= 700 
RATE = 233.7 
(i} COtK: < IJG / ML) = 6.6 .................... 
RIJf..j ::;AMF'LE # 20 
Ac,= 734 
RATE = 298.2 
(ii) COt-lC ( UG/ML) = 6.2 .................... 
RUN SAMPLE # 17 
Time = 3.0 hrs 
A,:,= 714 
RATE = 303.0 
(i) CONC ( UG .. ·'ML) = 7.3 
a a a a a a • • • a a a I • a I I I a I 
RUt..j SAMPLE # 18 
Ao:,= 743 
RATE = 310.2 
(ii) COt-lC ( UG/ML) = 9.3 . . . . . . . . . . . . . . . . . . . . 
RUN SAMPLE# 3 
Time= 4.0 hrs 
fie,= 640 
RATE= 306.0 
· (i) COt-lC ( UG/ML) = B. 1 
a • a a a a I • a I I a a a • I a I a I 
RUN SAMPLE# ~ 
Ao= . 674 
RATE= 301.7 
(ii) CONC ( UG/ML) = (A 0 . . . . . . . . . . . . . . . . . . . . . 
~tandard curve of protein determinations for Experiments C and D: 
Absorbances deteTIJ1ined with increasing am:>unts of protein, assayed by the 
























' fu.-periment C Experiment D 
(A) (B) AVERAGE (A) (B) 
0.0004 0.0003 0.000 0. 000(1) 0.000(4) 
0.054 0.090 0.072 0. 11 7 0.075 
0. 168 0. 150 0. 159 0. 192 0.212 
0. 217 0. 243 0. 230 0.270 0.308 
0.322 0.358 0. 340 0.394 0. 406 
0. 379 0.417 0. 398 0.503 0.479 
Standard curves for EA'J)eriments C (x) and D (• ) : 
/ 
/ 











































1.00 2 SISKA l 
50.0 LSR 
16.5 BKG 
1.00 2 SIGKA 8 
0 LL 
428 UL 
S1N6LE LABEL DPN·VERS:08/01/76 
U~~NOUN ID: 3k DP" 
S1A~DARDIZATION ID: 3H 11563 BECKMAN 
1. STANDARDS ID: 3K 11563 BECKIIAN 
2, UHK JD: 3H DPN 
UHKHOUH HORftALlZATlON FACTOR: 1.00000000 
J. DATA CH4~HEL: I 
4. OUENCH hODE: H 
BK6RD CONSTANT OUENCH! y 
5. ~Alf LJrE(DAYS): 44V2.5750 
6. CALCULATE COEFF.! M 
7. AVG BK6RD: 
CHAN 11: f9.8500 
8. PUEWCH COErFS(A,B,C,D>1 
60.55oooJ,- o.21i26s,- 0.00 1500, 0.00000,77 
9. OUEHCH LJNITS<LOU,HIGHI: 13.000000, 186.00000000 
Treatments 
Control 
Retinoic Acid (10-6M) 
DPH (SO ~gm/ml) 
DPH (SO µgm/ml)_ 
Retinoic Acid (10-~)_ 
·EXPERIMENT B 
. ·n . P~M. 
8 9 3 9 2 1 . 7 4 
5 4 8 7 8 9 • 9 2 
1 9 9 2 2 2 . 0 3 
3 4 6 0 8 5 . 4 4 
2 5 4 4 6 9 9 8 
3 2 6 2 9 1 . 7 4 
3 1 2 4 0 3 • 5 3 
9 0 5 9 8 . 0 7 
2 S 8 0 3 7 . 3 3 
2 6 6 9 8 0 • 0 S 
3 2 3 8 4 0 . 3 6 
3 8 3 6 8 1 . 5 S 
2 S 6 4 3 3 • 1 6 
2 S 4 6 2 2 . 1 0 
2 8 2 8 0 7 • 3 7 
1 6 S 7 7 1 . 8 2 
1 9 0 2 4 8 • 8 7 
9 1 9 7 0 6 7 9 
1 7 4 0 9 7 • 2 3 
2 S 3 2 0 8 . 7 7 
2 6 7 8 3 2 • 9 4 
1 9 0 S 4 6 5 4 
2 S 1 0 8 2 • 3 9 
1 9 8 4 9 4 • 4 9 
Only first 3 digits taken for calculations (Section 6.29.3) in 
DPM's {x thousand) and Results Table 20. 
Experiment C. DNA Synthesis and Protein Determinations 
(@750 nml 
Treatment: Average Protein D.P.M. D.P.M. (Thousands per 100 
'Absorbance . ( (!M) µ., - µ!J;M Erotein) 
Control 0.403 102 162652.14 160 
0.448 111 159142.04 143 
0.280 71 118802.34 168 
Q.537 134 196928.58 146 
0.352 88 143253.57 163 
0.382 96 173195.23 180 
Retinoic Acid (10-
6M) 0.502 126 232920.73 185 
0.513 129 198101.66 154 
0.382 96 146407. 18 152 
0.496 124 200319.95 161 
0.295 74 98875.20 134 
0.224 56 68386.73 121 
S-9 mix 0.372 94 137067.51 146 
0.549 138 245326.35 178 
0.542 134 252960.92 188 
0.367 91 144994.62 159 
0.383 96 135755.87 142 
0.548 137 189268.17 137 
Retinoic Acid (10-
6M} 0.230 58 50019.25 86 
+ S-9 mix 0.202 51 33726.09 67 
o. 198 50 42039.28 82 
0.266 67 89848.01 134 
0.214 43 56028.25 130 
0.298 74 96478.31 129 
Solvents 0.263 66 121131.00 183 
0.299 75 109988. 13 145 
0.278 70 111894.47 160 
0.295 74 104237.05 141 
0.266 67 108430.23 161 
0.529 133 191341.58 144 
DPH (interm) ~ 0.352 88 126425.00 143 
0.544 137 208352.95 152 
0.362 91 134222.49 147 
0~442 111 144962.53 131 
0.291 73 1Q4975.27 144 
0.270 68 110026.41 162 
DPH (interm) * 0.548 138 192200.76 139 
and Ret. Acid 0.538 135 220765.55 164 
(1 o-6M) 0.409 103 149396.30 141 
0.494 125 153475.74 123 
0. 171 43 21341.69 49 
0.076 19 6149.98 32 
(contd. next page ..• ) 
DPH (intennf 0.228 57 4310.5.78 75 
and S-9 mix 0.216 54 12531. l3 24 
0 .. 204 51 17640.86 35 
o. 160 40 14893.95 38 
0.169 41 30606.53 74 
0. 158 37 25088.22 66 
DPH (intenn) x 0.478 120 55221.22 45 
+ S-9 mix and 0.154 38 11217~92 28 
Retinoic Acid 0.-042 10 1653.42 20 
(10-6M) 0.056 14 2015.51 14 
0.034 8 1906.91 25 
0. 146 36 6626.83 19 . 
X = Approximately 50 pg/ml 
Experiment D .. DNA Synthesis and Protein Determinations 
(@750 run)_ 
Treatment: Average Protein D .. P .M, D.P.M. (TI1ousands per 100 
· ·Absotbance "(µ g.M) · · · · · · i.i?J.1 Erotein) 
Control 0.284 57 44025.13 77 
0.310 62 39830.50 64 
0.298 60 34615.80 58 
0.369 74 63084.30 85 
0.357 72 52564.03 74 
0.480 97 92148.69 95 
Retinoic Acid 0.435 88 53755.18 61 
(10-6M) 0.340 69 65065.52 94 · 
0.450 91 69787.07 77 
0.437 88 64065.97 73 
0.428 86 55693.76 65 
0.465 94 65547.96 70 
i 
DPH (SO µg/ml) * 0.400 81 78125.69 95 
0.321 64 42903.92 66 
0.484 98 72808.26 75 
0.535 108 72447.45 68 
0.350 70 42625 .18 61 
0.362 73 61704.20 85 
DPH (50 µg/ml) x 0.328 66 34013.32 52 
R~tinoic Acid 0.303 61 39154.39 64 
(10-6M) 0.357 72 28847.74 40 
0.328 66 27511.l2 44 
0.248 so 24833.45 50 
0.485 98 55287.11 56 
DPH (50 µg/ml) }{ 0.446 90 63361.39 70 
S-9 Mix 0.437 88 65165.99 74 
0.390 79 41222.21 52 
0.406 82 61415.97 74 
0.484 98 51508.98 53 
0.475 96 81812.20 85 
DPH (SO µg/ml)}{and 0.120 24 12642.28 50 
Retinoic Acid 0. 150 30 15490.33 53 
c10-6M) with o. 152 38 17874.70 47 
S-9 Mix 0. 165 33 14164.37 42 
0.104 21 7872. 70 . 38 
o. 101 20 8276.75 40 
m-hydroxy metabo'"'. · .. 0.496 100 189216.12 189 
lite (SO µg/ml)* 0.350 91 87071.98 96 
0.238 58 51906.28 90 
0.436 88 92214.14 105 
0.470 96 127796.41 133 
0.328 66 58062.19 88 . . . . . . . 
(contd. next page ••• ) 
m-hydroxy metabo-
lite and Ret. Acid 
(10-6M) 
p-hydroxy metabo-
lite (SO µg/ml)x 
p-hydroxy metabo-
lite~8:Ild Ret. Acid 
(10--M) 
0.308 
0 .. 336 






















-* = Approximate values 
54843~98 
























CHROMOSOME ABERRATION SCORE SHEET 
TREATMENT : 
CELL CH~OMOSOME MA.T{KERS OTHER 



















































8 FEB 1985 
SISTER CHROI1ATID EXCHANGE SCORE SHEET 
TREATMENT 
CELL CHROMOSOME SCEs . PER 
NUMBER COUNT MET APHASE 
1 
2 
3 
4-
5 
6 
7 
I 
8 
9 
10 
11 
12 -
13 
14 
. 15 
16 
17 
18 
19 
20 
. 21 
22 
23 
24 
~ 
· 25 
26 
c' 27 
28 
29 
30 
